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Abstract 
Honey has been used for centuries as a medicine to treat various ailments and 
infections.  A large amount of research has established that honey has potent 
antibacterial activity.  However, the sensitivity to honey of viral species that cause 
infections has been studied in only a small number of cases.  The aim of this study 
was to obtain data to clarify and extend knowledge obtained from these previous 
studies of honey’s antiviral activity, and especially study those viruses that cause 
localised infections which have limited or no therapy available, which are suitable 
to treatment with topically applied honey.   
 
The susceptible A549 cell line and viral isolates of Adenovirus serotypes 1, 3, and 
8, and Herpes simplex virus serotypes 1 and 2, were provided by the Waikato 
Hospital Virology Laboratory.  A number of types of honey were investigated 
from a range of sources: Manuka honey with high concentrations of 
methylglyoxal, “unique manuka factor” activity, and phenolics, Honeydew and 
Rewarewa honeys which have high antioxidant activity, and Ling Heather honey 
which is high in phenolic compounds. These honeys were selected due to their 
range of characteristic activities in order to make comparisons with antiviral 
activity.   
 
A variety of tests using cell culture were developed to evaluate the sensitivity of 
the viruses to whole honey.  Each test scored and monitored the development of 
morphological changes to the cells, to observe whether the honey treatment can 
prevent the development of these changes known as viral cytopathic effect.  These 
included tests for: protection, in which the cells were pre-treated with, and 
iii 
 
incubated either with or without honey; prevention, where honey was used to treat 
infected cells, and in plaque reduction assays, to examine whether it can reduce 
the resultant number of plaques; and neutralisation, in which the virus was 
directly exposed to the honey for a defined period. 
 
It was found with each type of test using cell culture that many of the honeys 
studied can lower the severity of viral cytopathic effect or delay its onset 
compared with the development observed with virus that was not treated with 
honey.  This can suggest that the antiviral activity may be a feature of more than 
one type of honey.  In general the antiviral effect increased with the concentration 
of honey and time the virus was exposed to it.  Manuka honey M116 at a 
concentration of 10% was effective in preventing the development of viral 
cytopathic effect of each of virus, after the viruses at concentrations in excess of 
the tissue culture infectious dose had been exposed to the honey for 8 hours. 
 
Enzyme-linked immunosorbant assays were used to measure the effect the 
successful treatments found in the extended neutralisation experiments had on 
viral surface proteins necessary for viral entry into the cells.  The results using this 
technique suggested that there was very little virus present in the samples that had 
been treated with honey and with the untreated virus.  Therefore it could not be 
shown whether the honey was acting via this mechanism. 
 
It is concluded from the findings in this study that honey is likely to be an 
effective antiviral treatment for the therapy of localised viral infections, this needs 
to be verified by clinical trials. 
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Chapter 1 
Introduction and Literature review 
This chapter aims to introduce the research area of this thesis, outlining the 
traditional and more recent therapeutic properties of honey.  It describes honey’s 
established antimicrobial activity, as well as methylglyoxal the speculative 
causative antimicrobial agent present in especially high levels in Manuka honey.  
It finally reports on previous investigations of honey’s antiviral activity and gives 
statements of the hypotheses and aims of this study. 
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Many viruses cause localised infections, few of which have therapeutic treatments 
available for the elimination of the infection or alleviation of the symptoms of the 
infection.  Studies have indicated that honey may have antiviral activity, which 
has raised the possibility of honey being an effective treatment for such infections 
caused by viruses.  Much research has been done on the antibacterial activity of 
honey but little on its antiviral activity.  Therefore this study has been undertaken 
to investigate honeys’ antiviral capacity. 
 
1.1 HONEY 
1.1.1 Traditional to more recent uses of honey 
Honey has been used for centuries as a traditional medicine for a range of 
ailments, Aristotle (384-322 BC) referred to pale honey being a “good salve for 
sore eyes and wounds”.  The ancient Egyptians, Assyrians, Chinese, Greeks and 
Romans all used honey in combination with other ingredients and alone to treat 
wounds and infections of the gut (Zumla & Lulat, 1989).  In 50 AD, Dioscorides 
described honey as being “good for all rotten and hollow ulcers” and “good for 
sunburn and spots on the face” (Gunther, 1934).  He further wrote that “honey 
heals inflammation of the throat and tonsils, and cures coughs.”  The use of honey 
has been sustained into present day folk medicine.  In India, lotus honey was said 
to be a panacea for diseases of the eye (Fotidar & Fotidar, 1945) and it has further 
been reported that honey can be used to treat eyes discharging pus (Meier & 
Freitag, 1955).  Traditionally honey has been used to treat colds and coughs (Beck 
& Smedley, 1944).  Honey also has a history of being used as therapy for infected 
leg ulcers (Ankra-Badu, 1992), for earache (Obi et al., 1994) and in the eyes in 
measles to prevent corneal scarring (Imperato & Traore, 1969).   
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The dominance of “superbugs”, those species of bacteria that contain multiple 
antibiotic-resistance genes, has led to a rediscovery of the therapeutic use of old 
remedies, including a re-evaluation of honey (Zumla & Lulat, 1989). 
 
More recently, it has been reported that honey has an inhibitory action against 
about 60 species of bacteria including both anaerobic and aerobic as well as both 
gram positive and negative (Molan, 1992a).  Antifungal activity in honey has been 
noted for some yeasts (Molan, 1992a) and dermatophytes (Brady et al., 1997).    
 
1.1.2 Constituents, antimicrobial, and antioxidant activity of honey 
It has been established through the volume of published literature that honey has 
significant antibacterial activity which has been comprehensively reviewed by 
Molan (1992a, 1992b).   
 
The antibacterial property of honey was firstly observed in 1892, by van Ketel 
(Dustmann, 1979).  It was assumed that this antibacterial activity was entirely due 
to the osmotic effect of honey, due to its high sugar content (Bose, 1982; Chirife 
et al., 1983; Condon, 1993; Keast-Butler, 1980; Mossel, 1980; Seymour & West, 
1951; Somerfield, 1991; Tovey, 1991).  Honey like other saturated sugar solutions 
has an osmolarity capable of inhibition of microbial growth (Chirife et al., 1983).  
If used to treat a wound, the wound exudate would dilute the osmolarity and cease 
the healing, however, it was found that upon dilution, the antibacterial action 
increased beyond the point where osmolarity would have been inhibitory (Cooper 
et al., 1999).  It was first observed and reported that the dilution of honey 
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increased antibacterial activity in 1919 (Sackett, 1919).  The explanation of this, 
that an enzyme within honey produces hydrogen peroxide when diluted was 
founded by White (1963).  Hydrogen peroxide is a well known antimicrobial 
agent.  It has been used for its antibacterial and cleansing properties in clinical 
practice (Turner, 1983).  Hydrogen peroxide is, however, harmful to tissues, 
causing inflammation and damage (Saissy et al., 1995).  The level of hydrogen 
peroxide in honey produced after dilution is typically 1000 times less than a 3% 
solution commonly used as an antiseptic.  The effects of hydrogen peroxide are 
more greatly reduced due to the sequestration and inactivation of free iron, which 
catalyses the formation of oxygen free radicals by hydrogen peroxide (Bunting, 
2001), as well as the ability to mop up oxygen free radicals (Frankel et al., 1998).  
It is possible that the antioxidant activity of honey may have an antiviral effect by 
decreasing the activation of NFκB.  Although the hydrogen peroxide level is low, 
it is still effective as an antimicrobial agent.   
 
In some honeys an additional antibacterial agent can be revealed by the removal 
of hydrogen peroxide by catalase (Adcock, 1962; Allen et al., 1991; Bogdanov, 
1984; Molan & Russell, 1988; Roth et al., 1986).  Usually such activity is at a low 
level, but in Manuka honey it was found to be at a high level (Allen et al., 1991).  
This component has become known as the unique manuka factor (UMF).  The 
level of this antibacterial activity can however show variation between honeys.  
Molan and Russell (1988) found a range of honey samples that showed varying 
additional activity from nil to almost whole of the activity of some Manuka 
honeys.  They also observed a correlation between the level of additional 
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antibacterial activity and the overall antibacterial activity of individual honey 
samples.  Very recently, it has been proposed that methylglyoxal described in 
Section 1.2 is the UMF as reported by Henle (2008) and Adams (2008). 
 
In addition to hydrogen peroxide and additional non-peroxide, antibacterial 
activity, the glucose content, and the acidic pH, may be aiding the increased 
lymphocyte and phagocytic activity of honey (Ryan & Manjno, 1977).  
 
1.1.3 Ailments and infections that can be treated with honey 
Honey has shown to be an effective therapeutic agent against a range of ailments 
and similarly a range of infections.  Many studies have shown the ability of honey 
to hasten the healing time of wounds and burns, where honey has been used as a 
dressing to treat a range of wounds as reviewed by Molan, 2006.   
 
Honey has shown to quicken the healing time of superficial to more severe burns 
compared with the control treatment silver sulfadiazine (reviewed by Molan, 
2006).  
 
With regard to the healing of wound infections, honey has shown with severe 
postoperative abdominal surgical wounds to more than half the: time to attain a 
negative swab of culture, duration of antibiotic treatment, resulting scar size, and 
days of hospitalisation (reviewed by Molan, 2006).  Likewise, honey has shown to 
be effective in treating large infected surgical wounds.  When other treatments had 
failed to heal the wounds after 14 days of therapy, the use of honey as a dressing 
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caused a marked clinical improvement after 5 days, and all wounds were closed, 
clean and sterile after 21 days (reviewed by Molan, 2006).  When honey was used 
to treat non-healing venous leg ulcers as a dressing under compression as the 
standard treatments for 12 weeks, honey caused significant reduction of ulcer size 
(32%), and complete healing in 7 out of 40 cases (reviewed by Molan, 2006). 
 
Honey also has few adverse effects when used as a therapeutic treatment.  
Allergic reactions are rare (Kiistala et al., 1995) and there have been numerous 
reports of honey being used clinically on open wounds where no adverse reactions 
have been recorded other than a transient stinging described by some patients (Al-
Waili & Saloom, 1999; Betts & Molan 2001; Dunford et al., 2000a; Dunford et 
al., 2000b; Natarajan et al., 2001; Robson et al., 2000; Subrahmanyam, 1996).  
This could be due to the acidity of the honey, as the stinging has not been noted 
when the acidity has been neutralised (Betts & Molan 2001). 
 
There have also been many reports of honey has been used for the treatment of 
eye infections (reviewed by Molan, 1999), and Al-Waili (2003) has shown that 
natural honey can be safely administered by inhalation using an ultrasonic 
nebulizer.   
 
1.1.4 Previous investigations of the antiviral activity of honey 
The antiviral activity of honey has been demonstrated in vivo by the research of 
Al-Waili (2004).  He investigated the effect of raw honey, topically applied, on 
recurrent attacks of herpes lesions, labial and genital, and compared this with the 
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effect of Acyclovir cream.  It was concluded that topical honey application is safe 
and effective in the management of signs and symptoms of recurrent lesions, of 
labial and genital herpes.  It is, however, unclear if this research showed that 
honey is antiviral or simply capable of reducing the associated symptoms by 
means of reducing inflammation, or both.  This study leaves open to investigation 
in vitro the effect of honey on Herpes simplex virus to confirm that it has an 
antiviral activity.   
 
Another study investigating the effect of honey, compared with thyme, on Rubella 
virus survival in vitro, by Zeina et al. (1996), showed that honey had anti-rubella 
activity, while thyme did not.  This investigation showed that it is possible to use 
cell culture (in vitro) to examine the antiviral activity of honey. 
 
Further, in a study by French (2002) Manuka honey and pasture honey at 
concentrations up to 25% were tested for their antiviral activity against HSV-1 in 
vitro.  The results of this investigation were suggestive of antiviral activity with 
Manuka honey and pasture honey at concentrations of 10% and 15% respectively. 
 
The French and Zeina studies did not reveal nature of honey’s antiviral activity 
thus it remains to be examined. 
 
1.2 METHYLGLYOXAL 
Methylglyoxyl has been found at a much higher level in Manuka honey than in 
any other honey and it has been speculated by Weigel (2004) and more recently 
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by Adams (2008) and Henle (2008) that the pronounced antibacterial activity of 
New Zealand Manuka honey directly originates from methylglyoxal.   
 
Methylglyoxal, a 1,2-dicarbonyl compound, is a cytotoxic metabolite produced 
during glycolysis that can react with cysteine, lysine and arginine residues on 
proteins.  This leads to the production of advanced glycation end products 
(AGEs).  The cytotoxicity of this compound was assessed by Weigel (2004) using 
HepG2 and HT29 cell lines.  Concentrations for 50% inhibition of cell growth, as 
measured by neutral red assay were 1.5 mmol/l for HepG2 and 0.9 mmol/l for 
HT29.   
 
Methylglyoxal, as a synthetic compound, has been found to have antiviral activity 
against Newcastle disease and influenza (Tiffany et al., 1957) as well as foot and 
mouth disease (Ghizatullina, 1976), which are all caused by RNA viral infections.   
 
With influenza a 2 mmol/l methylglyoxal solution was found to lower the 50% 
tissue culture infectious dose (TCID 50) levels to negative values after 5 hours at 
37°C in vitro (Tiffany et al., 1957). 
 
In the case of the foot and mouth disease virus (FMDV), the rate of inactivation of 
the virus was dependent upon drug concentration, incubation temperature, and the 
pH of the medium (Ghizatullina, 1976).  It was shown that treatment of the viral 
suspension with 0.1% (16.25 mM) methylglyoxal, at pH 7.6 at 23°C for 5 hours, 
resulted in complete inactivation of the virus shown by the reduction in TCID 50 
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levels with the methylglyoxal treatment.  It appeared that the effect of 
methylglyoxal on the virus increased with temperature: a concentration of 0.1% at 
pH 7.6 caused inactivation of the virus within 3 hours at 37°C and within 5 hours 
at 23°C.  It has been reported that methylglyoxal interacts with nucleic acid, 
specifically guanosine in nucleic acid, producing modified RNA (Staehelin, 
1959).  Egyud and Szent-Gyogyi (1966) showed that the reaction of 
methylglyoxal with nucleic acids was reversible thus in the Ghizatullina study the 
treated viral preparations were observed for increases in viral titre or other signs 
of re-activation, no such re-activation was observed.  The infectiousness of RNA 
isolated from methylglyoxal-treated and untreated virus was examined and it was 
found that RNA treated with methylglyoxal was not infectious on subcutaneous 
inoculation of white mice (Ghizatullina, 1976).   
 
Methylglyoxal has been reported to inhibit TNF-induced Nuclear Factor Kappa-B 
(NFκB) p65 activation and NFκB-dependent reporter gene expression, by 
inhibiting the DNA binding capacity of NFκB p65 (Laga et al., 2007).  This 
suggests that methylglyoxal can provide an additional control mechanism for 
modulating the expression of NFκB- responsive genes and that it may be 
responsible for inducing TNF-induced cell death in cells with NFκB activation.  
This maybe important in relation to the effect honey may have with inhibition of 
viral activity.  It is possible that methylglyoxal present in the honey suppresses the 
viruses’ ability to induce the transcription of genes important for its own 
replication and survival and so prevents viral activity. 
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A number of viral proteins activate NFκB as part of their life cycle due to NFκB’s 
anti-apoptotic activity, in order to prolong cell survival so as to maximise viral 
replication (Gilmore & Mosialos, 2003).  In other cases, activation of NFκB may 
be part of the host’s response to viral infection due to the role NFκB has in 
regulating genes of the innate immune response, which is achieved partially by 
NFκB-activated cytokine genes.  
 
1.3 AIMS OF THIS THESIS 
The hypothesis of this study is that honey has antiviral activity against Adenovirus 
and Herpes simplex virus.   
 
This study aims to confirm honey’s antiviral activity and to compare different 
types of honey for their antiviral activity.  By comparing the effects of honey on 
two DNA viruses that differ in structural characteristics it is aimed to evaluate the 
similarities and differences in the action of honey on these.  This should identify 
whether it is likely that honey’s action could be applied to treat other DNA 
viruses.  A further aim is to begin characterising honey’s antiviral activity via 
protein detection after treatment of the virus with and without honey. 
 
This thesis is intended to determine primarily, whether honey can provide 
protection from viral infection, prevent the spread of infection from infected to 
healthy cells, and neutralise each virus.  Also to be examined is whether 
methylglyoxal, present more greatly in some honeys, is contributing to or is 
responsible for the observed antiviral effects.   
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The study aims to provide a better understanding of the scope of honey’s antiviral 
activity and uncover the groundwork of this activity. 
 
Cultures of the susceptible human cell line A549 (lung epithelial cells) will be 
used as an in vitro model to observe any viral infection as morphological changes 
that have occurred to the cells caused by the virus known as cytopathic effect 
(CPE).  The experiments are to be carried using a range of honey concentrations 
to treat each virus and include controls to detect changes that occur to the cells 
after treatment with virus in the absence of honey and without virus at each of the 
honey concentrations.  The developing CPE is observed using phase contrast 
microscopy.  By detecting for changes to viral proteins the successful cell based 
experiments can be confirmed using immunochemical techniques, leading to a 
better understanding of the mechanism behind the antiviral activity.  
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Chapter 2   
Viruses studied in this thesis 
____________________________________________ 
This chapter reviews characteristics of the two viruses studied in this thesis, and 
explains why these viruses were chosen for this study.  It gives some detail of the 
structure, entry, and replication cycle, and outlines epidemiology as well as 
current treatment. 
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Both Adenovirus and Herpes simplex cause in addition to systemic infection, 
localised infections which are amenable to treatment with honey, and when used 
at a pharmacological level this could ensure effective treatment for such ailments. 
 
Where sources are not cited, the information in this chapter came from Fields 
Virology (2007). 
 
2.1 ADENOVIRUS 
2.1.1 Introduction and history 
Adenoviruses (Ad) were first isolated and characterised in 1953 by two groups 
searching for etiologic agents of acute respiratory infections (Hilleman & Werner, 
1954; Rowe et al., 1953).  The two isolated viruses were found to be related, and 
were named adenovirus after the tissue in which the prototype viral strain was 
identified (adenoid tissue) (Enders et al., 1956).  It was soon found after 
adenovirus was first cultured that multiple serotypes of these agents existed, and 
that they were antigenically related, by a group-specific complementation fixation 
antigen.  A nomenclature for adenoviruses was adopted in 1956, then 
adenoviruses were reclassified in 1999 (van Regenmortel et al., 2000).  
Adenoviridae is the accepted family name, and there are four accepted genera: 
Mastadenovirus, from mammals; Aviadenovirus, from birds; and Atadenovirus 
and Siadenovirus, from a broad range of hosts (Davison et al., 2003; van 
Regenmortel et al., 2000).  Human adenoviruses are split into six species, named 
A through F.  Fifty-one human serotypes have been identified on the basis of their 
resistance to neutralisation by antisera to other known human adenoviruses (De 
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Jong et al., 1999; Hierholzer et al., 1991), and are classified into these six species 
(Regenmortal, 2000) based on their ability to agglutinate red blood cells (Rosen, 
1960).   
 
The variety of adenoviruses can cause a wide range of common and sporadic 
infections, and there is no strict one-to-one relationship between the serotype and 
disease as seen in Table 2.1.  
 
Table 2.1 Classification of human Adenoviruses 
Subgroup/Species Serotype Tropism 
A 12, 18, 31 - 
B1 3, 7, 16, 21, 50 Respiratory and Ocular  
B2 11, 14, 34, 35 Renal 
C 1, 2, 5, 6 Respiratory and ocular 
D 8, 9, 10, 13, 17, 19, 20, 22, 23, 24, 
25, 26, 27, 28, 29, 30, 32, 33, 36, 
37, 38, 39, 42, 43, 45, 46, 47, 48, 
49, 51 
Ocular and other 
(hepatitis, pneumonia, 
encephalitis) 
E 4 Respiratory 
F 40, 41 Intestinal 
 
 
Traditionally, laboratory diagnosis has involved use of cell culture to identify 
adenoviral infection, through the development of a characteristic CPE.  The cells 
swell up, detach from the culture surface into grapelike clusters, and the nuclei 
become enlarged (Kasel, 1979). Eventually the cells lyse, leaving cell debris.  
This CPE is a result of the infection passing into the late stage of infection, when 
adenoviral DNA, messenger RNA (mRNA), and protein are being made in large 
quantities and virions are assembling in the cell nucleus.  The time from infection 
until CPE is present is dependent upon the amount of adenovirus present in the 
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inoculating specimen: the CPE can be seen in as little as one day and after periods 
as long as 14 days. More rapid approaches to diagnosis can be made using 
immunomicroscopy of adenovirus antigens in tissue samples.  And more recently, 
assays based on the polymerase chain reaction (PCR) are of high specificity and 
sensitivity can be used clinically (Pehler-Harrington et al., 2004). 
 
2.1.2 Structure 
Adenoviruses are non-enveloped, icosahedral particles, approximately 90 nm in 
diameter, with fiber proteins projecting from the vertices of the icosahedrons, the 
capsid (protein shell) surrounds the DNA containing core.   
 
2.1.3 Adenovirus genomes  
The human adenovirus genomes contain five early transcription units (E1A, E1B, 
E2, E3, and E4), three delayed early transcription units (IX, Iva2 and E2 late) and 
one late transcription unit that is processed to generate five families of late mRNA 
(L1 to L5), all of which are transcribed by RNA polymerase II (Pettersson & 
Roberts, 1986). 
 
2.1.4 Entry into the host 
Adenoviruses enter susceptible hosts either via the mouth, the nasopharynx, or the 
ocular conjunctiva.  The cell protein CAR (coxsackie-adenovirus receptor) is a 
receptor shared by two groups of unrelated viruses, is the target of the fiber 
protein in many, if not all, adenovirus serotypes in species A, C, D, E, and F 
(Bergelson et al., 1997; Roelvink et al., 1998).  The cell protein CD46 is a cellular 
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receptor for all species B adenoviruses except Ad3 and 7 (Gustafsson et al., 2006; 
Marttila et al., 2005), Ad3 has been shown to use cell protein CD80 and CD86 as 
cellular attachment receptors (Short et al., 2004).  Three species D adenoviruses 
including Ad8 appear to bind to sialic acid rather than a cell surface protein 
(Arnberg et al., 2000).   
 
Several integrins participate in adenovirus uptake into the cells, by interacting 
with the RGD motif on the adenovirus penton base protein (Zhang & Bergelson, 
2005).  The penton base binds to integrin types avβ3- and avβ5- that are abundant 
on most epithelial cells (Wickman et al., 1993).  This interaction leads to 
detachment of fibers, allowing a fiber-free virion to be endocytosed (Nakano et 
al., 2000).  Li (1998b) showed the clustering of intergrins induced by the penton 
base-integrin interaction that are activated by these transmembrane receptors, lead 
to induction of phosphatidylinositol-3-OH kinase (PI3K).  Li (1998a) also showed 
that once activated, PI3K induces Rac, Cdc42, and RhoA, stimulating 
rearrangements of the local actin cytoskeletal network to promote endocytosis of 
the virion into clathrin-coated vesicles (Guilfoyle & Weinmann, 1981; Varga et 
al., 1991).  Clatherin-coated vesicles mature into endosomes, and subviral 
particles free of fibers escape from endosomes into the cytosol (Greber et al., 
1996).  During this time virion surface polypeptides dissociate, and the 
intracellular reducing environment causes reactivation of the virion-associated 
viral protease and cleavage of protein VI that links the viral core to the capsid.  
This is necessary for the final disassembly of subvirion particles at the nuclear 
pore complexes and DNA import into the nucleus (Greber et al., 1996).  
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2.1.5 Activation of early viral genes  
E1A is the first transcriptional unit to be expressed after the viral chromosome 
reaches the nucleus (Moran et al., 1986).  E1A proteins influence transcription by 
binding to a variety of cellular transcription factors and regulatory proteins.  The 
large E1A protein is primarily responsible for activating transcription from early 
viral promoters (Montell et al., 1984; Montell et al., 1982; Moran et al., 1986; 
Ricciardi et al., 1981; Winberg & Shenk, 1984), and the small E1A protein 
activates transcription from the E2 early promoter specifically (Bagchi et al., 
1990; Kitajewski et al., 1986).  Figure 2.1 illustrates the order of transcription. 
 
Figure 2.1 Transcriptional map of Adenovirus 
From: Clonetech (2008) 
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2.1.6 Activation of the host cell  
Adenovirus activates the host cell to gain an optimal environment for virus 
production by inducing quiescent cells to enter the S phase of growth by the E1A 
proteins.  Open reading frames (orf) E4orf1 and E4orf4 function cooperatively to 
activate mTOR (protein kinase, mammalian target of rapamycin), leading to a 
high rate of protein synthesis in the absence of mitogens and nutrients, conditions 
which would otherwise greatly suppress translation in uninfected cells (O'Shea et 
al., 2005).  Functions also exist to inhibit apoptosis, for example, to suppress the 
level and activity of tumour suppressor p53, a transcription factor that activates 
genes leading to cell cycle arrest or apoptosis, is activated in response to abnormal 
stimulation of cell cycling, including the activation via E1A proteins (Debbas & 
White, 1993; Lowe & Ruley, 1993).  p53, E1B-55K, and an additional protein 
encoded in E4 (E4orf6) associate with each other (Sarnow et al., 1984), and a 
number of cellular proteins, to form an ubiquitin ligase complex that binds p53 
and directs its polyubiquination (Harada et al., 2002; Querido et al., 2001), this 
results in proteosomal degradation of p53 (Boyer & Ketner, 2000; Cathomen & 
Weitzman, 2000; Querido et al., 1997; Roth et al., 1998; Steegenga et al., 1998).  
By studying E4 mutants, it has been revealed that adenovirus inhibits the cellular 
DNA damage response (Carson et al., 2003).   
 
2.1.7 Viral DNA replication  
As the E2 proteins accumulate in response to transcriptional activation of the E2 
early promoter, by the large E1A (Berk et al., 1979; Jones & Shenk, 1979), and 
stimulation of E2F transcription factor binding by E4orf6/7 (Bagchi et al., 1990), 
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(Cress & Nevins, 1994; Marton et al., 1990; Obert et al., 1994), viral DNA 
replication can now commence, and continues until the host cell dies.   
 
In vivo studies suggest that DNA replication takes place in two stages (Lechner & 
Kelly, 1977).  Adenoviral late genes are expressed efficiently at the onset of viral 
DNA replication, where poly (A) site utilisation and splicing generate at least 
twenty unique mRNAs (Evans et al., 1977; Nevins & Darnell, 1978).  These are 
grouped based on the use of common poly (A) addition sites into L1 to L5 (Shenk, 
2001).  This large family of late mRNA is expressed via the major late promoter 
(MLP), which becomes more active compared with early activity after initial 
infection, as the DNA level increases (Shaw & Ziff, 1980).  Cellular mRNA is 
blocked as DNA replication begins and when all the late mRNAs are synthesised 
(Beltz & Flint, 1979), and in addition to their facilitated transport from the 
nucleus, viral mRNAs are preferentially translated when they reach the cytoplasm 
(Cuesta et al., 2000).   
 
2.1.8 Viral assembly and release from the cell 
Mutations in a variety of viral genes can interfere with the assembly of virions.  A 
number of systems exist that allow release of viral progeny, one mechanism leads 
the cell to more likely suffer from lysis, another mechanism involves an E3 11.6 
kd protein, which kills cells as it accumulates during the late stage of infection 
(Tollefson et al., 1996).  Further, free fiber trimers that interfere with CAR 
oligomerisation at the tight junctions of epithelial cells could promote the release 
of progeny to the airway in the respiratory tract (Walters et al., 2002).   
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2.1.9 Interactions with the host 
Adenovirus can maintain a long-term association with its human host, persisting 
for years after the initial infection.  Adenoviruses encode several proteins that can 
facilitate both initial primary infection and persistence by antagonising the 
antiviral responses of the host: E1A proteins and VA RNA repress the cellular 
response to interferon (IFN)-α and -β; VA RNA can in addition, repress the RNA 
interference process; and E3 coded proteins protect infected cells from destruction 
by cytotoxic lymphocytes, and apoptosis inducing cytokines. 
 
2.1.10  Immune response 
The virus must survive both immune and chemical defences of the host.  
Defensins are cationic peptides of 3 to 4.5 kd: some have been reported to inhibit 
replication of some adenovirus serotypes in cell culture (Harvey et al., 2005; 
Nazir & Metcalf, 2005).  Cellular defences include alveolar macrophages and 
Kupffer cells which can eliminate virus from the lung and liver respectively in 
murine models (Liu & Muruve, 2003; Nazir & Metcalf, 2005).  These cells can 
take up vectors quickly and release inflammatory cytokines such as TNFα, IL-6 
and Il-8.  Increased levels of TNFα, IL-6 and 8 have also been found in 
adenovirus infection of children (Mistchenko et al., 1994).  Adenovirus infection 
of cultured respiratory epithelial cells activates NFκB and mitogen-activated 
protein kinase pathways (Palmer et al., 2005).  Stimulation of type 1 interferons α 
and β is part of the innate immune response to adenoviral infection.  Adenovirus 
however can overcome these via at least two mechanisms as stated previously.   
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2.1.11  Other E3 protein functions  
E3-14.7K can bind to FIP-1, -2, and -3 (Carter & Roizman, 1996).  Li (2005) 
showed that FIP is identical to NEMO, a subunit of the IΚB kinase complex 
(IKK) that regulates the NFκB transcription factor that is critical to immune cell 
function.  Action of E3-14.7K with NEMO may contribute to the block in 
activation of NFκB induced by E3 functions (Friedman & Horwitz, 2002).  It is 
stated that this may be the mechanism by which E3 functions to repress TNFα 
induced expression of chemokines that are chemotactic for leukocytes (Lesokhin 
et al., 2002).  It is interesting that the E3 promoter includes NFκB binding sites 
and that NFκB is a potent inducer of E3 expression in T lymphocytes (Mahr et al., 
2003; Windheim et al., 2004).  This may result in a negative feedback loop 
whereby activation of NFκB in acutely and latently infected lymphocytes, results 
in activation of E3 functions that in turn repress NFκB, keeping NFκB activity at 
a low level in the face of cellular responses that normally activate NFκB. 
 
As noted in Chapter One (see Section 1.2), methylglyoxal can inhibit TNF- 
induced NFκB p65 activation and NFκB-dependent reporter gene expression, by 
inhibiting the DNA binding capacity of NFκB p65.  The E3 proteins function in 
part to regulate the expression of NFκB as stated above, it is possible that 
methylglyoxal disrupts these mechanisms and subsequently reduces the activity of 
the virus.  
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2.1.12  Epidemiology 
Adenoviral infections are present worldwide in humans as well as in some 
animals.  The transmission of adenovirus infection can differ from sporadic to 
epidemic where the pattern often correlates with the viral serotype and the age of 
children or adults of the susceptible population.   
 
A survey undertaken in Manchester, United Kingdom, indicated that 61.3% of 
patients with adenovirus infections were under the age of five, 24.2% were adults, 
and 5.6% were children aged between 5 and 18 years (Cooper et al., 2000).  The 
most prevalent serotypes were Ad2 (18.6%), Ad3 (14.9%), Ad1 (12.1%) and 
Ad41 (10.9%).   
 
Serological investigations have given some estimates of prevalence of adenovirus 
infection in various populations.  Antibodies to Ad1, 2 and 5 are most common 
and present in 40% to 60% of children and the presence of antibodies to Ad3, 4, 
and 7 was found to be much lower at the same ages (Badger et al., 1956; Brandt et 
al., 1969; Huebner et al., 1954).  This would explain the greater susceptibility to 
serotypes Ad3, 4, and 7.  It was also found that only about 75% of adenovirus 
infections were accompanied by an antibody response, as measured in a 
complement fixation (CF) test (Fox et al., 1969).  This could have been related to 
the insensitivity of the CF test or the lack of antibody production by some 
children.   
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2.1.13  Treatment 
Cidofovir is a potent, non-toxic inhibitor of adenovirus replication in cell culture 
(Kinchington et al., 2005; Naesens et al., 2005).  It is one of a group of drugs 
known as acrylic nucleoside phosphonates which are effective against a range of 
viruses (De Clercq & Holy, 2005).  Cidofovir is an analogue if 2’,3’-
dideoxycytosine.  As it is already exists as monophosphate, it does not require a 
viral enzyme, such as thymidine kinase, required to phospohorylate acyclovir, and 
cidovovir can be converted to the di- and triphosphate forms by cellular enzymes.  
Such compounds have a much higher affinity for DNA polymerase and so act as 
DNA synthesis chain terminators (De Clercq & Holy, 2005).   
 
The use of cidofovir against adenoviral ocular infections of humans was tested in 
a trial in the United States where it was shown that cidofovir was an efficient 
treatment.  However, the trial was discontinued due to the narrow efficacy-to-
toxicity ratio as well as associated rare cases of lachrymal canalicular blockade 
with off label use at higher doses for greater than one week (Kinchington, et al., 
2005).   Additionally, the finding of resistant adenovirus isolates to cidofovir 
raised concerns of the possible emergence of clinical resistance following 
widespread usage (Kinchington, et al., 2005).    
 
2.2 HERPES SIMPLEX VIRUS 
2.2.1 Introduction and history 
Herpes simplex virus (HSV) was recognised as an infectious agent from the last 
quarter of the 19
th
 century (from 1875), and was the first human virus to be 
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discovered.  They are also one of the most commonly studied human viruses due 
to their ability to cause a range of infections, remain latent in their host, and 
reactivate to cause lesions at or near the initial site of infection.  The clinical 
symptoms of primary HSV-1 infections varies greatly: infection can be 
asymptomatic, or, result in a combination of fever, sore throat, ulcerative and 
vesicular lesions, gingivostomatitis, odema, localised lymphadenopathy, anorexia, 
and malaise.  The onset of recurrent orolabial lesions is distinguished by pain, 
burning, tingling, or itching, which lasts for usually 6 hours before a vesicle 
begins to form.  The total area of involvement is usually localised where there 
may be three to five vesicles.  Within 72 to 96 hours, lesions progress to pustular 
or ulcerative, crusting stages.  Viral infections of the eye are usually caused by 
HSV-1 (Binder, 1977; Ostler, 1977; Scott, 1957).  Recurrent infections are 
common, and parallel that of herpes labialis infection.  Infections can also occur 
in the skin. 
 
Prior to viral DNA and amino acid sequencing, members of the Herpesviridae 
family were classified into three subfamilies (Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae) based on biological properties 
(Roizman et al., 1981).  Now the viruses have been further classified into genera 
based on DNA sequence similarity, similarities in genome sequence arrangement, 
and relatedness of important viral proteins shown by immunological methods.     
The members of the Alphaherpesvirinae subfamily were classified on the basis of 
a variable host range, reasonably short reproductive cycle, rapid spread in cell 
culture, efficient destruction of the host cells, and the capacity to develop latent 
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infections primarily in sensory ganglia.  This subfamily contains the genus 
Simplexvirus.   
 
Herpesviruses are widely distributed in nature and most animal species are 
susceptible to at least one herpesvirus.  The following herpesviruses, that have 
humans as their primary host, have been identified as: herpes simplex virus 1 
(HSV-1); herpes simplex virus 2 (HSV-2); human cytomegalovirus (HCMV); 
varicella-zoster virus (VZV); Epstein-Barr virus (EBV); and Human 
herpesviruses 6, 7 and 8 (HHV-6, HHV-7, and HHV-8). 
 
HSV like Ad is grown in cell culture where a characteristic CPE can be observed 
within 24 hours depending on the level of virus in the original inoculum.  CPE is 
presented as ballooned cells that over the course of infection can destroy the 
monolayer of cells.  Immunohistochemical techniques can also be used to identify 
viral infection of cells as well as PCR and more recently like Ad, real time PCR as 
diagnostic tools to identify the virus. 
 
2.2.2 Structure  
The herpes virion consists of four parts: an electronopaque core containing viral 
DNA; an icosahedral capsid surrounding the core; a largely unstructured 
proteinaceous layer known as tegument that surrounds the capsid; and an outer 
lipid bilayer envelope exhibiting spikes on the surface (Roizman & Furlong, 
1974).   
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Mature herpes virions can vary in size from 120 nm to as large as 260 nm 
(Roizman & Furlong, 1974).  The core contains a double stranded DNA (dsDNA) 
genome wrapped as a toroid (Furlong et al., 1972) or as shown by Zhou (1999) as 
a spool, in a liquid crystalline state (Booy et al., 1991).  Zhou (1999) further 
showed that the tegument is largely unstructured, apart from some icosahedral 
structure around the pentons and is made up of at least 20 viral proteins.  The 
most common of the proteins associated with the tegument are the viral protein 
(VP) VP16 virion transactivator protein (also known as α-trans-inducing factor 
(αTIF)), the virion host shut off (VHS) protein, VP22, and a very large protein 
(VP1-2) which may play a role in DNA release at the nuclear pore during viral 
entry (Batterson & Roizman, 1983).  One purpose of the tegument is to carry into 
newly infected cells an assortment of already synthesised proteins that can 
immediately begin to manage the host environment, such as shutting down host 
protein synthesis, inhibiting infection-triggered cell defences, and stimulating 
viral gene expression.   
 
Electron microscope studies show that the viral envelope has a typical trilaminar 
appearance (Epstein, 1962).  It is made up of a lipid bilayer with approximately 11 
different viral glycoproteins embedded in it, gB, gC, gD, gE, gG, gH, gI, gL, and 
gM.  The capsid is made up of 162 capsomeres (150 hexons and 12 pentons) and 
the outer shell of the capsid is composed of four viral proteins, VP5, VP26, VP23, 
and VP19C.  It is assumed that HSV gains the envelope lipids from its host: this 
hypothesis is supported by Spear and Roizman (1967).   
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2.2.3 Replicative cycle overview  
To begin infection the virus must attach to the cell surface receptors, to allow 
fusion of the envelope with the plasma membrane.  The de-enveloped tegument-
capsid can then be transported to the nuclear pores where viral DNA is released 
into the nucleus.  Transcription of the viral genome, replication of viral DNA, and 
assembly of the new capsids takes place in the nucleus.  Viral DNA is transcribed 
throughout productive infection through the action of the host RNA polymerase 
II, with the involvement of viral factors at all stages of infection.  Viral gene 
expression is co-ordinately regulated and sequentially ordered in a cascade 
fashion.  The α genes (immediate early) expressed first, are produced in the 
absence of de novo viral replication, the products of which are involved in 
activating the expression of β or delayed early genes.  Many of these gene 
products are involved in DNA replication and include enzymes and DNA binding 
proteins.  The γ genes are then transcribed, and these gene products are largely 
involved in assembly of progeny virions.  Assembly of the virus occurs over 
several stages, after packaging of DNA into preassembled capsids, the filled 
capsid or nucleocapsid matures into a virion and acquires full infectivity by 
budding through the inner lamella of the nuclear membrane.  In fully permissive 
cell culture this takes approximately 18-20 hours. 
 
2.2.4 Entry into the host cell 
Transmission of herpesvirus is dependent upon intimate, personal contact between 
a susceptible individual (seronegative) and someone excreting HSV.  The virus 
must come into contact with mucosal surfaces or abraded skin for infection to be 
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initiated.  Clinical experience would suggest that after primary infection, the 
replication of the virus at the entry portal, mucosa of the oral or genital region, 
results in infection of the sensory nerve endings.  The virus then travels to the 
dorsal root ganglia (Baringer & Swoveland, 1973; Bastian et al., 1972; Stevens & 
Cook, 1974).  The fundamental principle of disease pathogenesis is: the tendency 
of the virus to replicate at the mucosal surface; be transported to dorsal root 
ganglia; and to become latent.  With reactivation, the virus is detected at 
mucocutaneous sites, appearing as skin vesicles or mucosal ulcers.   
 
HSV can enter the host cell via attachment to the cell surface.  This is a reversible 
process and involves the binding of virion gC and gB to glycosaminoglycans 
(GAG) (Herold et al., 1991; Shieh et al., 1992; WuDunn & Spear, 1989).  The 
next step in one pathway involves the interaction of gD with a specific receptor 
and fusion of the envelope with the plasma membrane.  gD can interact with 
nectins, herpes virus mediator (HVEM), and a selected form of 3-O-sulfated 
heparin sulphate (3-OS HS) (Cocchi et al., 2000; Geraghty et al., 1998; 
Montgomery et al., 1996; Shukla et al., 1999; Warner et al., 1998) and together 
with gB, gH, and gL, allow the fusion of the envelope with the plasma membrane 
(Campadelli-Fiume et al., 2000; Spear & Longnecker, 2003).   
 
The translocation of the capsids to the nucleus was found by two studies 
(Miyamoto & Morgan, 1971; Morgan et al., 1968) to not require the dissolution of 
the capsids from the membrane where release of viral DNA takes place through 
some port in the capsids.  Evidence of release at nuclear pores came from studies 
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of a tsB7 mutant (Batterson et al., 1983; Knipe et al., 1981), and several 
laboratory studies show that the capsids are transported from the site of de-
envelopment to the nuclear pore along the microtubular network (Kristenson et 
al., 1986; Sodeik et al., 1997; Topp et al., 1996).   
 
Once viral DNA enters the nucleus, viral transcription, DNA replication, 
encapsidation, and egress take place.  By remodelling the host cell nucleus, the 
virus then has a structurally sound base for efficient viral DNA replication and 
late DNA transcription.   
 
2.2.5 Viral gene expression 
During productive infection, over 80 HSV proteins are expressed. The host RNA 
polymerase II mediates transcription of all viral genes on the viral DNA during 
infection (Alvine et al., 1974; Costanzo et al., 1977), even though viral gene 
products may modify its activity and structure.   
 
Very soon after infection (2-4 hours), the viral α or immediate early (IE) genes are 
expressed.  These genes code for six proteins known as ICP0, ICP4, ICP22, 
ICP27, ICP47 and US1.5.  Although transcription of the α genes requires no 
previous viral protein synthesis, an HSV protein brought in with the virion 
tegument, VP16, stimulates the transcription of the α genes.  Five of the six α 
genes products, including ICP4, ICP0, ICP27, ICP22 and US1.5 stimulate β gene 
expression. Overall, HSV encodes one site-specific transcriptional activator 
(VP16), three proteins whose function is to block cellular silencing machinery 
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(ICP0, US3, US3.5), one sequence-specific repressor (ICP4), and one sequence 
independent transcription factor (ICP4).  HSV infection prevents host 
transcription, RNA splicing and transport, and protein synthesis, to enable the 
transition from cellular to viral gene expression.   Expression of the next subset (β 
genes) requires at least the presence of functional ICP4 but not the onset of viral 
DNA synthesis, and between 4 to 8 hours after infection these β proteins are 
expressed.  These proteins are involved in replication of viral DNA and nucleotide 
metabolism and promote viral DNA replication and the expression of late γ or late 
genes.  Two general groups of β proteins exist.  Β1 genes are expressed within a 
short time after or almost concurrently with the onset of synthesis of α proteins, 
and are exemplified by UL23 encoding thymidine kinase (TK).  Some β genes 
require ICP27 for their expression. The γ or late genes are expressed at peak times 
after viral DNA synthesis has begun, and their expression is enhanced by viral 
DNA synthesis.  They, like the β genes, have been categorised into two groups, γ1, 
early/late, or leaky late, and one called γ2, late, or true late genes.  The typical γ1 
gene (ICP5, glycoproteins B and D, and γ34.5) is expressed relatively early in 
infection and is stimulated a few fold by viral DNA synthesis.  ICP5 is made both 
early and late in infection (major capsid protein).  In contrast, typical γ2 genes 
(UL44, the gene encoding glycoprotein C, UL41, UL36, UL38, and UL11) are 
expressed late in infection and are not expressed in the presence of effective 
concentrations of inhibitors of viral DNA synthesis.  
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2.2.6 Initiation of viral gene expression 
There are at least two sequences of events that take place in the first few minutes 
after infection.  The first, and least well understood, is the activation of calcium 
signalling (Cheshenko et al., 2003), activation of NFκB (Mogensen & Paludan, 
2001; Patel et al., 1998), and induction of the IFN pathway (Mossman et al., 
2001; Nicholl et al., 2000; Preston et al., 2001).  The second sequence of events 
takes place after entry of viral DNA into the nucleus and shapes the outcome of 
infection.  Cellular proteins either with affinity for viral DNA silence it, or 
transcriptional activators attempt to express its genes.  The finding that residues 
537 to 613 of ICP0 are homologous without gaps to those of amino acids 3 to 79 
of CoREST led to evidence that ICP0 plays a direct role in blocking the silencing 
of HSV DNA (Gu et al., 2005; Roizman et al., 2005).  US3 and US3.5 kinases, 
whether newly synthesised or brought into the cells as components of the 
tegument, further enhance the expression of post-α genes by phosphorylating 
histone deacetylase (HDAC) I and II.  The synthesis of ICP8 enables viral DNA 
synthesis and enhances γ gene expression.   
 
2.2.7 Viral DNA Replication 
Once the β proteins are expressed, a number of these proteins localise into the 
nucleus and assemble in DNA replication complexes at pre-replicative sites.   
 
The first steps in HSV DNA replication involve the binding of UL9 protein, and/or 
ICP8, or both, to the origin sequences, where the looping and distortion of the 
origins by UL9 helicase activity unwinds the DNA.  The helicase-primase 
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complex is then recruited to the origin by interactions with UL9, ICP8, or both.  
Leading strand synthesis involves the unwinding of DNA and synthesis of a 
primer by the HSV helicase-primase complex, from which leading strand 
synthesis can be accomplished by the HSV pol-UL42 holoenzyme.  Alternatively, 
primers may be synthesised by cellular polymerase α-primase.  Lagging strand 
synthesis is then accomplished by primer synthesis and pol-UL42 extension of the 
DNA strand.  Seven viral proteins are required for viral DNA replication: viral 
DNA polymerase catalytic subunit (UL30) and its processivity factor (UL42); an 
origin binding protein (UL9); the ICP8 ssDNA binding protein (SSB; UL29); and 
the helicase-primase complex of three proteins, UL5, UL8 and UL52 (Challberg, 
1986; Conley et al., 1981; Purifoy et al., 1977; Wu et al., 1988).  Host cell factors 
are presumed to be involved also but have not been identified largely due to HSV 
DNA replication involving origin-dependent initiation, and synthesis having not 
been achieved in vitro.   
 
2.2.8 Viral assembly and release from the cell 
After the γ capsid proteins are synthesised they are localised into the infected cell 
nucleus where capsid assembly occurs.  Empty shells containing scaffolding are 
assembled first, and the scaffolding is lost on insertion of viral DNA into the 
capsid.  As the DNA is being transferred into the capsid, a head full sensing 
mechanism causes cleavage of the genome at conserved sequences that identify 
genomic termini.  The conserved viral proteins are responsible for causing 
rearrangement of the nuclear lamina that allows for nuclear egress.  There is 
fundamental agreement that herpesviruses can be enveloped at the inner nuclear 
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membrane, and evidence that the nuclear membrane and nuclear lamina must 
undergo extensive modification by at least three viral proteins (US3, PK, UL31, 
and UL34) (Reynolds et al., 2000; Reynolds et al., 2001; Reynolds et al., 2002; 
Simpson-Holley et al., 2004).  The exact mechanism of viral egress from the 
nucleus to the extracellular space is a hotly debated issue.  Three models exist to 
describe virion egress (Epstein, 1962; Stackpole, 1969; Wild et al., 2005).  
 
2.2.9  Interactions with the host  
DNA microarray studies validated by northern blot analysis and real-time PCR 
indicated that a substantial fraction of total mRNA was up or down regulated 
(Esclatine et al., 2004; Taddeo et al., 2002; Taddeo et al., 2003a), and a 
substantial amount of the upregulated mRNA was NFκB dependent.  The 
activation of NFκB occurs at two stages, one early after exposure of virus to cells 
and at a later time.  The major stimulus for NFκB activation at later times is 
activated PKR (Taddeo et al., 2003b).  Also, HSV-1 requires NFκB proteins for 
its replication (Taddeo et al., 2006a).  It has been shown that US11 protein 
expressed early in infection blocks the activation of PKR (Cassady et al., 1998).  
In cells infected with viruses lacking UL11 NFκB was not activated (Taddeo et al., 
2003b).  Likewise NFκB was not activated in PKR -/- cells infected with wildtype 
virus, but was in PKR 
+/+
 cells (Taddeo et al., 2003b).  In murine cell lines lacking 
p50, p65, or both NFκB genes yielded 10 to 30 times less wildtype virus than 
p50
+/+
/p65
+/+
 (Taddeo et al., 2004).  The activation of PKR is a way for HSV-1 to 
ensure that NFκB is induced.  These findings relate to earlier observations that 
cells expressing a dominant negative form of IκB protein yield less virus than 
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wild type cells (Amici et al., 2001; Patel et al., 1998).  This can lead to a general 
question of how NFκB functions in viral replication.  It has been debated that 
NFκB induces antiapoptotic functions (Goodkin et al., 2003; Gregory et al., 
2004).   
 
2.2.10  Reactivation of virus from a latent state 
In humans, latent viral infection is reactivated after local stimuli such as injury to 
tissues innervated by neurons harbouring latent virus, or by systemic stimuli, 
which may reactivate virus simultaneously in neurons of diverse ganglia.  
Evidence shows that the most plausible common denominator is that injury or 
stimulation of cells innervated by dorsal root neurons harbouring latent virus is a 
common trigger of recrudescence of lesions caused by reactivated virus.  At the 
time of reactivation, LAT transcript levels decrease (Spivack & Fraser, 1988) and 
the histones associated with the LAT gene become deacetylated (Amelio et al., 
2006).  At the same time, lytic genes including ICP0 gene become associated with 
acetylated histones (Amelio et al., 2006), and lytic gene transcripts accumulate 
(Devi-Rao et al., 1994; Kosz-Vnenchak et al., 1993).   
 
2.2.11  Epidemiology 
Orolabial herpes simplex virus infection ranges from the more usual mild illness, 
non-discernable in most individuals, to sporadic, severe, and life-threatening 
disease in a few infants, children, and adults.  Much overlap in epidemiology is 
seen between HSV-1 and HSV-2, although they involve transmission via different 
routes and different areas of the body and humans are the sole reservoir for 
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transmission of HSV to other humans.  Due to the latency effect of this virus, over 
half the world’s population has been infected by HSV and so exists the capability 
of transmitting HSV during episodes of productive infection.   
 
Using serological assays, the seroprevalence of HSV-1 and HSV-2 was redefined: 
HSV-1 is more common than HSV-2.  The trigeminal ganglia houses HSV-1 
latent infection, which reactivates, leading to recurrent herpes labialis.  Studies 
accessing the frequency and severity of the immunocompentent host are limited.  
A positive history of recurrent herpes labialis was observed in 38% of 1800 
graduate students (Ship et al., 1960; 1961).  The new lesions occurred at a 
frequency of one per month in 5% of the affected students, and in intervals of 2 – 
11 months in 34%.  Recurrences of one per year or less were found in 61%.   
 
Both HSV-1 and HSV-2 can cause genital herpes.  Antibodies to this virus 
generally do not occur before the age of sexual activity (Adam et al., 1979; 
Schillinger et al., 2004; Xu et al., 2002).  The overall seroprevalence rates of 
HSV-2 in the United States, is about 22%, a 30% increase over the past decade 
(Fleming et al., 1997).  The importance of serological observations is the potential 
for women to reactivate HSV-2 at the time of delivery and transmit infection to 
their children.  Likewise with orolabial lesions, latent infection of the sacral 
ganglia is the largest reservoir for HSV-2, and reactivation leads to recurrent 
HSV-2 infection.  Overall, nearly 90% of patients infected with HSV-2 will have 
one or more recurrences per year, 38% more than six recurrences, and 20% more 
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than ten (Benedetti et al., 1994).  HSV-1 infection recurs less frequently than 
HSV-2 infection (Benedetti et al., 1994; Lafferty et al., 1987).   
 
2.2.12  Prevention and treatment 
Presently the only mechanism for prevention of mucocutaneous HSV infection is 
to avoid contact with infected secretions.  No proven post-exposure antiviral 
therapy or vaccines are presently available. 
 
In the 1970s, virarabine (an adenine analogue) became the first licensed antiviral 
therapeutic treatment for herpes simplex encephalitis and neonatal infections.  
However, virarabine was soon replaced by acyclovir for the treatment of all 
herpesvirus infections.  Now, acyclovir, and its prodrug valacyclovir, as well as 
peneciclovir and famiciclovir, are the most useful and widely used therapeutics 
for the treatment of HSV infections.  Ocular infections are typically treated with 
toptrifluorothymidine, with or without concomitant oral acyclovir, valacyclovir, 
or famiciclovir.  Resistance to these drugs is possible through mutations in the 
thymidine kinase TK gene and HSV DNA polymerase which as a consequence 
causes these treatments to be inactive. 
 
2.3 HOW HONEY COULD BE USED TO TREAT SUCH INFECTIONS 
From the evidence given in Chapter One, indicating the ancient to more recent 
uses of honey, a range of infections can be potentially treated with honey.  This 
can include the common cold, eye infections such as conjunctivitis, as well as 
Herpes coldsores and genital lesions.  As described these viruses cause localised 
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infections, and these are amendable to treatment with an effective level of honey 
that can be maintained through re-application, to ensure efficient treatment. 
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Chapter 3   
Materials and Methods 
____________________________________________ 
This chapter outlines the general materials and methods used throughout this 
study. 
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3.1 MATERIALS 
3.1.1  Honey  
A number of New Zealand honeys were used throughout this investigation:  
Manuka honey which contains high concentrations of methylgyloxal, UMF 
activity, and phenolics, sourced from Summer Glow apiaries, Denis Watson, 
Spirits Bay, and Waikuku; Ling Heather honey which is generally high in 
phenolics sourced from Waikato Honey Products; Rewarewa honey and 
Honeydew honey which both show a high level of antibacterial activity due to 
hydrogen peroxide, and high iron-binding activity sourced from Mossops and 
Tom Penrose Rangiora respectively.  Each was stored at 4°C. 
 
These honeys show a range of antibacterial and antioxidant activity levels (see 
Chapter 4) and were selected to allow comparisons to be made between 
characteristic properties and antiviral activity.   
 
3.1.2  Viral isolates 
Isolates of Ad1, Ad3, Ad8, HSV-1 and HSV-2 were from patients of Waikato 
Hospital, they were samples that had been cultured in the Virology Laboratory 
that had been approved for use in accepted research.  They were obtained as swab 
samples within a cell culture medium.   
 
3.1.3  Cell culture materials 
The A549 cell line (human lung carcinoma epithelial cells) was kindly provided 
by the Waikato Hospital Virology Laboratory.  This cell line was cultured in 
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RPMI 1640 containing Hepes, obtained from Invitrogen.  This culture medium 
was supplemented with foetal calf serum from ICP Biologicals or Invitrogen at 
10% or 1% to make growth or maintenance medium respectively, with the 
following antimicrobials added: gentamycin from Bomac Laboratories Ltd (final 
concentration 50 μg/ml), ampicillin from Roche pharmaceuticals (final 
concentration 50 μg/ml), vancomycin from Eli Lilly (final concentration 50 
μg/ml), and amphotericin B from Gibco (final concentration 5 μg/ml).  
 
3.2 METHODS 
3.2.1 Growth, maintenance, and freezing down of cell line 
Once a confluent monolayer of A549 cells had been attained in a tissue culture 
flask after growth within 10% growth medium at 37°C for a minimum of 24 hours 
based on cell density, the cells were detached from the culture vessel using 1 mM 
trypsin EDTA from Invitrogen (1-3 ml based on the size of the flask) with 
incubation at 37°C for approximately 5-20 minutes.  After detachment of the cells, 
for further growth the cell suspension was diluted 1:3 with growth medium (using 
15 ml for small flasks and 45 ml for large flasks), then distributed appropriately 
into flasks or plates from Greiner Bio-One at an average density of 4.1 x 10
5
 cells 
per ml.  To freeze down the cell line, 2-6 ml of growth medium was added to the 
cell suspension and the cells were distributed into 1.5 ml Eppendorf centrifuge 
tubes then centrifuged for 2 minutes at 6000 rpm.  The cells were re-suspended 
using a pasture pipette in 1 ml 10% foetal calf serum in Dimethyl sulphoxide 
(10% FCS/DMSO), and transferred to 1.5 ml freezing tubes which were frozen at 
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-70°C initially within a cell freezing chamber (surrounded by isopropanol), then 
without a freezing chamber. 
 
3.2.2 Growth, maintenance, and freezing down of viral isolates 
As described in Section 3.2.1 cells were detached from the tissue culture flask and 
supplemented with growth medium. These were distributed in appropriate 
volumes to a number of 10 ml securely capped tubes or 25 ml flasks and were 
incubated overnight at 37°C.  Once the cells were confluent, the medium was 
replaced with maintenance medium and inoculated with 200 µl of the appropriate 
viral isolate from the samples obtained from the Waikato Hospital Virology 
Laboratory.  The cells were further incubated at 37ºC and observed daily for 
characteristic morphological changes caused by the virus (CPE).  Once the level 
of CPE was quite severe (see Chapter 4, Figure 4.6, CPE 3-5) the tubes or flasks 
were frozen at -70°C overnight.  After freezing, the tubes or flasks were thawed at 
room temperature for further lysis of the cells to release viral particles, the 
medium was then removed from the flasks or tubes and re-frozen in a number of 
1.5 ml Eppendorf centrifuge tubes at -70°C for further use. 
 
3.2.3 Determining viral titre 
Tubes of viral stock suspension prepared as described in Section 3.2.2 were 
thawed slowly in the fridge at 4°C.  Once thawed, 100 µl of the stock viral 
solution was serially diluted from 10
-1
 to 10
-9
 in maintenance medium.  Confluent 
A549 cells prepared in 24 well plates were inoculated with 1 ml of 10
-5
-10
-9
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dilutions in triplicate.  The plates of inoculated A549 cells were then incubated at 
37°C and observed daily for development of characteristic CPE. 
 
The dilution of the stock viral suspension that gave CPE in 1/3 of the replicates 
followed by absence of CPE in the sequential dilution was taken as the maximum 
dilution that would lead to infection.  This was termed the TCID as it was the 
minimum concentration of virus required to detect viral CPE, and gave a rough 
indication of the overall concentration of virus present within the stock 
suspension. 
 
3.2.4 Measuring the density of honey 
To determine each type of honey’s density, 5 ml of distilled water was measured 
into a 25 ml measuring cylinder and tared on a balance beam.  Five grams of 
honey at room temperature was added to the cylinder with special care taken not 
to touch the sides of the cylinder with the honey.  The new volume within the 
measuring cylinder was read and recorded.  The densities were expressed as 
grams of honey per ml. 
 
3.2.5 Measuring the antibacterial activity of honey 
The antibacterial activity with and without catalase added to remove activity due 
to hydrogen peroxide, was measured according to the method described by Allen 
et al. (1991).  The activity measured by this method is expressed as the 
concentration of phenol with equivalent antibacterial activity. 
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3.2.6 Measuring the methylglyoxal level of honey 
Methylglyoxal levels were determined by Dr. C. Adams by means of RP-HPLC 
using an indirect orthophenylenediamine (OPD) derivatisation method as 
described in Adams et al. (2008) which was based on the method outlined in 
Weigel et al. (2004) with minor changes to the chromatography.  The 
methylglyoxal levels were given in mg per kg of honey. 
 
3.2.7 Measuring the antioxidant activity of honey 
The antioxidant activity of the honeys was measured by a modification of the 
method of Baltrusaityte (2007) in which the removal of the coloured ABTS 
radical was measured spectrophotmetrically.  The trolox equivalent antioxidant 
capacity (TEAC) values were expressed as mmol trolox per kg of honey.  
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Chapter 4   
Initial experiments and results 
 
____________________________________________ 
This chapter gives the results of the preliminary experiments investigating: the 
characteristic properties of each honey, the development of viral CPE and scoring 
system, viral titre, and the A549 cell line toleration of honey. 
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The first part of this study involved determining the characteristics of each honey 
type to be tested including the: density; total antibacterial activity; non-peroxide 
antibacterial activity; methylglyoxal levels; and antioxidant capacity.  It also 
involved the culture of each viral isolate within the A549 cell line, followed by 
development of a CPE scoring system on which to base measurement of future 
observations of viral infection.  This preliminary investigation further included 
finding the concentrations of each honey that could be tolerated by the cells in 
culture. 
 
4.1 GROWTH OF VIRAL ISOLATES AND CYTOPATHIC EFFECT 
SCORING 
4.1.1 Introduction  
To detect the presence of viral infection, the susceptible A549 cell line was used 
as it clearly exhibits the development of characteristic CPE.  By examining viral 
CPE observations are inexpensive as they can be made visually using phase 
contrast microscopy.  The CPE can be qualitatively measured by comparing 
visually the level of infection against a specifically developed CPE scoring 
system.   
 
Thus, after the cell line had been successfully grown, each viral isolate was 
cultured to establish viral stocks, determine an approximate time period from 
point of infection until viral infection was apparent at a moderate level in the form 
of CPE, and to establish a scoring system and viral titre. 
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4.1.2 Methods 
As outlined in Section 3.2.2 A549 cells were cultured in tubes and flasks which 
once confluent were inoculated with virus.  The inoculated cells were further 
incubated at 37°C and observed daily for CPE development. 
 
4.1.3 Results 
The results of CPE development of each viral isolate are shown in Figures 4.1 to 
4.5.  The results for the CPE scoring system are shown in Figure 4.6 where the 
score is outlined with each illustration.   
 
CPE development was observed for a number of days until a moderate to high 
level was obtained with each viral isolate. 
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Figure 4.1 CPE resulting from infection of A549 cells with Ad1: (a) cultured in 
tubes, and (b) cultured in flasks 
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Figure 4.2 CPE resulting from infection of A549 cells with Ad3: (a) cultured in 
tubes, and (b) cultured in flasks 
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Figure 4.3 CPE resulting from infection of A549 cells with Ad8: (a) cultured in 
tubes, and (b) cultured in flasks 
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Figure 4.4 CPE resulting from infection of A549 cells with HSV-1 cultured in 
tubes 
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Figure 4.5 CPE resulting from infection of A549 cells with HSV-2 cultured in 
tubes 
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With HSV-1 and HSV-2 a CPE score of 3 was obtained by 24 hours after 
infection using A549 cells cultured in flasks.  No further observations were made 
as a moderate level has been attained within a short period. 
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Figure 4.6 CPE scoring system of: (a) Adenovirus, and (b) Herpes simplex virus 
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(b) Herpes simplex virus 
 
      
     
                     
 
 
 
 
CPE 1 CPE 2 
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4.1.4 Discussion 
4.3.4.1 Evaluation of viral culture using A549 cells grown in tubes 
Figures 4.1 to 4.3 show the CPE development of the adenoviral isolates.  With 
Ad1 low levels of CPE were recorded over the observation period, more moderate 
levels were obtained with Ad8, and Ad3 in contrast within 3 days had reached a 
high level of CPE as shown by Figure 4.2.  
 
Both Herpes virus strains caused evident infection from an early stage and with 
HSV-2 a characteristic CPE level was seen from the second day of observation.  
HSV-1 CPE was delayed and did not increase to as high a level as seen with 
HSV-2 until day seven.   
 
Due to the delay in the onset of more lucid viral infection with HSV-1 compared 
with HSV-2, the medium of HSV-1 was tested for potential contaminants.  A 
yeast contaminant was identified by the presence of “budding” at 400 times 
magnification and therefore the antifungal agent amphotericin B (final 
concentration 5 μg/ml) was added to the medium.  It is likely that the contaminant 
was present in the viral inoculum, and its presence might explain the delay of viral 
growth.   
 
Once a CPE level of 2-3 was obtained with each virus, the viral medium was 
frozen for further use at -70°C.    
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From these growth plots, preliminary experimental periods were able to be 
estimated for each viral isolate.  It was clear that experiments with adenovirus 
needed to be run for two to seven days, in which evident CPE can be expected 
from day two.  With HSV, experiments need to be run for one to seven days, 
where from days one to two CPE can be expected.  
  
4.3.4.2 Evaluation of viral culture using A549 cells grown in flasks 
Further culture of each viral isolate was required to establish stocks.  The stock 
viral solutions were grown up in flasks containing prepared confluent cells.  A 
1:10 dilution of the original viral inoculum was cultured.  The growth of larger 
volumes of virus enabled greater accuracy in the detection of viral infection as a 
CPE score, and a better approximation of the period after infection to reach such 
levels.   
 
The data showed for Ad1 (Figure 4.1 (b)), that the degree of CPE did not increase 
over the course of infection, where only early levels were observe.  Ad1 would 
require further growth if it was to be used as a test viral sample.   
 
Figure 4.2 showed that Ad3 grew successfully with clearly visible infection 
present from 24 hours after inoculation of the cells which increased to CPE 4 by 
day three.   
 
Ad8 took one day longer to obtain CPE 2 compared with Ad3, however, the level 
of infection increased to CPE 3 by day four (Figure 4.3 (b)).   
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The herpes isolates both reached CPE levels of 3 from 24 hours after infection.  
This observation supports the lack of growth seen previously of HSV-1 being 
likely caused by the presence of a fungal contaminant.   
 
Each of the viral isolates upon satisfying a moderate to high level of CPE (CPE 2-
3) were frozen at -70°C in their flask to allow for freeze-thawing the following 
day.  The freezing then thawing aimed to release further viral particles from the 
cells due to cellular lysis.  Each viral solution was then distributed into smaller 
volumes for storage at -70°C for experimental use.  
 
4.3.4.3 Overall evaluation of viral culture 
From these initial attempts to culture each viral isolate, it was found that each had 
a different growth rate and CPE within the A549 cells.  Owing in addition to the 
limited time span of this study, it was for this reason that, Ad1 was omitted from 
further examination based on its delay in onset of viral infection compared with 
the other adenoviral isolates Ad3 and Ad8.  Viral isolates to be assessed in this 
study that could be tested over the course of one week were more ideal. 
 
4.2 VIRAL TITRE 
4.2.1 Introduction 
To find the titre of each viral isolate, tissue culture infectious doses (TCID) were 
tested for.   
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4.2.2 Methods  
As described in Section 3.2.3 viral stock suspension was thawed and used to 
serially inoculate confluent A549 cells prepared in 24 well plates in triplicate.  
The cells were then incubated at 37°C and observed daily for the development of 
characteristic CPE.   
 
4.2.3 Results 
The results of the CPE scores observed with serial dilutions of each virus are 
shown in Tables 4.1 to 4.5. 
 
Table 4.1 CPE resulting from serially diluted Ad3 at (a) 24 and (b) 48 hours 
after infection 
 
(a) 24 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 1 1 1 1 0 
Replicate 2 1 1 1 0 0 
Replicate 3 1 1 1 1 0 
 
 
(b) 48 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 2 2 2 2 1 
Replicate 2 2 2 2 2 2 
Replicate 3 2 2 2 2 1 
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Table 4.2 CPE resulting from serially diluted Ad8 at (a) 24, (b) 48, and (c) 72 
hours after infection 
 
 
(a) 24 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 0 0 0 0 0 
Replicate 2 0 0 0 0 0 
Replicate 3 0 0 0 0 0 
 
 
 
(b) 48 hours post infection 
 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 1 2 1 1 0 
Replicate 2 2 2 1 1 0 
Replicate 3 2 2 1 1 1 
 
 
(c) 72 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 3 2 2 2 1 
Replicate 2 2 3 2 2 1 
Replicate 3 2 2 2 2 2 
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Table 4.3 CPE resulting from serially diluted HSV-1 at (a) 24, (b) 48, and (c) 72 
hours after infection 
 
 
(a) 24 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 1 1 1 1 1 
Replicate 2 1 1 1 1 0 
Replicate 3 1 1 1 1 0 
 
 
(b) 48 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 2 1 1 0 1 
Replicate 2 2 1 1 1 1 
Replicate 3 2 1 1 1 0 
 
 
(c) 72 hours after infection 
Viral Dilution 10-6 10-7 10-8 10-9 10-10 
Replicate 1 2 2 2 1 1 
Replicate 2 3 2 2 2 1 
Replicate 3 3 2 2 2 1 
 
 
 
Table 4.4 CPE resulting from serially diluted HSV-2 at (a) 24 and (b) 48 hours 
after infection  
 
(a) 24 hours after infection 
Viral Dilution 10-5 10-6 10-7 10-8 10-9 
Replicate 1 0 0 0 0 0 
Replicate 2 0 0 0 0 0 
Replicate 3 0 0 0 0 0 
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(b) 48 hours after infection  
Viral Dilution 10-5 10-6 10-7 10-8 10-9 
Replicate 1 3 3 2 2 2 
Replicate 2 3 3 3 2 2 
Replicate 3 3 3 3 2 2 
 
 
 
Table 4.5 CPE resulting from further serially diluted HSV-2 at (a) 24, (b) 48, 
and (c) 72 hours after infection  
 
 
(a) 24 hours after infection 
Viral Dilution 10-8 10-9 10-10 10-11 10-12 
Replicate 1 0 0 0 0 0 
Replicate 2 0 0 0 0 0 
Replicate 3 0 0 0 0 0 
 
 
 
(b) 48 hours after infection 
Viral Dilution 10-8 10-9 10-10 10-11 10-12 
Replicate 1 1 1 0 0 0 
Replicate 2 1 1 1 0 0 
Replicate 3 1 1 1 0 0 
 
 
 
(c) 72 hours after infection 
 
Viral Dilution 10-8 10-9 10-10 10-11 10-12 
Replicate 1 2 1 0 0 0 
Replicate 2 2 1 1 0 0 
Replicate 3 2 1 1 0 0 
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4.2.4 Discussion 
Determining the TCID or viral titre aimed to ascertain suitable dilutions to 
investigate each virus with, in one million or one thousand fold excesses of this 
value.   
 
This was achieved as described in Section 4.2.2 and the TCID was determined as 
the dilution of virus that from which visible viral infection was absent, or the 
dilution that showed substantially less infection across its replicates compared 
with the preceding dilution at 48-72 hours after inoculation of the cells.   
 
The first virus examined was HSV-2.  Serial dilutions from 10
-5
 through 10
-9
 were 
investigated as a gauge of the TCID.  It was shown by this initial experiment that 
with each dilution a CPE 2 score was obtained.  In this case the viral stock needed 
to be further diluted to detect the TCID value, and thus the experiment was 
repeated using dilutions from 10
-8
 to 10
-12
.  It was shown that the 10
-10 
dilution 
was the point from which visible viral infection was undetectable.  Thus the tissue 
infectious dose for HSV-2 was 10
-10 
and
 
indicated a rough viral titre of 10
10
 viral 
particles per ml within the stock solution.   
 
The other three viruses were also tested, using dilutions from 10
-6
 to 10
-10
, their 
results likewise gave TCID values of 10
-10
.   
 
In further experiments each viral isolate was to be tested at one million fold, then 
if unsuccessful one thousand fold excess of 10
-10
, thus at dilutions of 10
-4
 and 10
-7
. 
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4.3 HONEY DENSITY 
4.3.1 Introduction 
To accurately measure out honey for the preparation of different concentrations of 
honey as percentages by volume for the use in further experiments investigating 
antiviral activity, it was necessary to determine the density of each honey so that 
the required volume could be obtained by measuring out an appropriate weight of 
honey. 
 
4.3.2 Methods 
As described in Section 3.2.4, a known volume of distilled water was measured in 
a measuring cylinder and tared on a balance beam.  A specific weight of honey 
was added to the cylinder and the new volume measured and recorded.    
Calculations of the required grams of honey per ml of solution were determined as 
shown in Table 4.6. 
 
4.3.3 Results 
Honey density calculations are shown in Table 4.6. 
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Table 4.6 Honey density calculations 
 
Honey type NV 
(ml) 
NV/OW   
(ml/g) 
NV-OV 
(ml) 
Density  
OW/NV-
OV  
(g/ml) 
Manuka M116, M112, M157, 
M151, M155 
8.5 8.5/5 = 
1.7 
8.5 - 5  
= 3.5 
5/3.5 = 1.4 
Honeydew HD19 8.5 8.5/5  
= 1.7 
8.5 – 5 
 = 3.5 
5/3.5 = 1.4 
Rewarewa R19/06 8.5 8.5/5 
 = 1.7 
8.5 – 5 
 = 3.5 
5/3.5 = 1.4 
Ling Heather LH27 9 9/5 
 = 1.8 
9 - 5  
= 4 
5/4 = 1.2 
 
Key: NV new volume, OV original volume, OW original weight.  
 
 
4.4 INVESTIGATING THE CHARACTERISTIC PROPERTIES OF 
HONEY  
4.4.1 Introduction  
The range of honeys used were chosen to have different characteristics so that 
comparisons could be made between antiviral activity and any particular 
characteristic.  These characteristics were measured for repeatedly over the course 
of this study in case they changed. 
 
4.4.2 Methods 
Using the methods outlined in Chapter 3, Sections 3.2.5 to 3.2.7, the standard 
method for the assay of antibacterial activity of honey, the method described by 
Adams (2008) to measure methylglyoxal levels, and the trolox equivalent 
antioxidant capacity (TEAC) method to detect free radical scavenging activity, 
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were used to detect the total activity and non-peroxide activity, methlyglyoxal and 
antioxidant capacity levels of each honey at 0, 6, and 12 monthly intervals.   
 
4.4.3 Results 
Results are shown in Table 4.7.  
 
Table 4.7 Average activity levels over course of study 
 
Honey TA (w/v) 
phenol % 
NPA (w/v) 
phenol % 
TEAC 
mmol/kg 
MGO 
mg/kg 
M116 28.10 27.25 0.62 1241.70 
M112 23.73 22.02 0.97 772.40 
M157 20.85 20.25 1.27 745.50 
M151/M155 0 0 1.09 116.95 
LH27 19.50 0 1.08 2.45 
R19/06 17.10 0 1.42 25.70 
HD19 15.10 0 1.73 6.80 
 
Key: TA total antibacterial activity, NPA non-peroxide antibacterial activity, 
TEAC trolox equivalent antioxidant capacity, MGO methylglyoxal. 
 
4.4.4 Discussion 
The Manuka honeys have generally high total (the majority of which is non-
peroxide) and non-peroxide antibacterial activity, and methylglyoxal levels.  The 
other honeys generally have lower levels of total antibacterial activity and 
methylglyoxal levels, and do not have non-peroxide antibacterial activity, 
however, they characteristically have high levels of antioxidant capacity.   
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4.5 THE A549 CELL LINE TOLERANCE OF HONEY 
4.5.1 Introduction  
There was a possibility that morphological changes of the cells could be due to the 
highly osmotic nature of honey.  The maximum concentration of each honey that 
was tolerable by the A549 cell line was therefore determined. 
 
In order to detect morphological changes, confluent A549 cells were prepared 
then treated with 0% to 5% concentrations of honey.  Observations were made 
over two days to record any morphological changes of the cells and to allocate a 
specific score so as to monitor the level of change. 
 
4.5.2 Methods 
First and second examinations 
A549 cells were seeded in 24 well plates as described in Section 3.2.1.  Once 
confluent, 0% to 5% honey solutions of the first honeys to be tested were prepared 
in maintenance medium using the densities outlined in Table 4.1, at 1% intervals, 
and then in the next experiment 0% to 3% concentrations at 0.5% intervals, these 
were mixed and filter sterilised.  The cell medium was removed from the cells and 
replaced with 1 ml of these various honey solutions.  Observations were made 
daily to record any changes that occurred to the cells due to the presence of honey 
within the cell culture medium and change was recorded using the scoring system 
outlined in Table 4.8.  The first experiment was done twice in duplicate, and the 
second experiment done once in duplicate. 
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Table 4.8 Morphological scoring system 
 
Morphology Score 
100% dividing, 0% swollen  0 
75% dividing, 25% swollen  1 
50% dividing, 50% swollen 2 
25% dividing, 75% swollen 3 
0% dividing, 100% swollen 4 
All cells dead  5 
 
 
 
4.5.3 Results 
The observed morphological changes of the cells due to the honey solutions are 
shown in Figures 4.7 to 4.8.  Where the duplicates gave identical results one bar 
indicates the level of morphological change.  Table 4.9 summarises the maximum 
concentrations of honey that can be tolerated by the A549 cells. 
 
First examination of the A549 cell line tolerance to honey 
After 1 hour exposure of the cells to the various honey solutions no changes had 
yet occurred.   
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Figure 4.7 Morphological changes caused by each honey treatment at: (a) 24 
hours, (b) 24 hours repeat, (c) 48 hours, and (d) 48 hours repeat 
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(b) 24 hours repeat 
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(c) 48 hours 
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(d) 48 hours repeat 
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Second examination of the A549 cell line tolerance to honey 
Figure 4.8 Morphological changes caused by each honey treatment at: (a) 24 
hours, (b) 48 hours, and (c) 72 hours 
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(b) 48 hours 
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(c) 72 hours 
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Table 4.9 Maximum concentrations of honey that can be tolerated without 
causing morphological changes shown by: (a) the first examination, and (b) the 
second examination 
 
(a) The first examination 
 
Honey Experiment 1  Experiment 2 
M157 2% 2% 
HD19 2% 2% 
R19/06 2% 2% 
LH27 1% 1% 
M151 2% 1% 
A200 2% 2% 
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(b) The second examination 
Honey 
M157 2% 
HD19 2% 
R19/06 2% 
LH27 1.5% 
M151 2% 
A200 2% 
 
 
4.5.4 Conclusion 
The maximum concentration of each honey type that could be used without 
causing any morphological changes in the A549 cells is shown in Table 4.9. 
 
4.5.5 Effect of hydrogen peroxide from honey on the A549 cell line 
In order to eliminate the possibility that hydrogen peroxide (a product of diluted 
honey) was being responsible for the observed effects on cell morphology, an 
experiment was done with and without catalase using Ling Heather honey LH27 
which has the highest antibacterial activity made up of hydrogen peroxide of the 
non-Manuka honeys.   
 
4.3.5.1 Methods 
Confluent A549 cells were prepared as described in Section 3.2.1.  Catalase 
solution was made to 2 mg/ml in distilled water and was filter sterilised.  Honey 
solutions from 0% to 2.5% were prepared at 0.5% intervals in maintenance 
medium, and maintenance medium plus catalase (maintenance medium:catalase 
equal volumes designated by total volume required for the concentration of the 
honey solution), these were mixed and filter sterilised. 
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4.3.5.2 Results  
The results are shown in Figure 4.9. 
 
Figure 4.9 Effect of hydrogen peroxide on cell morphology 24 hours after 
treatment of Ling Heather honey LH27 with or without catalase 
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4.3.5.3 Discussion  
There was no difference recorded in the presence or absence of catalase, therefore 
the previous observations that Ling Heather honey (LH27) caused changes to the 
cells from a concentration of 2% were reconfirmed, and it was shown that 
hydrogen peroxide was not the cause of the morphological changes to the cells. 
 
The level of catalase used in this trial was at the same concentration as used in the 
experiments testing for non-peroxide antibacterial activity.  It was thus a sufficient 
level to mop up any artefact activity due to hydrogen peroxide.  The more 
damaging honeys may be more osmotic or may have cytotoxic components that 
may be responsible for the morphological changes to the cells. 
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Chapter 5   
The antiviral activity of honey: 
Preliminary studies 
 
______________________________________________ 
This chapter describes the first investigations of the antiviral activity of honey. 
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5.1  INTRODUCTION  
In order to evaluate the antiviral activity of honey, a range of methods were used to 
examine different aspects of the hypothesised antiviral effect.  The methods aim to 
investigate the protective, preventative, and neutralisation capacities, with the goal of 
gaining a better understanding of the underlying nature of honey’s antiviral activity. 
 
These primary experiments tried using cell culture and one type of honey to 
investigate the feasibility of methodology, to ascertain methods that were most 
suitable to be used with a range of honey types.   
 
The ability of honey to protect the cells from infection by viruses was evaluated 
through the culturing of confluent A549 cells within honey-containing growth 
medium, followed by removal of this medium for inoculation of the cells with a 
particular viral isolate.  This approach aimed to test whether pre-treatment of the cells 
with honey can prevent the development of viral CPE following inoculation of the 
cells with virus.  Honey was also included into culture medium after inoculation of 
the cells, to test whether continued exposure of the cells to honey gave better 
protection by means of more greatly inhibiting the development of viral CPE.   
 
A positive result obtained in such an investigation can provide support towards the 
use of honey as a preventative treatment for viral infections. 
 
The ability of honey to prevent infection of the cells developing after the initial 
infection with virus was examined through the exposure of the cells to honey after 
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inoculation.  Honey was included in the medium continuously after inoculation, to 
test further whether frequent replacement of honey can allow for even lower levels of 
viral CPE. 
 
This type of investigation can show whether honey can be used as a treatment for 
viral infections once infection has taken place. 
 
The neutralisation effect of honey on viruses was evaluated through the exposure of 
each viral isolate to honey prior to inoculation of prepared A549 cells with the honey-
treated virus.  This experiment can show whether honey could be used as a therapy 
for treating viral infections, as if neutralisation is found to occur with a short period 
of exposure of virus to honey, it may be possible for the virus to be inactivated 
between being shed and infecting other cells. 
 
5.2 PROTECTION OF THE CELLS FROM VIRAL INFECTION 
5.2.1 Protection of the cells from viral infection: by pre-exposure of the cells to 
honey 
The first experiments investigating the protective effects of honey against viral 
infection aimed to evaluate the differences in the consequential levels of viral CPE 
when the cells were infected with viral culture prepared in medium with or without 
honey.  These experiments further examined the influence of washing off the residual 
honey-containing growth medium from the cells prior to inoculation with virus 
compared with only removing the honey-containing growth medium.  The aim of this 
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was to determine whether the remaining traces of honey had an effect on the 
development of viral CPE. 
 
5.2.1.1 Methods 
Growth medium was prepared containing 0%, 0.5%, 1%, and 2% concentrations of 
Manuka honey M157, these were mixed and filter sterilised.  Stocks of A549 cells 
were prepared for seeding into 24 well plates as described in Section 3.2.1.  
Appropriate volumes of the cell suspension in trypsin EDTA were mixed with the 
honey solutions as done in Section 3.2.1 based on the size of the flask of cells.  One 
ml volumes of the cell-honey solutions were distributed into 24 well plates and 
incubated overnight at 37°C until confluent.  The viral inoculum (diluted to 10
-4
) was 
prepared in (1) maintenance medium or (2) honey solutions prepared in maintenance 
medium immediately prior to inoculation of the cells.  The honey-containing growth 
medium was removed and (a) the cells were washed twice with PBS or (b) the cells 
were left un-washed.  The viral inoculum was then used to infect the cells for 1 hour 
at 37°C.  Controls of each honey concentration without virus were also tested.  The 
inoculum was removed and the cells were supplemented with 1 ml of maintenance 
medium.  The plates of cells were incubated at 37°C and observations of the 
development of viral CPE were made daily and a score allocated based on the 
severity using the system outlined in Section 4.1 Figure 4.6.  Each experiment was 
completed in duplicate. 
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5.2.1.2 Results 
The results of the experiments are presented as plots of developing CPE in Figures 
5.1 to 5.10.  The controls of each honey concentration without virus were shown to 
not cause morphological changes of the cells over the observation period.  Where the 
different treatments gave identical results, one graph illustrates the levels of CPE 
observed. 
 
Figure 5.1 CPE from Ad3 after pre-treatment of the cells with honey  
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells, and with the honey just aspirated, not washed off the cells, with 
the viral inoculum prepared in medium without honey. 
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Figure 5.2 CPE from Ad3 after pre-treatment of the cells with honey  
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells, and with the honey just aspirated, not washed off the cells, with 
the viral inoculum prepared in honey solutions. 
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Figure 5.3 CPE from HSV-1 after pre-treatment of the cells with honey (washed off 
and inoculum without honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells and viral inoculum prepared in medium without honey.  
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Figure 5.4 CPE from HSV-1 after pre-treatment of the cells with honey (not 
washed and inoculum without honey)  
A549 cells were pre-treated with various concentrations of honey, with the honey just 
aspirated, not washed off the cells and viral inoculum prepared in medium without 
honey.  
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Figure 5.5 CPE from HSV-1 after pre-treatment of the cells with honey (washed off 
and inoculum with honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells and viral inoculum prepared in honey solutions. 
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Figure 5.6 CPE from HSV-1 after pre-treatment of the cells with honey (not 
washed and inoculum with honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
solution just aspirated, not washed off the cells and viral inoculum prepared in honey 
solutions. 
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Figure 5.7 CPE from HSV-2 after pre-treatment of the cells with honey (washed off 
and inoculum without honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells and viral inoculum prepared in medium without honey. 
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Figure 5.8 CPE from HSV-2 after pre-treatment of the cells with honey (not 
washed and inoculum without honey) 
A549 cells with HSV-2 virus were pre-treated with various concentrations of honey, 
with the honeys just aspirated, not washed off the cells and viral inoculum prepared 
in medium without honey.  
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Figure 5.9 CPE from HSV-2 after pre-treatment of the cells with honey (washed off 
and inoculum with honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
washed off the cells and viral inoculum prepared in honey solutions. 
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Figure 5.10 CPE from HSV-2 after pre-treatment of the cells with honey (not 
washed and inoculum with honey) 
A549 cells were pre-treated with various concentrations of honey, with the honey 
solution just aspirated, not washed off the cells and viral inoculum prepared in honey 
solutions. 
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5.2.1.3 Summary of results 
As shown with each figure, there was a temporal delay observed in the development 
of CPE when the cells had been pre-exposed to honey.  In general the higher 
concentrations of honey reduced the severity of CPE for the longest period. 
 
With Ad3 and HSV-1 there were no differences observed with the resulting CPE 
levels between washing the honey off the cells, or, just removing it without washing, 
prior to inoculation of the cells with virus.  Nor, with Ad3, were there any differences 
in CPE resulting from the preparation of the viral inoculum with or without honey in 
the maintenance medium.  With HSV-2 there were similar observations between the 
washing off of the honey from the cells and just removing it.  However, with the virus 
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prepared in medium containing honey, greater differences were observed between the 
washing off and removing of the honey from the cells, shown by the levels of 
resulting CPE observed unseen with the other experiments.  These observations can 
suggest little effect of the residual honey on the development of CPE.  Likewise, the 
brief exposure of virus to honey in the solutions used to prepare the virus for 
inoculation of the cells made little to no difference to the resulting CPE. 
 
5.2.2 Protection of the cells from viral infection: by continued exposure to 
honey 
Experiments were carried out in which honey was included in the medium after 
inoculation of the cells with virus.  These experiments were done to examine the 
effect of continued exposure of the cells to honey on the development of viral CPE.  
It was expected that if the honey was having a protective effect on the cells then if 
honey was present continuously after inoculation that lower levels of viral CPE 
would be observed compared with the first protection experiments. 
 
5.2.2.1 Methods 
The method used was similar to that described in Section 5.2.1.1  The honey was 
removed from the cells, not washed off, and the viral inoculum (diluted to 10
-4
) was 
prepared in maintenance medium.  The cells however, were incubated with honey-
containing maintenance medium after inoculation with virus, with the honey at the 
same concentrations as used during pre-exposure.  Each experiment was completed in 
duplicate. 
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5.2.2.2 Results 
The results of the experiments are presented as plots of developing CPE in Figure 
5.11.  The controls of each honey concentration without virus were shown to not 
cause morphological changes of the cells over the observation period. 
 
 
 Figure 5.11 CPE from (a) Ad3, (b) HSV-1, and (c) HSV-2 after pre-treatment of 
the cells with honey and continued exposure to honey after inoculation with virus 
A549 cells were pre-treated with various concentrations of honey, and after 
inoculation with virus were continuously exposed to honey at the same 
concentrations as in the pre-treatment. 
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(b) HSV-1 
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5.2.2.3 Summary of results 
As with the first protection experiments a temporal delay was observed with the 
honey treatments, where generally the higher concentrations of honey used the more 
greatly reduced was the severity of the CPE.   
 
It was hypothesised that the honey would have a greater effect against the 
development of a CPE when the cells were continuously exposed to it after the 
inoculation with virus.  However, this was found not to be the case as lower levels of 
CPE were observed only in the Adenovirus experiment as shown in Figure 5.11 (a) in 
which the 2% honey concentration prevented the development of viral CPE. 
 
5.2.3 Protection of the cells from viral infection: by frequent supplement of 
honey 
These experiments which involved frequently replacing the cell medium with fresh 
honey-containing medium aimed to investigate the impact of repetitive re-
supplementation of the cells with honey on the development of CPE.  It was reasoned 
that even lower levels may be observed compared with the previous methodologies, 
as a daily dose of antiviral agent was being used on the cells.  It was thought possible 
that during the observation period antiviral factors in the honey may be destroyed by 
chemical reaction or cellular metabolism.  
 
5.2.3.1 Methods 
The method used was the same as that described in Section 5.2.2.1. The cells 
however, were incubated with honey-containing maintenance medium which was 
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removed each day and replaced with fresh honey-containing maintenance medium, 
the honey was used at the same concentrations as during the pre-exposure. 
 
 
5.2.3.2 Results 
The results are presented in Figure 5.12 as plots of developing CPE.  The controls of 
each honey concentration without virus were shown to not cause morphological 
changes of the cells over the observation period. 
 
Figure 5.12 CPE from (a) Ad3, (b) HSV-1, and (c) HSV-2 after pre-treatment of 
the cells with honey and continued exposure to fresh honey each day  
A549 cells were pre-treated with various concentrations of honey, and after 
inoculation with virus were continuously exposed to honey which was replaced each 
day with fresh honey solution. 
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(b) HSV-1 
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5.2.3.3 Summary of results 
With these experiments, greater suppression of viral CPE was hypothesised to be 
seen. With each virus the observations that were made were similar to those of the 
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first protection experiments, suggesting very little effect from the frequent 
replacement of the medium with fresh honey-containing medium.   
 
5.3 PREVENTION OF VIRAL INFECTION 
These experiments aimed to test whether incubation of the cells with honey can 
prevent the spread of the virus from infected cells to uninfected cells and whether 
frequent replacement of the honey-containing medium would give lower levels of 
viral CPE.  In these experiments the cells were firstly infected with virus before the 
honey was added as part of the medium. 
 
5.3.1 Methods 
A549 cells were seeded into 24 well plates and incubated at 37°C overnight until 
confluent as described in Section 3.2.1.  The virus (diluted to 10
-4
) was prepared in 
maintenance medium.  The growth medium was removed from the cells, and 200 µl 
of viral solution was used to inoculate the cells for 1 hour at 37°C, including controls 
without virus using each of the honey concentrations tested.  The residual inoculum 
was removed from the cells at the conclusion of the inoculation period, and 
maintenance medium containing honey at 0%, 0.5%, 1%, and 2% was added to the 
cells.  Each experiment was completed in duplicate. 
 
Further experiments were done in the same way but with the daily replacement of the 
honey solutions with freshly made ones.   
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5.3.2 Results 
The results are presented in Figures 5.13 and 5.14 as plots of CPE development.  No 
morphological changes of the cells were observed in the controls without virus. 
 
Figure 5.13 CPE from infection of A549 cells with: (a) Ad3, (b) HSV-1, and (c) 
HSV-2, with the cells treated after inoculation with various concentrations of 
honey 
 
(a) Ad3 
0
1
2
3
4
5
1 2 3 4 5
Days after infection
C
P
E
 S
c
o
re
0% honey 0.50% honey 1% honey 2% honey
 
(b) HSV-1 
0
1
2
3
4
5
1 2 3 4 5
Days after infection
C
P
E
 S
c
o
re
0% honey 0.50% honey 1% honey 2% honey
 
 
Chapter Five The antiviral activity of honey: Preliminary studies 
110 
 
 
(c) HSV-2 
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Figure 5.14 CPE from infection of A549 cells with: (a) Ad3, (b) HSV-1, and (c) 
HSV-2, with the cells treated after inoculation with various concentrations of 
honey which were replaced daily with fresh ones 
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(b) HSV-1 
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5.3.3 Discussion 
In these experiments, the honey has been shown to have an effect against the spread 
of virus from infected cells to uninfected cells, as shown by the lower levels of viral 
CPE observed with the honey treatments compared with the untreated virus over the 
course of observation. 
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In the first experiments, treating the cells after inoculation with various 
concentrations of honey, each honey treatment suppressed the severity of viral CPE, 
where the higher concentrations had the greatest effect with each virus.  In the second 
experiments involving frequent replacement of honey-containing medium, with Ad3 
overall higher levels of viral CPE were observed with each treatment compared with 
the first experiments.  Similarly, with HSV-2, the honey treatments had little effect.  
With HSV-1, however, the replacement of the medium with fresh honey solutions 
caused suppression of the virus with honey at a concentration of 2% over the 
observation period.  The other honey treatments had little effect.  
 
5.4  NEUTRALISATION 
By exposing each viral isolate to solutions of honey for a defined period, this aimed 
to test whether honey had a direct effect on the virus.  Neutralisation can be observed 
as the absence of viral CPE after inoculation of the cells with the honey-treated 
viruses. 
 
5.4.1 Methods 
A549 cells were seeded into 24 well plates and incubated overnight at 37°C until 
confluent as described in Section 3.2.1.  Honey at concentrations of 0%, 0.5%, 1%, 
and 2%, and viruses diluted to 10
-6
 (in initial experiments) and to 10
-3 
(in subsequent 
experiments) were prepared in maintenance medium.  One hundred μl of the diluted 
virus (10
-6
 or 10
-3
) was added to 900 μl of honey solution to give an appropriate final 
dilution of the virus at 10
-7
 or 10
-4
, these viral-honey solutions, the 0% honey-viral 
solution and honey solutions without virus serving as controls, were incubated with 
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shaking for 1 hour (in the initial experiments) or 1, 2, 4, 8, 12, 24, or 48 hours (in the 
subsequent experiments) using a shaking incubator at level 3-4 set at 37°C.  At the 
conclusion of the neutralisation period, the growth medium was removed from the 
growing cells, and 200 µl of viral-honey solution was used to inoculate the cells for 1 
hour at 37°C.  The residual viral-honey inoculum was removed from the cells and the 
cells were washed with PBS, the cells were then supplemented with maintenance 
medium.  Observations were made daily to record the development of CPE for up to 
7 days or until a high level of CPE had developed with untreated virus (0% honey-
viral solution).  Each experiment was completed in duplicate. 
 
5.4.2 Results 
The results are presented in Figures 5.15 to 5.23 as plots of the development of viral 
CPE after inoculation of the cells with virus.  Figures 5.15 to 5.18 show the results 
after exposure of the viruses to honey for 1 hour.  Figures 5.19 to 5.23 show the 
results after exposure for longer periods.  With these figures, the results for each 
replicate have been given and each successive bar with each concentration of honey 
indicates a different exposure period of the viruses to honey.  These exposure periods 
are shown above the appropriate bars with the first concentration of honey, to indicate 
which bar corresponds to which period. 
 
In each experiment the honey solutions without virus caused no morphological 
changes to the cells over the course of observation. 
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Figure 5.15 CPE resulting from infection of A549 cells with HSV-2 at a dilution 
of: (a) 10
-7
 and (b) 10
-4
, after 1 hour exposure of the virus to honey 
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Figure 5.16 CPE resulting from infection of A549 cells with HSV-1 at a dilution 
of: (a) 10
-7
 and (b) 10
-4
 after 1 hour exposure of the virus to honey 
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Figure 5.17 CPE resulting from infection of A549 cells with Ad3 at a dilution of: 
(a) 10
-7
 and (b) 10
-4
, after 1 hour exposure of the virus to honey 
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Figure 5.18 CPE resulting from infection of A549 cells with Ad8 at a dilution of: 
(a) 10
-7
 and (b) 10
-4
, after 1 hour exposure of the virus to honey 
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Figure 5.19 CPE resulting from infection of A549 cells with HSV-2 at a dilution of 
10
-4
 after: (a) 1 to 8 hours and (b) 12 to 48 hours exposure of the virus to honey 
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Figure 5.20 CPE resulting from infection of A549 cells with HSV-2 at a dilution of 
10
-4
 after: (a) 1 to 8 hours and (b) 12 hours exposure of the virus to honey 
 
(a) 1 to 8 hours 
 
 
 
 
 
1 2 
4 8 
Chapter Five The antiviral activity of honey: Preliminary studies 
121 
 
 
(b) 12 hours 
 
 
 
 
 
 
 
12 
Chapter Five The antiviral activity of honey: Preliminary studies 
122 
 
 
Figure 5.21 CPE resulting from infection of A549 cells with HSV-1 at a dilution of 
10
-4
 after: (a) 1 to 8 hours and (b) 12 to 48 hours exposure of the virus to honey 
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Figure 5.22 CPE resulting from infection of A549 cells with HSV-1 at a dilution of 
10
-4
 after: (a) 1 to 8 hours and (b) 12 to 48 hours exposure of the virus to honey 
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Figure 5.23 CPE resulting from infection of A549 cells with Ad3 at a dilution of  
10
-4
 after: (a) 1 to 8 hours and (b) 12 to 48 hours exposure of the virus to honey 
 
(a) 1 to 8 hours 
 
 
 
 
 
4 
1 2 
8 
Chapter Five The antiviral activity of honey: Preliminary studies 
127 
 
 
(b) 12 to 48 hours 
 
 
 
 
 
 
 
 
 
 
 
 
12 24 48 
Chapter Five The antiviral activity of honey: Preliminary studies 
128 
 
 
5.4.3 Summary of results 
The neutralisation method was firstly tested with HSV-2 at a dilution of 10
-7
.  These 
experiments indicated that the method was able to show CPE and an effect of honey 
on the level of CPE when compared with the untreated virus.  However, it was shown 
that a low level of CPE was obtained using this dilution of virus even when the virus 
had not been treated with honey.  With the experiments using virus diluted to 10
-4
, a 
higher level of viral CPE was observed, and the honey was shown to temporarily 
suppress the level of CPE compared with the untreated virus.   
 
With HSV-1 and Ad3 it was further seen that the honey temporarily suppressed CPE 
levels compared with the untreated virus.  Ad8 took a longer period post-inoculation 
of the cells to display signs of CPE.  Due to the desire to have the CPE reach a high 
level within a short period and with the difficulty in the culture and recognition of 
Ad8 viral infection, it was decided that Ad8 be excluded from further investigation at 
this stage, if time permitted, Ad8 would be re-cultured and examined at a later time.   
 
As described, the results shown by Figures 5.15 to 5.18 revealed temporal 
suppression of development of viral CPE after treatment of the virus with honey.  To 
establish whether greater neutralisation periods were sufficient to inhibit the 
development of CPE at these honey concentrations, exposure periods of up to 48 
hours were tested with each of the viral isolates using the virus diluted to 10
-4
, this 
was to ensure accurate recognition and development of a high level of CPE with the 
untreated virus which served as a control. 
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In the first extended neutralisation experiment with HSV-2, shown in Figure 5.19, it 
was observed with the viruses untreated with honey that were exposed to longer 
incubation (4 hours or more) that lower levels of CPE were seen compared with the 
shorter incubation treatments when observed the same length of time after inoculation 
of the cells.  With the untreated virus one would expect CPE to be present from 
similar times after inoculation of the cells whatever the period of incubation.  The 
temperature of the shaking incubator was checked and was found to fluctuate to 39°C 
during the course of the neutralisation period, although the thermostat was set to 
37°C.  Despite setting the thermostat 2°C lower, the correct temperature was still not 
attained.  The high temperature during the longer neutralisation periods was likely to 
be inactivating the virus, and this may be able to explain the absence of CPE with 
even the untreated virus, with the long incubation treatments.   
 
The repeat work with HSV-2 shown in Figure 5.20 using a more insulated incubator 
during the neutralisation period gave temporal suppression of the development of 
CPE, and with the longer periods of exposure of the virus to honey there was 
evidence of neutralisation activity.  The 24 and 48 hour neutralisation treatments did 
not show any resultant viral CPE.  However, nor did any CPE develop with the virus 
not exposed to honey.  Therefore even with the correct temperature within the 
incubator there was an effect of prolonged incubation on the virus.   
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Observations of viral CPE after the 1 hour exposure period were very similar to those 
seen in the initial experiments, thus the method was shown to be quite reproducible.  
 
With HSV-1, CPE was observed much later after infection with virus exposed honey 
after the 24 hour neutralisation treatment compared with the shorter treatments.  As 
with HSV-2, no CPE was seen with the 48 hour neutralisation treatment.  With the 
honey treatments, suppression of CPE was observed compared with the untreated 
virus, and as with HSV-2, evidence of neutralisation was seen with the honey 
treatments after longer neutralisation periods.  Again, similar observations were made 
after the 1 hour exposure to honey as within the first examination. 
 
Ad3 with the 1 to 8 hour neutralisation treatments showed the most apparent trends of 
a reduction of CPE related to the concentration of honey and time of exposure to it.  
Again, with the longer neutralisation treatments at higher honey concentrations, 
evidence of neutralisation was observed.  Further, similar suppression of viral CPE 
was observed after the 1 hour exposure period as within the first examination.   
 
In each experiment, suppression of CPE was observed with the honey treatments, and 
further evidence of neutralisation was seen with the longer neutralisation treatments.  
The method produced similar results in both sets of experiments and indicated the 
feasibility to further evaluate honey’s antiviral activity by following the development 
of CPE for 7 days.  The observation from the 12 hour neutralisation treatment and 
longer revealed that less CPE developed after prolonged incubation of the virus with 
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no honey present, therefore further investigations can be done with incubation up to 
only 8 hours.  To further evaluate honey’s neutralisation capacity, the use of higher 
concentrations of honey is desirable.  The osmotic effect on the A549 cells of using 
higher concentrations of honey, however, would need to be overcome. 
 
5.5 DISCUSSION 
The results from this Chapter suggest that honey acts by more than one mode of 
action.  It was observed with the first protection experiments, that there was less CPE 
after pre-treatment of the cells with the higher concentrations of honey compared 
with the untreated virus.  These observations can suggest that the honey has an effect 
on the cells by possibly penetrating the cell and working internally, acting against the 
virus during its replication. The honey may be causing an antiviral response of the 
cells which then works on the virus after infection.  Alternatively, the honey may be 
coating the cellular receptors preventing the virus from attaching to the cell which is 
necessary for viral infection.  The consequent CPE observed after infection could be 
explained by the shedding of the cell membrane which in effect removes the honey 
from the cell.  Further, the toxic nature of honey on the cells may be thought to slow 
cellular growth eliminating the optimal environment for viral infection which is most 
efficient when the cells are actively dividing, this could explain the delay of CPE.  In 
each case, however, it would be expected that the continued exposure to honey, and 
the further daily replacement of the medium with fresh honey solution would cause 
lower levels of CPE to be observed, this was not always the case.   
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The neutralisation experiments were undertaken to test whether the honey had a 
direct effect on the virus by treating the virus with honey in the absence of cells, 
followed by inoculation and observation of CPE development.  The results show that 
the honey treatments temporally suppressed CPE development and in some cases 
prevented CPE from developing over the observation period.  The direct effect of the 
honey on the virus may be being caused by the honey targeting internal or external 
proteins of the viral particle, which causes unsuccessful attachment to, penetration of, 
or replication within the cell.  
 
These two sets of experiments (protection and neutralisation) have shown that the 
honey acts both on the cells and directly on the virus in the absence of the cells.     
 
The results of the prevention of viral infection experiments further propose an effect 
of the honey on the cells and directly on the virus.  These experiments were 
undertaken to evaluate the potential therapeutic benefit of honey as a treatment for 
viral infection once infection has taken place.  As with the other experiments looking 
to test protective and neutralisation capacities of honey, temporal suppression of CPE 
development was observed with the honey treatments most greatly with the 1% and 
2% concentrations.  These effects can be explained by the same theories used to 
describe the protective and neutralisation antiviral activity: the honey may be acting 
on the virus being released from the cell, on cell surface receptors preventing further 
infection, or possibly by causing a cellular antiviral response.   
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With each of these experiments honey has shown an antiviral effect.  Honey can 
potentially be used as an antiviral agent to aid the immune system in response to viral 
infection by adenovirus and herpes simplex virus, by slowing the rate of infection to 
allow the body’s own defences to help eliminate the virus. 
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Chapter 6   
The antiviral activity of honey: 
Neutralisation 
 
____________________________________________ 
This chapter describes the extended investigation of the neutralisation capacity of 
a range of New Zealand honeys on viruses.   
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Neutralisation has been used classically to test drug sensitivity of viruses.  It 
involves directly exposing the virus to various concentrations of the drug of 
interest for specified periods.  The evaluation of sensitivity can be done by 
observing the development of CPE within susceptible cells.   
 
6.1 INTRODUCTION  
It was shown by the preliminary results in Chapter 5 that honey can temporarily 
suppress the development of CPE.  It was desirable to test a range of honeys at 
higher concentrations to determine whether greater suppression or neutralisation 
of the viruses can be achieved, and whether some honeys are more effective than 
others. 
 
These previous experiments used honey up to a concentration of 2% (v/v), as at 
this concentration the cells remain microscopically unaffected by the honey.  In 
these experiments however, higher concentrations of honey were to be 
investigated for their ability to neutralise each virus, as these potentially would 
have a greater effect on the development of viral CPE due to the reduced levels of 
viral CPE associated with the concentration of honey and time of exposure to it 
observed in the earlier experiments.  By using higher concentrations of honey the 
shorter neutralisation periods may give successful results to what was achieved 
with the longer neutralisation periods which used lower concentrations of honey.  
This would help avoid the complication of reduced levels of viral infection with 
the untreated viruses which was observed with some of the >8 hour treatments in 
earlier investigations.   
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To ensure the health of the cells was not jeopardised by the increased honey 
concentration the inoculation period of the cells was reduced, and involved using 
centrifugation to hasten the viral attachment process, rather than allowing the 
attachment to take place over an hour of incubation.  This was to overcome and so 
minimise the osmotic effect the increased concentrations of honey may have had 
on the cells during this inoculation period.   
 
After inoculation the cells were incubated at 37°C for 7 days and daily 
observations were made to detect viral CPE.  Likewise, any presence of osmotic 
effects in both the tests and controls (each honey concentration without virus) 
were looked for over the observation period.  The cells were allocated a numerical 
score for CPE as described in Section 4.1, Figure 4.6.  The honeys tested for 
neutralisation capacity are described in Chapter 3. 
 
The experiments in this chapter aimed to compare the neutralisation capacity of a 
range of New Zealand honeys, to determine concentrations of honey and duration 
of treatment required to eliminate, delay, and/or reduce the severity of CPE 
resulting from infection of the cells with the treated virus.  Further to: determine 
whether honey’s antiviral activity was a found with more than one type of honey; 
and to ascertain a range of treatments suitable for further experiments. 
 
It was hypothesised: that honey from a range of floral sources has neutralisation 
activity against Ad3, HSV-1, and HSV-2 and that there will be differences within 
and between different types of honey in the potency of their antiviral activity; that 
the reduced CPE will be related to the concentration and time of exposure of the 
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virus to the honey; that the honeys (other than Manuka) high in phenolic 
compounds may display similar antiviral activity to Manuka honey; and that the 
observed antiviral activity can be linked to a characteristic property within the 
honey. 
 
6.2 METHODS 
A549 cells were prepared and grown overnight in 24 well plates at 37°C until 
confluent as described in Section 3.2.1.  Bijoux or 1.5 ml Eppendorf tubes were 
prepared by labelling: 0%, 1%, 2%, 2.5%, 5%, 10% (for honey concentration) and 
1, 2, 4, and 8 hour (for neutralisation periods).   
 
Once the cells were confluent, a total volume of 15 ml of stock honey solutions 
were prepared in sterile universals as shown in Table 6.1 (based on honey density 
calculations: see Section 4.3 Table 4.6). 
 
Table 6.1 Dilutions to prepare 15 ml honey solutions 
 
Honey 
Conc. 
(v/v) 
Wt. honey 
(g) most 
honeys 
Vol. medium (ml) 
most honeys 
Wt. honey 
(g) 
for LH27 
Vol. medium (ml) 
for LH27 
0% 0 15 0 15 
1% 0.214 14.785 0.187 14.812 
2% 0.428 14.571 0.375 14.625 
2.5% 0.535 14.464 0.468 14.531 
5% 1.071 13.928 0.937 14.062 
10% 2.142 12.857 1.875 13.125 
 
 
The honey solutions were mixed and filter sterilised then added to the 
appropriately labelled tubes.  Serial dilutions of each viral isolate (Ad3, HSV-1, 
and HSV-2) were prepared in maintenance medium to a dilution of 10
-3
 taking 
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100 µl each time to 900 µl of maintenance medium.  The honey solutions were 
inoculated with 100 µl of viral dilution to make the final dilution of 10
-4
 and 
honey solutions at 9/10 of the stated concentration. The viral-honey solutions 
were then incubated at 37°C with shaking (using the shaking incubator at level 3 
to 4 for 1, 2, 4, or 8 hours depending on treatment).  Upon completion of the 
neutralisation period, the viral-honey solutions were either immediately used to 
inoculate the cells, or were frozen at -70°C for later examination.   
 
To inoculate the cells, the growth medium was removed from the cells and 200 µl 
of the appropriate viral-honey solution was added to the wells in duplicate, this 
included testing each concentration of honey without virus.  The plates were 
centrifuged for 15 minutes at 2000 rpm at 25°C.  After centrifugation, the residual 
viral-honey solution was removed from the cells and replaced with 1 ml of 
maintenance medium.  The plates were incubated at 37°C and observed for the 
development of CPE daily.  Any spare viral/honey solutions were frozen at -70°C 
for use in later experiments testing for virucidal or virustatic activity. 
 
Two experiments for each honey and virus type were done on separate days in 
duplicate to compare consistency of this experimental method. 
 
6.3 RESULTS 
Figures 6.1 to 6.12 show the development of CPE with each virus and Manuka 
honey treatment and Figures 6.13 to 6.21 show CPE development with each virus 
and treatment with other honeys for each of the 1, 2, 4, and 8 hour neutralisation 
periods.  With these figures, the results for each replicate have been given and 
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each successive bar with each concentration of honey indicates a different 
exposure period of the viruses to honey.  These exposure periods are outlined 
above the appropriate bars with the first concentration of honey, to indicate which 
bar corresponds to which period.  The plots are followed by a summary of the 
combinations of treatments that suggested neutralisation had been achieved, by 
the absence of any CPE after inoculation of the cells over the observation period.  
The first column of this table gives details of the type, concentration, and time of 
exposure to the honey.  The average activity levels of each of the honeys tested 
has also been included for comparisons to be made.   
 
The honey solutions without virus in each experiment did not cause any 
morphological changes to the cells over the course of observation, and those 
treatments that did not show any kind of viral CPE at any time during the 
observation period were omitted from graphing. 
Chapter Six The antiviral activity of honey: Neutralisation 
140 
 
 
Figure 6.1 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Manuka honey M116 at various concentrations for 1, 2, 4, or 8 
hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1  
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(b) Experiment 2 
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Figure 6.2 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Manuka honey M116 at various concentrations for 
1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.3 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Manuka honey M116 at various concentrations for 
1, 2, 4, or 8 hours: (a) Experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.4 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Manuka honey M112 at various concentrations for 1, 2, 4, or 8 
hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
 
 
 
 
 
 
 1  2  4  8 
Chapter Six The antiviral activity of honey: Neutralisation 
147 
 
 
(b) Experiment 2 
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Figure 6.5 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Manuka honey M112 at various concentrations for 
1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.6 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Manuka honey M112 at various concentrations for 
1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.7 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Manuka honey M157 at various concentrations for 1, 2, 4, or 8 
hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.8 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Manuka honey M157 at various concentrations for 
1, 2, 4, or 8 hours 
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Figure 6.9 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Manuka honey M157 at various concentrations for 
1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.10 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Manuka honey M151 at various concentrations for 1, 2, 4, or 8 
hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.11 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Manuka honey M151 at various concentrations for 
1, 2, 4, or 8 hours 
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Figure 6.12 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Manuka honey M151 at various concentrations for 
1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.13 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Ling Heather honey LH27 at various concentrations for 1, 2, 
4, or 8 hours 
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Figure 6.14 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Ling Heather honey LH27 at various concentrations 
for 1, 2, 4, or 8 hours 
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Figure 6.15 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Ling Heather honey LH27 at various concentrations 
for 1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.16 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Rewarewa honey R19/06 at various concentrations for 1, 2, 4, 
or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.17 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Rewarewa honey R19/06 at various concentrations 
for 1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.18 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Rewarewa honey R19/06 at various concentrations 
for 1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.19 CPE resulting from infection of A549 cells with Ad3 after treatment 
of the virus with Honeydew honey HD19 at various concentrations for 1, 2, 4, 
or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.20 CPE resulting from infection of A549 cells with HSV-1 after 
treatment of the virus with Honeydew honey HD19 at various concentrations 
for 1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
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(b) Experiment 2 
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Figure 6.21 CPE resulting from infection of A549 cells with HSV-2 after 
treatment of the virus with Honeydew honey HD19 at various concentrations 
for 1, 2, 4, or 8 hours: (a) experiment 1 and (b) experiment 2 
 
(a) Experiment 1 
 
 
 
 
 
 
 
 1  2  4  8 
Chapter Six The antiviral activity of honey: Neutralisation 
177 
 
 
(b) Experiment 2 
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Table 6.2 Summary of the results shown in Figures 6.1 to 6.21  
 
Honey Treatment Ad3 HSV-1 HSV-2 
Manuka M116  
8 hr treat. 10% 
   
Manuka M116  
8 hr treat. 5% 
 
 
 
Manuka M112  
8 hr treat. 10% 
 
  
Manuka M112  
4 hr treat. 10% 
  
 
Manuka M112 
2 hr treat. 10% 
  
 
Manuka M157  
8 hr treat. 10% 
  
 
Ling Heather LH27  
8 hr treat. 10% 
  
 
Ling Heather LH27 
8 hr treat. 5% 
  
 
Ling Heather LH27 
8 hr treat. 1% - 10% 
  
   * 
Ling Heather LH27 
4 hr treat. 10%  
  
 
Ling Heather LH27 
4 hr treat. 5% 
  
 
Rewarewa R19/06 
8 hr treat. 10% 
 
 
 
Rewarewa R19/06 
8 hr treat. 5% 
 
 
 
Rewarewa R19/06 
4 hr treat. 10%  
 
 
 
Honeydew HD19  
8 hr treat. 10%  
*
1
 
 
 
Honeydew HD19  
8 hr treat. 5%  
*
1
 
  
 
* Neutralisation shown in Figure 6.15 (b), some not shown in Figure 6.15 (a). 
*
1
 Neutralisation shown in Figure 6.18 (a), not in Figure 6.18 (b). 
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Table 6.3 Summary of the average activity levels of each honey  
 
Honey ID Total Activity 
(w/v) phenol 
% 
Non-peroxide 
Activity (w/v) 
phenol % 
(UMF) 
TEAC 
mmol/kg 
MGO 
mg/kg 
Manuka 
M116 
28.10 27.25 0.62 1241.70 
Manuka 
M112 
23.73 22.02 0.97 772.40 
Manuka 
M157 
20.85 20.25 1.27 745.50 
Manuka 
M151 
0 0 1.09 116.95 
Ling Heather 
LH27 
19.50 0 1.08 2.45 
Rewarewa 
R19/06 
17.10 0 1.42 25.70 
Honeydew 
HD19 
15.10 0 1.73 6.80 
 
 
6.4 DISCUSSION 
6.4.1 Comparisons between neutralisation treatments  
The results show that in most experiments that the reduction of CPE was related 
to the concentration of honey and the time of exposure to it: lower levels of CPE 
compared with the untreated virus were observed with increasing honey 
concentration and duration of neutralisation period.  The higher concentrations of 
honey, 5% and 10%, with the longest neutralisation periods, 4 and 8 hour, had the 
greatest effect on the resulting severity of viral infection by causing delays in the 
onset of viral infection and lower levels of infection over the course of 
observation compared with the shorter treatments and to their respective control 
of untreated virus. 
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In some cases the longer neutralisation treatments resulted in no or great delay in 
the onset of CPE with both the treated and untreated virus, suggesting an effect of 
prolonged heating at 37°C during the neutralisation period on the virus.  If 
prolonged heating of the virus was not a factor, signs of viral infection with the 
untreated virus should have been expected to appear from the same time after 
inoculation of the cells as with the shorter treatments.  In most experiments this 
was not the case and delays in the onset of CPE were observed.  This impact of 
heating may have then accounted for some of the supposed greater antiviral 
activity of the longer neutralisation treatments, especially the 8 hour treatment 
with honey.  To counteract this, the differences in CPE scores between the 
untreated virus and honey-treated virus were looked at, and in most experiments 
the 8 hour treatments seemed to give a greater difference between honey-treated 
virus and untreated virus than the shorter honey treatments. 
 
6.4.2 Comparisons between neutralisation-causing treatments 
Table 6.2 shows that the Manuka honeys were generally more effective against 
more than one viral isolate.  It would seem that HSV was more greatly affected by 
the other honeys than Ad3 was.  Ad3 was neutralised by just one of the other 
honeys studied, Honeydew honey HD19.  It would further seem that the other 
honeys studied work effectively against specific viral isolates for example Ling 
Heather honey with HSV-2 suggested a range of successful treatments in one or 
both experiments more so than the Manuka honeys did.   
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6.4.3 Evaluation of experimental design 
These experiments aimed to compare the neutralisation capacity of many honeys, 
with the goal of determining successful neutralisation treatments for each virus, 
measured by means of absence of any kind of viral CPE over the course of 
observation which was compared with the untreated virus.  It has been shown with 
these experiments completed on different days that many of the honeys tested 
were able to achieve this with the 10% honey concentration.   
 
6.4.3.1 Evaluation of modified neutralisation methodology 
It was clear that by increasing the concentration of honey from 2% (v/v) up to 
10% (v/v) that a greater range of honeys showed antiviral activity.  
 
Based on the earlier experiments testing the tolerance of the cells to honey, these 
higher concentrations of honey were likely to have potentially caused changes to 
cells morphology over the observation period, if the inoculation period had 
remained at 1 hour.  However, the shorter inoculation period of the cells 
incorporating centrifuging overcame the negative effects of using these 
concentrations of honey.  It was shown with this shorter inoculation period that 
viral CPE appeared after the usual time after infection of the cells, indicating that 
it was a sufficient time period to allow for viral entry.  This short inoculation 
period was also likely to have minimised any effect the honey present in the 
inoculum may have had on the cells, in previous work (Chapter 4, Section 4.5) it 
was not until 24 hours that changes to the cells were apparent, and with the 
replacement of the inoculum with maintenance medium any remaining honey 
would have been greatly diluted to well below inhibitory levels. 
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In almost all experiments the replicates matched.  It was found though that many 
results between the experiments were dissimilar, even between the untreated 
viruses, including: reverse trends as seen in Figures 6.1 (b), 6.4 (a), 6.5 (b), 6.6 
(b), 6.7 (b), 6.10 (a) and (b), 6.12 (a), 6.15 (a), 6.18 (a), 6.20 (a) and (b), with one 
or more of the treatments;  random variance as shown in Figures 6.4 (b), 6.13, 
6.14, 6.16 (a), 6.18 (a), 6.19 (a) and (b), with one or more of the treatments; 
unconfirmed neutralisation as shown in Figures 6.1 (b), 6.3 (b), 6.6 (b), 6.19 (b); 
or additional neutralisation treatments unseen in the first experiment as shown in 
Figures 6.7 (b), 6.15 (b), 6.17 (b); absence of any CPE with the untreated virus in 
Figures 6.5 (b), 6.15 (a), 6.18 (a), and complete absence of viral CPE over the 
course of observation with four experiments testing Manuka honeys M157 and 
M151, and Ling Heather honey with HSV-1, and Ling Heather honey with Ad3 
(data not graphed).  It would have been ideal to observe that with a specific 
honey-treatment on a particular day after inoculation of the cells that a certain 
level of CPE would be shown.  Despite in most cases the overall result being the 
same between experiments whether or not neutralisation had occurred, the 
discrepancies show that this method can not be used to specifically designate 
scores; this method simply gives an idea of whether or not honey had any activity 
against the virus of interest.  
 
6.4.4 Comparisons with the activity table  
Table 6.3 outlines the activity levels of the honeys investigated for neutralisation 
capacity.  Manuka honeys M116 and M112 with the highest antibacterial activity 
ratings, especially the highest levels of methylglyoxal, had the greatest effect and 
so neutralised HSV-2.  It was further observed that neutralisation occurred with 8 
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hours treatment with Honeydew honey HD19 at 10%.  Perhaps in addition to high 
methylglyoxal requirements, exceptional antioxidant activity has an effect on viral 
infection of HSV-2.  Likewise, Ling Heather honey LH27 too caused 
neutralisation of HSV-2 suggesting perhaps an effect of phenolic compounds 
known to be found at high levels in Ling Heather honey (Castro-Vazquez, 2009).  
Similarly, high levels of phenolic compounds are found in Manuka honey, 
suggesting that it may be the phenolics rather than methylglyoxal that are 
responsible for the neutralising action of Manuka honey.   
 
HSV-1 too appears to be affected by the honeys containing the highest levels of 
methylglyoxal and was also prevented from causing infection with Rewarewa 
honey, despite the far lower methylglyoxal levels (lower than levels of other 
honeys that did not eliminate this virus) and lower levels of antioxidant capacity, 
compared with Honeydew honey HD19 which did not eliminate HSV-1 viral 
infection.   
 
Ad3 was neutralised by Manuka honeys M157, M116, and Honeydew honey 
HD19, therefore there was no correlation between increasing methylglyoxal and 
non-peroxide antibacterial activity and the prevention of viral infection.  It cannot 
be assumed then that high methylglyoxal and non-peroxide antibacterial activity 
dictate a reduction of adenoviral infection, as Manuka honey M112 which did not 
cause neutralisation of Ad3, has higher activity levels than Manuka honey M157.  
This can suggest that either a combination of components or some other 
component within honey may be wholly or partly responsible for the observed 
antiviral effects.   
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Honeydew honey HD19 caused neutralisation of Ad3 after 8 hours exposure of 
the virus to 5% and 10% solutions of honey, further suggesting some effect of this 
high antioxidant honey on viral infection.  This honey acted most broadly against 
the viral isolates, compared with the other non-Manuka honeys tested. 
 
6.4.5  Further study  
Due to the limited time span of this study it was appropriate at this stage to reduce 
the number of honey types and samples used in the subsequent part of this study, 
and so focus the remainder of the investigation on those honeys that showed most 
promise and that had characteristic properties that could be potentially responsible 
in part for the antiviral activity.   
 
As there was no correlation between an increase in methylglyoxal level and 
antiviral activity Manuka honeys M112 and M157 can be excluded from further 
analysis, leaving the extremes of non-peroxide antibacterial activity for 
investigation.  The honeys amenable to further study were the highest and lowest 
non-peroxide antibacterial activity Manuka honeys, and the non-Maunka honeys 
with the highest antioxidant content; similarly the highest total antibacterial 
activity honey, Ling Heather which was effective against HSV-2.  It is for these 
reasons that Manuka honeys M116 and M151, and Honeydew honey HD19 and 
Ling Heather LH27 were chosen as being suitable for further study. 
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Chapter 7   
The antiviral activity of honey: 
virustatic or virucidal 
 
____________________________________________ 
This chapter aims to describe results of the virucidal activity of honey, an 
investigation subsequent to the results of the neutralisation experiments in Chapter 
6.   
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Virucidal activity of a drug implies that it has caused deactivation of the virus, 
which prevents it from causing successful infection within a host cell.  This can 
suggest that the drug perhaps has a greater effect on a virus than observed with 
neutralisation experiments, as the absence of CPE caused by the neutralisation 
effect may be due to either virustatic (temporary prevention of infection) or 
virucidal (permanent prevention of infection) activity.  These types of activity can 
be tested for through the diluting of the drug of interest to sub-inhibitory levels 
and observing for any consequential viral growth within susceptible cells.  
 
7.1 INTRODUCTION  
The investigation described in Chapter 6 extended the preliminary experiments 
and has shown that after the direct treatment of the virus with honey, viral CPE 
can be inhibited as shown in Table 6.2 or temporarily suppressed.  It was 
unidentified whether the honey treatments had deactivated the viruses and so 
permanently prevented any kind of further viral growth and therefore CPE.  In 
order to determine whether the viruses had been deactivated by the neutralisation 
treatments, after the 8 hour treatment with 5% and 10% solutions of each honey 
type, the honey solutions containing the viruses were diluted in maintenance 
medium.  The aim was to decease to an ineffective level any residual honey which 
may be inhibiting the virus from attaching to, or replicating within the cells and so 
preventing CPE.  This can assess whether the honey is a virucidal agent against 
the viruses being tested. 
 
7.2 METHODS 
Confluent A549 cells were prepared in 24 well plates as described in Section 
3.2.1.  The growth medium was removed from the cells and was replaced with 0.8 
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ml of maintenance medium and 0.2 ml of thawed 5% and 10% honey solutions 
containing virus that had been frozen at -70°C at the conclusion of the 8 hour 
neutralisation period (see Section 6.2 for details of the neutralisation 
methodology).  This diluted each virus to 1/15 of the original 10
-4
 viral dilution, 
6.6
-6
 (to approximately 6.6
4 
viral particles per ml)
 
and a 9/50 dilution of the 
original honey concentration to 0.9% or 1.8% respectively.  The cells were 
incubated at 37°C and observed daily for the development of viral CPE for 15 
days.  Each experiment was completed in quadruplet. 
 
7.3 RESULTS 
The results of CPE development after inoculation of the cells with diluted honey-
treated virus after treatment with 5% and 10% solutions of honey are presented in 
Tables 7.1 to 7.6.  The bold values in the tables outline where viral CPE became 
apparent, and the captions indicate the virus and honey type being tested. 
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Table 7.1 CPE from Ad3 after treatment of the virus with Manuka honeys: (a) 
M116 and M157, (b) M112, and (c) M151 
 
(a) Manuka honeys M116 and M157 
 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 0 0 0 0 0 0 
Day 8 0 0 0 0 0 0 0 0 0 0 0 0 
Day 9 0 0 0 0 0 0 0 0 0 0 0 0 
Day 10 0 0 0 0 0 0 0 0 0 0 0 0 
Day 11 0 0 0 0 0 0 0 0 0 0 0 0 
Day 12 0 0 0 0 0 0 0 0 0 0 0 0 
Day 13 0 0 0 0 0 0 0 0 0 0 0 0 
Day 14 0 0 0 0 0 0 0 0 0 0 0 0 
Day 15 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
(b) Manuka honey M112 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 0 0 0 0 0 0 
Day 8 0 0 0 0 0 0 0 0 0 0 0 0 
Day 9 0 0 0 0 0 0 0 0 0 0 0 0 
Day 10 0 0 0 0 0 0 0 0 0 0 0 0 
Day 11 0 0 0 0 0 0 0 0 0 0 0 0 
Day 12 0 0 0 0 0 0 1 0 0 0 0 0 
Day 13 0 0 0 0 0 0 2 1 0 0 0 0 
Day 14 0 0 0 0 0 0 3 2 0 0 0 0 
Day 15 0 0 0 0 0 0 4 3 0 0 0 0 
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(c) Manuka honey M151 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 2 2 0 0 0 0 
Day 8 0 0 0 0 0 0 3 3 0 0 0 0 
Day 9 0 0 0 0 0 0 3 3 0 0 2 2 
Day 10 0 0 0 0 0 0 4 4 0 0 2 2 
Day 11 0 0 0 0 0 0 4 4 0 0 3 4 
Day 12 0 0 0 0 3 3 5 4 2 2 3 4 
Day 13 0 0 0 0 3 3 5 4 3 3 4 4 
Day 14 0 0 0 0 4 4 5 4 2 2 4 5 
Day 15 0 0 0 0 4 4 5 5 2 2 5 5 
 
 
Table 7.2 CPE from Ad3 after treatment of the virus with: (a) Honeydew honey 
HD19, (b) Rewarewa honey R19/06, and (c) Ling Heather honey LH27 
 
(a) Honeydew honey HD19 
 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 2 2 0 0 2 2 0 0 
Day 7 0 0 0 0 3 3 0 0 3 3 0 0 
Day 8 0 0 0 0 4 4 0 0 4 4 0 0 
Day 9 0 0 0 0 4 4 0 0 4 4 0 0 
Day 10 0 0 0 0 4 4 0 0 4 4 0 0 
Day 11 0 0 0 0 5 5 0 0 5 5 0 0 
Day 12 0 0 0 0 5 5 0 0 5 5 0 0 
Day 13 0 0 0 0 5 5 2 2 5 5 0 0 
Day 14 0 0 0 0 5 5 2 2 5 5 0 0 
Day 15 0 0 0 0 5 5 3 3 5 5 2 2 
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(b) Rewarewa honey R19/06 
 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 2 2 0 0 2 2 0 0 
Day 7 0 0 0 0 3 3 0 0 3 3 0 0 
Day 8 0 0 0 0 4 4 2 2 4 4 0 0 
Day 9 0 0 0 0 4 4 3 3 4 4 2 2 
Day 10 0 0 0 0 4 4 4 4 4 4 3 3 
Day 11 0 0 0 0 4 4 4 4 4 4 3 3 
Day 12 0 0 0 0 4 4 4 4 4 4 4 4 
Day 13 0 0 0 0 5 5 4 4 5 5 4 4 
Day 14 0 0 0 0 5 5 5 4 5 5 4 4 
Day 15 0 0 0 0 5 5 5 4 5 5 4 4 
 
 
(c) Ling Heather honey LH27 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 2 2 0 0 0 0 
Day 8 0 0 0 0 0 0 2 2 0 0 2 2 
Day 9 0 0 0 0 0 0 3 3 0 0 3 3 
Day 10 0 0 0 0 0 0 4 4 0 0 4 4 
Day 11 0 0 0 0 0 0 4 4 0 0 4 4 
Day 12 0 0 0 0 2 2 5 4 2 2 4 4 
Day 13 0 0 0 0 3 3 5 4 2 2 4 4 
Day 14 0 0 0 0 3 3 5 5 2 2 4 4 
Day 15 0 0 0 0 4 4 5 5 3 2 5 5 
 
 
 
Chapter Seven The antiviral activity of honey: virustatic or virucidal 
191 
 
 
Table 7.3 CPE from HSV-1 after treatment of the virus with Manuka honeys: 
(a) M116, M112, and M157, and (b) M151 
 
(a) Manuka honeys M116, M112, and M157 
 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 0 0 0 0 0 0 
Day 8 0 0 0 0 0 0 0 0 0 0 0 0 
Day 9 0 0 0 0 0 0 0 0 0 0 0 0 
Day 10 0 0 0 0 0 0 0 0 0 0 0 0 
Day 11 0 0 0 0 0 0 0 0 0 0 0 0 
Day 12 0 0 0 0 0 0 0 0 0 0 0 0 
Day 13 0 0 0 0 0 0 0 0 0 0 0 0 
Day 14 0 0 0 0 0 0 0 0 0 0 0 0 
Day 15 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
(b) Manuka honey M151 
 0% honey 
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 2 2 0 0 2 2 
Day 7 0 0 0 0 0 0 2 2 0 0 3 3 
Day 8 0 0 0 0 0 0 3 3 0 0 3 3 
Day 9 0 0 0 0 0 0 3 3 0 0 3 3 
Day 10 0 0 0 0 0 0 3 3 0 0 3 3 
Day 11 0 0 0 0 0 0 3 3 0 0 3 3 
Day 12 0 0 0 0 0 0 3 3 0 0 4 4 
Day 13 0 0 0 0 0 0 4 4 0 0 4 4 
Day 14 0 0 0 0 0 0 4 4 0 0 4 4 
Day 15 0 0 0 0 0 0 4 4 0 0 4 4 
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Table 7.4 CPE from HSV-1 after treatment of the virus with: (a) Honeydew 
honey HD19, (b) Rewarewa honey R19/06, and (c) Ling Heather honey LH27 
 
(a) Honeydew honey HD19 
 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 3 3 0 0 3 2 0 0 
Day 6 0 0 0 0 3 3 2 2 3 3 2 2 
Day 7 0 0 0 0 4 4 2 2 4 4 2 2 
Day 8 0 0 0 0 5 5 2 2 5 5 2 2 
Day 9 0 0 0 0 5 5 3 3 5 5 3 3 
Day 10 0 0 0 0 5 5 3 3 5 5 3 3 
Day 11 0 0 0 0 5 5 4 3 5 5 3 3 
Day 12 0 0 0 0 5 5 4 3 5 5 3 3 
Day 13 0 0 0 0 5 5 4 4 5 5 4 4 
Day 14 0 0 0 0 5 5 4 4 5 5 4 4 
Day 15 0 0 0 0 5 5 4 4 5 5 4 4 
 
 
(b) Rewarewa honey R19/06 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 1 1 0 0 0 0 0 0 
Day 8 0 0 0 0 1 1 2 2 0 0 0 0 
Day 9 0 0 0 0 1 1 2 2 0 0 0 0 
Day 10 0 0 0 0 1 1 3 3 0 0 0 0 
Day 11 0 0 0 0 1 1 3 3 0 0 0 0 
Day 12 0 0 0 0 1 1 3 3 0 0 0 0 
Day 13 0 0 0 0 2 2 3 3 2 2 0 0 
Day 14 0 0 0 0 3 3 3 3 2 2 0 0 
Day 15 0 0 0 0 3 3 5 4 3 3 2 2 
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(c) Ling Heather honey LH27 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 2 2 0 0 0 0 
Day 7 0 0 0 0 0 0 2 2 0 0 0 0 
Day 8 0 0 0 0 0 0 2 2 0 0 0 0 
Day 9 0 0 0 0 0 0 2 2 0 0 0 0 
Day 10 0 0 0 0 0 0 2 2 0 0 0 0 
Day 11 0 0 0 0 0 0 3 3 0 0 0 0 
Day 12 0 0 0 0 0 0 3 3 0 0 0 0 
Day 13 0 0 0 0 0 0 3 3 0 0 2 2 
Day 14 0 0 0 0 0 0 3 3 0 0 2 2 
Day 15 0 0 0 0 0 0 3 3 0 0 2 2 
 
 
Table 7.5 CPE from HSV-2 after treatment of the virus with Manuka honeys: 
(a) M116, M112, and M157, and (b) M151 
 
(a) Manuka honeys M116, M112, and M157 
 0% honey 
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 0 
Day 7 0 0 0 0 0 0 0 0 0 0 0 0 
Day 8 0 0 0 0 0 0 0 0 0 0 0 0 
Day 9 0 0 0 0 0 0 0 0 0 0 0 0 
Day 10 0 0 0 0 0 0 0 0 0 0 0 0 
Day 11 0 0 0 0 0 0 0 0 0 0 0 0 
Day 12 0 0 0 0 0 0 0 0 0 0 0 0 
Day 13 0 0 0 0 0 0 0 0 0 0 0 0 
Day 14 0 0 0 0 0 0 0 0 0 0 0 0 
Day 15 0 0 0 0 0 0 0 0 0 0 0 0 
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(b) Manuka honey M151 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 1 2 0 0 0 0 0 0 
Day 6 0 0 0 0 2 3 0 0 0 0 0 0 
Day 7 0 0 0 0 2 4 2 2 0 0 0 0 
Day 8 0 0 0 0 2 5 3 3 2 2 3 3 
Day 9 0 0 0 0 2 5 3 3 2 2 3 3 
Day 10 0 0 0 0 2 5 3 3 2 2 3 3 
Day 11 0 0 0 0 2 5 3 3 2 2 3 3 
Day 12 0 0 0 0 2 5 3 4 2 2 3 4 
Day 13 0 0 0 0 2 5 3 4 2 2 3 4 
Day 14 0 0 0 0 3 5 3 5 2 2 4 4 
Day 15 0 0 0 0 3 5 3 5 2 2 4 4 
 
 
Table 7.6 CPE from HSV-2 after treatment of the virus with: (a) Honeydew 
honey HD19, (b) Rewarewa honey R19/06, and (c) Ling Heather honey LH27 
 
(a) Honeydew honey HD19 
 
 0% honey 
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 2 2 0 0 0 0 0 0 
Day 5 0 0 0 0 3 3 0 0 0 0 0 0 
Day 6 0 0 0 0 4 4 0 0 0 0 0 0 
Day 7 0 0 0 0 4 4 0 0 0 0 0 0 
Day 8 0 0 0 0 5 5 0 0 2 2 0 0 
Day 9 0 0 0 0 5 5 0 0 2 2 0 0 
Day 10 0 0 0 0 5 5 0 0 2 2 0 0 
Day 11 0 0 0 0 5 5 0 0 2 3 0 0 
Day 12 0 0 0 0 5 5 0 0 2 3 0 0 
Day 13 0 0 0 0 5 5 0 0 2 3 0 0 
Day 14 0 0 0 0 5 5 0 0 2 3 0 0 
Day 15 0 0 0 0 5 5 0 0 3 4 0 0 
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(b) Rewarewa honey R19/06 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 2 2 0 0 0 0 0 0 
Day 6 0 0 0 0 2 2 2 2 0 0 0 0 
Day 7 0 0 0 0 2 2 2 2 0 0 0 0 
Day 8 0 0 0 0 2 2 2 3 0 0 0 0 
Day 9 0 0 0 0 2 2 3 3 0 0 2 2 
Day 10 0 0 0 0 2 2 3 3 0 0 2 2 
Day 11 0 0 0 0 2 2 3 4 0 0 2 2 
Day 12 0 0 0 0 2 2 3 4 0 0 2 2 
Day 13 0 0 0 0 2 2 3 4 0 0 2 2 
Day 14 0 0 0 0 2 2 3 5 0 0 2 2 
Day 15 0 0 0 0 3 3 3 5 0 0 2 2 
 
 
(c) Ling Heather honey LH27 
 0% honey  
(without virus) 
5% honey 10% honey 
Day 1 0 0 0 0 0 0 0 0 0 0 0 0 
Day 2 0 0 0 0 0 0 0 0 0 0 0 0 
Day 3 0 0 0 0 0 0 0 0 0 0 0 0 
Day 4 0 0 0 0 0 0 0 0 0 0 0 0 
Day 5 0 0 0 0 0 0 0 0 0 0 0 0 
Day 6 0 0 0 0 0 0 0 0 0 0 0 3 
Day 7 0 0 0 0 0 0 0 0 0 0 0 3 
Day 8 0 0 0 0 0 0 2 2 0 0 2 3 
Day 9 0 0 0 0 0 0 2 2 0 0 2 4 
Day 10 0 0 0 0 0 0 3 2 0 0 3 4 
Day 11 0 0 0 0 0 0 3 3 0 0 3 5 
Day 12 0 0 0 0 0 0 3 3 0 0 3 5 
Day 13 0 0 0 0 0 0 3 3 0 0 4 5 
Day 14 0 0 0 0 0 0 3 3 0 0 4 5 
Day 15 0 0 0 0 0 0 4 3 0 0 4 5 
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7.4 DISCUSSION  
As described in the Section 7.2 the honey-treated virus solutions were diluted with 
the aim of removing any residual honey from the viruses.  The final dilution of the 
virus was within the TCID thus it was expected to display CPE.  The final honey 
concentrations previously have shown to be unable to prevent the development of 
CPE when used under these experimental conditions (see Section 5.3), it was 
therefore likely that the remaining honey would be too dilute to inhibit the 
development of CPE. 
 
7.4.1 Ad3 
The Manuka honeys M116 and M157 that caused neutralisation of Ad3 in the 
previous work were shown to have virucidal activity in the current experiments 
shown by the absence of CPE over the observation period in Table 7.1 (a). 
 
Manuka honey M112, however, although also having a high level of non-peroxide 
antibacterial activity and methylglyoxal, in the neutralisation experiment did not 
cause neutralisation of Ad3 after treatment with either the 5% honey or 10% 
honey solutions, so it was reasoned that some CPE may have been seen over the 
observation period in this experiment.  As expected CPE was detected, it was seen 
from day 12 after treatment of the virus with 5% honey concentration as shown in 
Table 7.1 (b).   
 
Virus treated with 5% Manuka M151 likewise displayed CPE from day 7 after 
infection as seen in Table 7.1 (c).  This honey in the neutralisation experiment did 
not cause neutralisation at either the 5% honey or 10% honey concentrations, thus 
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it was expected to show some evidence of CPE at some stage over the observation 
period. 
 
With of the other honeys tested CPE was evident from days 6 to 7 after infection 
following the treatment with 5% honey, and from day 8 with some of the 
treatments with 10% honey (see Table 7.2) this was despite the neutralisation 
observed previously with Honeydew HD19 at 10%: this result can suggest 
virustatic activity of this honey against Ad3.   
 
7.4.2 HSV-1 and HSV-2 
Tables 7.3 (a) and 7.5 (a) suggest that each of the Manuka honeys have virucidal 
activity that caused neutralisation in the previous work.  As expected CPE 
developed with Manuka honey M151 (see Tables 7.3 (b) and 7.5 (b)) which 
previously did not prevent CPE development.  The CPE, however, developed with 
just one set of replicates with HSV-1 exposed 5% and 10% honey.   
 
With the other honeys tested CPE developed despite the previous neutralisation of 
HSV-1 observed with Rewarewa honey R19/06, and with each of the other 
honeys with HSV-2, this can suggest virustatic activity of these honeys against 
HSV-1 and HSV-2.   
 
7.4.3 Comparisons with the activity table  
When comparing the above trends with the activity levels of each honey type (see 
Table 6.3) it appears that those honeys which show virucidal activity typically 
have the highest levels of methylglyoxal.  This can suggest that perhaps 
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methylglyoxal contributes to the virucidal activity of honey as the honeys with 
lower methylglyoxal levels were unable to prevent viral CPE developing over the 
15 days of observation, and with many treatments CPE was seen within the usual 
7 day observation period.  
 
7.5 TESTING METHYLGLYOXAL BY ITSELF 
It was necessary to confirm whether methylglyoxal found in the honey was acting 
alone to deliver the observed virucidal activity.  This was achieved by using 
commercially available methylglyoxal at the equivalent levels found within whole 
honey as 5% and 10% solutions, and exposing each of the viruses to these 
equivalent concentrations for 8 hours as done in the neutralisation experiments, 
the same method then being followed as in this present investigation to determine 
the virucidal activity.  
 
7.5.1 Methods  
A stock solution was prepared as a 100 fold dilution in water of synthetic 
methylglyoxal obtained as 40% (6500 mM) solution from the Sigma-Aldrich 
chemical company.  The stock solution was diluted further to prepare 4 ml 
methylglyoxal solutions of concentrations equivalent to that in 5% and 10% 
Manuka M116, M112, M157, and M151 as shown in Table 7.7.  These are based 
on the concentrations of methylglyoxal found in whole honey.  The concentration 
of methylglyoxal in 5% and 10% solutions of honey was determined then 
converted to mmol/l by dividing the new concentration by the molecular weight of 
methylglyoxal 72.06, then further dividing this figure by the density of honey 1.4 
g/ml (1/1.4 l) to give the final concentration. 
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Table 7.7 Calculations to prepare methylglyoxal at equivalent concentrations to 
that in 5% and 10% Manuka honeys 
 
Honey 
ID 
MGO 
mg/kg 
MGO in 5% 
solution of 
honey 
mg/kg 
Final 
concentration 
mmol/l 
MGO in 
10% 
solution of 
honey 
mg/kg 
Final 
concentration 
mmol/l 
M116 1241.7 62.1 1.2 124.2 2.4 
M112 772.4 38.6 0.8 77.2 1.5 
M157 745.5 37.3 0.7 74.6 1.5 
M151 116.4 5.9 0.1 11.7 0.2 
 
Key: MGO methylglyoxal 
 
Serially diluted stock viral solutions of Ad3, HSV-1, and HSV-2 (diluted to 10
-3
) 
were made in maintenance medium, and the final serial dilution was added to an 
appropriate volume (based on numbers of wells inoculated) of equivalent 
methylglyoxal solution to give 10
-4
 viral dilution.  The viral-methylglyoxal 
solutions and methylglyoxal solutions without virus were incubated with shaking 
using a shaking incubator at level 3-4 set at 37°C for 8 hours.  Confluent A549 
cells were prepared and supplemented with 800 µl of maintenance medium and 
200 µl of methylglyoxal-viral solution or methylglyoxal solution without virus.  
This was done in quadruplet.  
 
7.5.2 Results 
Tables 7.8 to 7.10 present the development of CPE recorded over a number of 
days after the inoculation of the cells with virus that had been treated for 8 hours 
with equivalent concentrations of methylglyoxal to that found in 5% and 10% 
solutions of Manuka honey.  Where the scores were found to be identical across 
the quadruplets, one value is given in the table.  The methylglyoxal solutions 
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without virus did not cause morphological changes to the cells over the course of 
observation. 
 
 
Table 7.8 CPE resulting from infection of the cells with Ad3 treated with 
methylglyoxal at levels equivalent to that found in Manuka honey: (a) M116, 
(b) M112, (c) M157, and (d) M151 
 
(a) Manuka honey M116 
 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 2 2 
Day 3 0 3 3 3 
Day 4 0 3 3 3 
 
 
(b) Manuka honey M112 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 2 2 
Day 3 0 3 3 3 
Day 4 0 3 3 3 
 
 
 
(c) Manuka M157 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 2 2 
Day 3 0 3 3 3 
Day 4 0 3 3 3 
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(d) Manuka M151 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 2 2 
Day 3 0 3 3 3 
Day 4 0 3 3 3 
 
 
Table 7.9 CPE resulting from infection of the cells with HSV-1 treated with 
methylglyoxal at levels equivalent to that found in Manuka honeys: (a) M116, 
(b) M112, (c) M157, and (d) M151 
 
(a) Manuka M116 
 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 0 0 0 
Day 3 0 2 1 1 1 2 2 2 1 1 
Day 4 0 2 2 1 1 2 2 2 2 1 
Day 5 0 2 2 2 2 2 1 
Day 6  0 3 2 1 1 3 3 2 3 2 2 2 2 
Day 7 0 3 2 1 1 3 3 2 2 2 
Day 8 0 4 2 1 1 4 3 3 2 2 
 
 
(b) Manuka honey M112 
 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 0 0 0 
Day 3 0 2 1 1 1 2 2 
Day 4 0 2 2 1 1 2 2 
Day 5 0 2 2 2 2 2 3 
Day 6 0 3 2 1 1 3 3 2 3 3 2 2 3 
Day 7 0 3 2 1 1 3 3 
Day 8 0 4 2 1 1 4 4 3 3 4 
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(c) Manuka honey M157 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 0 0 0 
Day 3 0 2 2 1 
Day 4 0 2 2 2 1 1 1 
Day 5 0 2 2 2 1 1 1 
Day 6 0 3 2 2 2 1 1 
Day 7 0 3 3 2 
Day 8 0 4 4 3 3 4 2 
 
(d) Manuka M151 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 0 0 0 
Day 3 0 2 2 2 
Day 4 0 2 2 2 
Day 5 0 2 2 2 
Day 6 0 3 3 3 2 3 3 
Day 7 0 3 3 3 2 3 3 
Day 8 0 4 4 4 
 
 
 
Table 7.10 CPE resulting from infection of the cells with HSV-2 treated with 
methylglyoxal at levels equivalent to that found in Manuka honeys: (a) M116, 
(b) M112, (c) M157, (d) M151 
 
(a) Manuka honey M116 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 1 1 1 0 0 
Day 3 0 2 0 0 
Day 4 0 2 3 2 2 2 2 3 1 0 
Day 5 0 3 2 2 3 2 0 
Day 6 0 4 4 0 
Day 7 0 4 4 2 0 2 2 
Day 8 0 4 4 3 
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(b) Manuka honey M112 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 1 1 1 0 0 
Day 3 0 2 0 1 2 2 0 
Day 4 0 2 3 2 2 2 2 3 3 0 
Day 5 0 3 3 0 
Day 6 0 4 4 0 
Day 7 0 4 4 2 
Day 8 0 4 4 4 
 
 
(c) Manuka honey M157 
 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 1 1 2 2 0 
Day 3 0 3 3 2 2 3 3 2 2 0 
Day 4 0 3 3 0 
Day 5 0 4 4 0 
Day 6 0 4 4 0 
Day 7 0 4 4 0 2 2 2 
Day 8 0 4 4 1 2 2 2 
 
 
(d) Manuka honey M151 
 
 0% MGO 
(no virus) 
0% MGO 
(virus) 
5% 
Equivalent 
10% 
Equivalent 
Day 1 0 0 0 0 
Day 2 0 2 1 1 2 1 2 1 1 2 2 2 1 
Day 3 0 3 3 2 2 3 3 2 2 2 
Day 4 0 3 3 3 
Day 5 0 4 4 4 3 4 3 
Day 6 0 4 4 4 
Day 7 0 4 4 4 
Day 8 0 4 4 4 
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7.5.3 Discussion 
The results in Tables 7.8 with Ad3 and 7.9 with HSV-1 show that methylglyoxal 
at equivalent concentrations to that in Manuka honeys M116, M112, M157, and 
M151 at 5% and 10% concentrations was unable to suppress the development of 
CPE.  Therefore it cannot be concluded that methylglyoxal is solely responsible 
for the observed virucidal effects of Manuka honeys M116, M112 and M157.   
 
With HSV-2, methylglyoxal treatments at levels equivalent to that in Manuka 
honeys M116, M112, and M157, results shown in Table 7.10 indicate a temporal 
delay of CPE.  This suggests that perhaps there is a virustatic effect of 
methylglyoxal at these higher concentrations against HSV-2. 
 
Methylglyoxal used at 2 mmol/l previously had been shown to reduce the TCID 
of influenza virus by 50% (Tiffany et al., 1957).  In the current study many of the 
concentrations used were lower than this concentration and as shown were unable 
to inhibit the development of CPE compared with the untreated virus.  The 
concentrations of methylglyoxal used in the current experiments at equivalent 
levels to that found 10% solutions of Manuka honeys M116, M112, and M157 
were higher than what had been shown by Weigel (2004) to cause inhibition of 
cell growth of HepG2 and HT29 cell lines.  However, as indicated, the 
methylglyoxal solutions without virus did not cause any morphological changes to 
the cells over the observation period.   
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Chapter 8   
The antiviral activity of honey: 
Prevention of viral infection 
 
____________________________________________ 
This chapter describes the results of subsequent work continuing that in Chapter 
5, testing the effect honey has on the spread of viral infection using two cell based 
methods: the mixing of infected and healthy cells treated and untreated with 
honey, and plaque reduction assays.  This chapter also describes further testing of 
the duration of tolerance of the cells to the higher concentrations of honey and 
whether the cells revive from the exposure to honey, work that was done first to 
find if higher concentrations of honey could be used to treat the infected cells for 
long periods. 
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8.1 INTRODUCTION  
Viral spread experiments test to see whether the drug of interest can inhibit the 
spread of virus within susceptible cells.  This can be achieved as described in 
Chapter 5 by treating inoculated cells immediately with the drug, honey-
containing medium then following the development of CPE.  Or, as done in this 
chapter, by inoculating the cells with virus and then treating these infected cells 
with honey for a defined period, the mixing of these treated-infected cells with 
healthy uninfected cells allows CPE development to be followed, to test whether 
the honey treatment can prevent or delay infection spreading to further cells 
compared with those infected cells that were not treated.  Further, plaque 
reduction assays can be used to test quantitatively whether the honey when 
included in an agarose overlay can cause fewer viral plaques from forming 
compared with the plaques numbers produced with the untreated viruses.   
 
For therapeutic relevance it was of interest to observe whether honey can prevent 
the virus from spreading from infected cells to healthy uninfected cells.  This was 
to find whether honey would be a suitable treatment for infections caused by 
viruses once infection has taken place.   
 
In the previous work, treatment of the viruses with a 10% (v/v) honey solution 
caused inhibition of viral CPE with some of the honeys studied.  The length of 
exposure of the cells to this concentration and lower concentrations of honey was 
15 minutes during the inoculation of the cells with honey-treated virus (from 
which the honey could not be removed).  Afterward, the viral-honey solution was 
removed from the cells and replaced with maintenance medium.  It was important 
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to observe the tolerance of the cells to this concentration of honey before the 
osmotic nature of honey caused the cells to change morphologically so as to give 
the length of time before the changes would occur.  It was also of interest to test 
whether the cells can revive from their honey treatment, by allowing the cells to 
change to a specific morphological level, then replacing the honey-containing 
medium with maintenance medium, and observing for any changes.   
 
After the additional experiments testing the tolerance of the cells to honey, honeys 
at two concentrations were used to treat virally infected cells for up to 4 hours.  
The cells were then detached from the culture flask and mixed in specific ratios 
with healthy uninfected cells.  The development of viral CPE was followed for a 
number of days and a score given based on the level observed.  Further, plaque 
reduction assays were undertaken to test the effect of honey against each virus 
quantitatively. Once CPE had been identified with the untreated-agarose overlay, 
the cells were fixed then stained with crystal violet to observe for plaque 
formation.  Plaques were likely to form with the treated viruses and represent 
those cells that were infected during the period of inoculation prior to overlay. 
 
8.2 THE A549 CELL LINE TOLERANCE OF HONEY   
The prolonged exposure of the cells to 5% and 10% concentrations of honey were 
likely to cause morphological changes to the cells.  To find whether the cells can 
resume a more healthy morphology after exposure to honey, a specified level of 
morphological change was obtained before the honey-containing medium was 
removed and replaced with maintenance medium (that did not contain honey). 
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8.2.1 Methods 
Confluent A549 cells were seeded in 24 well plates as described in Section 3.2.1.  
Honey solutions of Manuka honeys M116, and M151, Honeydew honey HD19, 
and Ling Heather honey LH27 were prepared in maintenance medium at 
concentrations of 0%, 5%, and 10%.  These were mixed for 5 minutes and filter 
sterilised.  The culture medium was removed from the cells, and was replaced 
with 1 ml of the appropriate honey solution in duplicate for each morphological 
score to be tested (scores 1 to 4).  Morphological changes were observed and 
recorded hourly, and allocated an appropriate score based on the criteria shown in 
Table 8.1. 
 
Table 8.1 Morphological scoring system 
 
Morphology Score 
100% dividing, 0% swollen  0 
75% dividing, 25% swollen  1 
50% dividing, 50% swollen 2 
25% dividing, 75% swollen 3 
0% dividing, 100% swollen 4 
All cells dead  5 
 
 
 
Once morphological changes had occurred to scores of 1, 2, 3, and 4, the honey 
solution was removed from the appropriate cells and replaced with 1 ml of 
maintenance medium.  The cells were observed to test whether they could resume 
a more healthy morphology and scores were appropriately allocated.  Each 
experiment was completed in duplicate. 
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8.2.2 Results 
Figures 8.1 to 8.4 show the morphological scores recorded over 7 days with each 
honey treatment.  The first graph with each type of honey represents the 24 to 52 
hour observation period, the second graph with each type of honey represents the 
54 to 168 hour observation period.  The four successive bars at each honey 
concentration indicate which cells were to reach which score before medium 
replacement.  The score values are outlined above the appropriate bars with the 
first concentration of honey, to indicate which bar corresponds to which score.   
The asterisks indicate when the medium was replaced, from which point on the 
observations were monitoring cell revival. 
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Figure 8.1 Morphological changes caused by Manuka honey M116 over: (a) 24 
to 52 hours, and (b) 54 to 168 hours 
 
(a) 24 to 52 hours 
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(b) 54 to 168 hours 
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Figure 8.2 Morphological changes caused by Manuka honey M151 over: (a) 24 
to 52 hours, and b) 54 to 168 hours 
 
(a) 25 to 52 hours 
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(b) 54 to 168 hours 
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Figure 8.3 Morphological changes caused by Honeydew honey HD19 over: (a) 
24 to 52 hours, and (b) 54 to 168 hours 
 
(a) 24 to 52 hours 
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(b) 54 to 168 hours 
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Figure 8.4 Morphological changes caused by Ling Heather honey LH27 over: 
(a) 24 to 52 hours, and (b) 54 to 168 hours 
 
(a) 24 to 52 hours 
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(b) 54  to 168 hours 
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8.2.3 Discussion 
With each of the 5% honey treatments after the honey solution had been replaced 
with maintenance medium, revival to a more normal morphology was seen within 
24 hours.  This was not observed with the treatments using honey at a 
concentration of 10%, the cells after the honey solution had been replaced either 
progressively worsened with respect to morphology or remained at the 
morphological level to which they had deteriorated.  The treatments with 10% 
honey caused a score of 4 within 32 hours and this score was seen to be observed 
earlier or at the same time with the cells that had already had their honey 
treatment replaced with maintenance medium.  The 5% honey treatment did not 
cause a morphological score of 4 within the observation period.  It can be 
suggested then that the cells can tolerate treatment of 5% honey for a much longer 
period than a treatment of 10% honey.    
 
It can be concluded that treatment of the cells with 10% honey causes great 
change to cell morphology that can not be reversed by the removal of the honey 
solution from the cells.  Treatment of the cells with a 5% honey solution causes 
far less change to the cells and the morphology of the cells can be restored 
through removal of the honey. 
 
8.3 PREVENTION OF THE SPREAD OF VIRAL INFECTION 
Experiments on the preventative effects aim to determine whether the honey has 
an effect on the spread of the virus by limiting the development of viral CPE over 
the course of observation.   
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8.3.1 Methods 
Confluent A549 cells were prepared in flasks or tubes for treatment with virus and 
honey, and for the mixing with treated-infected cells, as described in Section 
3.2.1.  Each viral isolate was prepared at a dilution of 10
-4 
in maintenance 
medium, and was used to inoculate the confluent cells (200 µl of viral dilution per 
1 ml cell culture) for 1 hour at 37°C.  During this time honey solutions of Manuka 
honeys M116 and M151, Honeydew honey HD19, and Ling Heather honey LH27 
at concentrations of 0%, 2%, and 5% were prepared in maintenance medium.  
These were mixed and filter sterilised.  At the conclusion of the inoculation 
period, the viral inoculum was removed and the cells were washed with PBS.  The 
cells were supplemented with 1 ml of honey solution.  These were incubated at 
37°C for 1, 2, or 4 hours.  At the conclusion of each exposure period, the honey 
solution was removed and the cells were washed with PBS.  Trypsin EDTA was 
used to detach the treated and untreated cells, which were then mixed together to 
make 1 ml volumes of 1:0, 0:1, 1:1, 1:2, 1:5, 1:10, ratios of infected:healthy cells 
in duplicate in 24 well plates.  These were incubated at 37°C and observed daily 
for developing CPE and a score was recorded as described in Section 4.1, Figure 
4.6.   
 
The first experiments were done without honey to test for CPE development after 
mixing the infected cells with healthy cells.  
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8.3.2 Results 
Table 8.2 show the results of the first experiments without honey and give the 
CPE scores recorded over 7 days.  Each of the replicates gave identical scores. 
 
 
Table 8.2 CPE resulting from mixing healthy cells with cells infected with virus 
in various ratios: a) Ad3, b) HSV-1, and c) HSV-2 
 
(a) Ad3 
 
Ratio of infected:healthy cells 0:1 1:1 1:2 1:5 1:10 
Day 1 0 0 0 0 0 
Day 2 0 0 0 0 0 
Day 3 0 0 0 0 0 
Day 4 0 0 0 0 0 
Day 5 0 0 0 0 0 
Day 6 0 0 0 0 0 
Day 7 0 2 2 1 0 
 
 
(b) HSV-1 
Ratio of infected:healthy cells 0:1 1:1 1:2 1:5 1:10 
Day 1 0 0 0 0 0 
Day 2 0 0 0 0 0 
Day 3 0 0 0 0 0 
Day 4 0 0 0 0 0 
Day 5 0 0 0 0 0 
Day 6 0 0 0 0 0 
Day 7 0 0 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Eight The antiviral activity of honey: Prevention of viral spread 
221 
 
 
(c) HSV-2 
Ratio of infected:healthy cells 0:1 1:1 1:2 1:5 1:10 
Day 1 0 0 0 0 0 
Day 2 0 0 0 0 0 
Day 3 0 0 0 0 0 
Day 4 0 2 2 2 0 
Day 5 0 4 3 2 2 
Day 6 0 4 3 3 2 
Day 7 0 5 5 5 2 
 
 
8.3.2.1 Experiments with honey 
Figures 8.5 to 8.7 describe the results with each virus and Manuka honey M116 
for each period of exposure, Figures 8.8 to 8.10 describe the results with each 
virus and Manuka honey M155, Figures 8.11 to 8.13 describe the results with 
each virus and Honeydew honey HD19, and Figures 8.14 to 8.16 describe the 
results with each virus and Ling Heather honey LH27.  The observations of 
developing viral CPE from 1 to 7 days are plotted against honey concentration, 
and results are given for each replicate.  With each honey concentration, each 
successive bar represents a different ratio of infected:healthy cells, these are 
outlined above the appropriate bars with the first concentration of honey, to 
indicate which bar corresponds to which ratio.   
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Figure 8.5 CPE from Ad3 after treatment with Manuka honey M116 for: a) 1 
hour, b) 2 hours, and c) 4 hours 
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M116 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.6 CPE from HSV-1 after treatment with Manuka honey M116 for: a) 1 
hour, b) 2 hours, and c) 4 hours 
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M116 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
 
 
 
 
 
 1:0 0:1 1:1 1:2 1:5 1:10 
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(b) 2 hours 
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(c) 4 hours 
 
 
 
 
 
 
 
 
 
 1:0 0:1 1:1 1:2 1:5 1:10 
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Figure 8.7 CPE from HSV-2 after treatment with Manuka honey M116 for: (a) 
1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M116 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.8 CPE from Ad3 after treatment with Manuka honey M155 for: 1 
hour, 2 hours, and 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M155 for: 1 hour, 
2 hours, and 4 hours. 
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Figure 8.9 CPE from HSV-1 after treatment with Manuka honey M155 for: 1 
hour, 2 hours, and 4 hours 
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M155 for:  1 hour, 
2 hours, and 4 hours. 
 
 
 
 
 
 
 
 
 
 
 1:0 0:1 1:1 1:2 1:5 1:10 
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Figure 8.10 CPE from HSV-2 after treatment with Manuka honey M155 for: 1 
hour, 2 hours, and 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Manuka honey M155 for: 1 hour, 
2 hours, and 4 hours. 
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Figure 8.11 CPE from Ad3 after treatment with Honeydew honey HD19 for: (a) 
1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Honeydew honey HD19 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 1:0 0:1 1:1 1:2 1:5 1:10 
Chapter Eight The antiviral activity of honey: Prevention of viral spread 
236 
 
 
(c) 4 hours 
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Figure 8.12 CPE from HSV-1 after treatment with Honeydew honey HD19 for: 
(a) 1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Honeydew honey HD19 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.13 CPE from HSV-2 after treatment with Honeydew honey HD19 for: 
(a) 1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Honeydew honey HD19 for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.14 CPE from Ad3 after treatment with Ling Heather honey LH27 for: 
(a) 1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Ling Heather honey for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.15 CPE from HSV-1 after treatment with Ling Heather honey LH27 
for: (a) 1 hour, (b) 2 hours, and (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Ling Heather honey for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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Figure 8.16 CPE from HSV-2 after treatment with Ling Heather honey LH27 
for: (a) 1 hour, (b) 2 hours, (c) 4 hours  
Healthy uninfected A549 cells were mixed at varying ratios with A549 cells 
infected with virus treated with 0%, 2%, or 5% Ling Heather honey for: (a) 1 
hour, (b) 2 hours, and (c) 4 hours. 
 
(a) 1 hour 
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(b) 2 hours 
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(c) 4 hours 
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8.3.3 Discussion 
The results from the preliminary experiments shown in Table 8.2 (without 
treatment with honey) show that CPE appeared much later after infection of the 
cells with virus compared with previous experiments (in Chapters 4, 5, 6) even 
with the 1:0 ratio of infected to healthy cells.  HSV-1 did not display any CPE 
over the usual 7 days of observation likewise Ad3 gave signs of viral infection 
only from the final day of observation.  It was thus expected using this method for 
the detection of viral spread of infection that high levels of CPE may not be seen.  
However, in most of the subsequent experiments higher CPE scores were 
obtained. 
 
Many of the honeys were able to delay or prevent the development of viral CPE 
over the course of observation.  Figures 8.5 (b) and (c), 8.7 (a) and (c), 8.11 (a), 
(b), and (c), 8.13 (a), (b), and (c) show inhibition of spread of Ad3, and HSV-2 
infection with treatments of Manuka honey M116 and Honeydew honey HD19.  
None of the honeys were able to inhibit the development of HSV-1 CPE.  With 
the previous neutralisation experiments, HSV-1 was affected by higher 
concentrations of Manuka honeys M116 and M112, and Rewarewa honey R19/06 
only, whereas Ad3 and HSV-2 were affected by Manuka honey M116, Honeydew 
honey HD19, and Ling Heather honey LH27 (with HSV-2).  
 
Reverse trends were observed (higher CPE scores with high concentrations of 
honey and low CPE scores with low concentrations of honey) between ratios of 
infected to healthy cells (see Figures 8.12 (a), (b), and (c), and 8.16 (a) and (c)) 
and no effect of the honey on CPE development was seen in Figures 8.6 (c), 8.8, 
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8.9 or 8.10.  This further suggests the minimal effect of Manuka honey M155 on 
each virus. 
 
Manuka honey M116 and Honeydew honey HD19 were the most successful 
treatments and Ling Heather in these experiments had little impact on the 
development of CPE showing its greatest effect after the 4 hour treatment with 
each honey concentration.  
 
The aim of varying the length of exposure of the infected cells to the honey 
solutions was to test if greater exposure to honey could have a greater effect on 
inhibition of CPE development.  It appears that the increased period of exposure 
had little influence on the consequent development of CPE, and if the honey was 
to be effective against CPE development, it showed these effects after one hour of 
exposure of the infected cells to honey.  
 
It was reasoned that with the greater dilutions of infected cells to healthy cells that 
less viral infection can be observed given the lower amount of virus present.  The 
CPE scores resulting from the mixing of infected cells with healthy cells show 
clearly that infection was spreading to the healthy cells from the infected cells, 
with similar CPE levels reached by the conclusion of the observation period.  
With Manuka honey M116, however, the 5% treatment with the 1:10 ratio of 
infected to healthy cells gave low levels of CPE compared with the untreated virus 
(shown in Figure 8.5, and 8.7 (a) and (c)).  In most other cases little difference 
was observed between the two concentrations of honey and ratios tested. 
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From these results, it is concluded that when honey is used to treat infected cells it 
can only delay CPE developing in healthy cells, it cannot prevent it. 
 
8.4 PREVENTION OF VIRAL SPREAD: PLAQUE REDUCTION 
ASSAYS 
Plaque reduction assays can be used to measure quantitatively the effect an 
antiviral agent has against a virus.  A plaque can be defined as a cleared zone 
within the monolayer of cells that does not stain with crystal violet.    
 
8.4.1 Methods 
A 4% agarose in double distilled H2O was prepared and sterilised by autoclaving.  
Confluent A549 cells were prepared as described in Section 3.2.1 in 24 well plates 
and these were inoculated for the preliminary experiment with HSV-2 serially 
diluted to 10
-6
 for 1 hour at 37°C.  In subsequent experiments with honey, the 
virus was used at a dilution of 10
-4
 and 0%, 10% and 20% honey solutions of 
Manuka honeys M116  and M155, Honeydew honey HD19, and Ling Heather 
honey LH27 were prepared in doubly concentrated maintenance medium (RPMI 
1640 with Hepes, 2% FCS, supplemented with antimicrobials ampicillin and 
gentamycin at final concentrations of 100 µg/ml and amphotericin B at a final 
concentration of 10 µg/ml), these were mixed and filter sterilised.  The previously 
prepared agarose was melted in a 45°C water bath.  The viral inoculum was 
removed from the cells and was replaced with either 0.25 ml of doubly 
concentrated maintenance medium alone, or, 0.25 ml of honey solution with 0.25 
of agarose to obtain 5% and 10% concentrations of honey.  The overlay was 
allowed to set on the cells and the plates were incubated at 37°C.  CPE 
development was observed through the thin overlay and was allocated an 
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appropriate score over a number of days.  Once a moderate level of CPE had been 
reached with the viruses that had not had honey included in their agarose overlay, 
the cells were fixed with 20% trichloroacetic acid (TCA) for 5 minutes.  After 
fixing the TCA was aspirated off and the overlay was removed, the cells were 
then stained with crystal violet working solution (20 ml stock (1% crystal violet 
made in 20% ethanol), 40 ml 95% ethanol, and 150 ml distilled water) for 30 
minutes.  The stain was washed off with distilled water and the plaques were 
counted at low power.  In further experiments honey was used at a final 
concentration of 2% with virus diluted from 10
-1
 to 10
-4
.  Each experiment was 
completed in duplicate, and with the testing honey two experiments were 
completed on separate days. 
 
8.4.2 Results  
Table 8.3 describes the plaque counts of the first experiment using HSV-2 diluted 
from 10
-1
 to 10
-6
.  Figure 8.17 gives the plaque counts of each virus and honey 
type, this is followed by Table 8.4 which describes the mean, standard deviation, 
coefficient of variation and average percent reduction in plaque numbers with the 
honey treatments for each of the plaque counts.   
 
The preliminary experiments using honey at a final concentration of 5% and 10% 
were too concentrated for the cells to tolerate, and resulted in destruction of the 
monolayer.  The Figure below outlines the counts using honey at a final 
concentration of 2%.   
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The further experiments using a range of viral dilutions from 10
-1
 to 10
-4
 were 
unsuccessful due to continual contamination of the honey-agarose overlay and 
consequent destruction of the monolayer.  
 
Table 8.3 Plaque counts after infection of A549 cells with HSV-2, counted on 
day 7 after infection 
 
 10
-1
 10
-2
 10
-3
 10
-4
 10
-5
 10
-6
 
Replicate 
1 
Monolayer 
destroyed 
>100 
plaques 
33 
plaques 
30 
plaques 
20 
plaques 
15 
plaques 
Replicate 
2 
Monolayer 
destroyed 
>100 
plaques 
30 
plaques 
30 
plaques 
18 
plaques 
12 
plaques 
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Figure 8.17 Plaque counts of each replicate after infection of A549 cells with: 
(a) Ad3, (b) HSV-1, (c) HSV-2, diluted to 10
-4
, treated with agarose containing 
various types of honey at final concentrations of 2%, counted on day 7 after 
infection 
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(c) HSV-2 
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Table 8.4 Plaque count means, standard deviations, coefficients of variation, 
and % inhibition with each honey (data from Figure 8.17) with (a) Ad3, (b) 
HSV-1, (c) HSV-2 
 
 
(a) Ad3 
 
 Control M116 M155 HD19 LH27 
Mean 100 8 2.25 17 8.25 
SD 0 9.66 2.22 9.02 5.06 
CV 0 120.8 98.7 53.1 61.3 
% Inhibition - 92.0 97.0 83.0 91.7 
 
 
(b) HSV-1 
 
 Control M116 M155 HD19 LH27 
Mean 90.5 5.25 2.75 17.75 9.75 
SD 19 6.07 4.27 8.06 6.45 
CV 20.99 115.62 155.27 45.51 66.15 
% Inhibition - 94.2 97.0 80.4 89.2 
 
 
(c) HSV-2 
 Control M116 M155 HD19 LH27 
Mean 99.5 12 19.75 28.5 11.25 
SD 1 1.41 2.98 1.73 4.03 
CV 1.01 11.75 15.09 6.07 35.82 
% Inhibition - 87.9 80.2 71.4 88.7 
 
 
8.4.3 Discussion 
The results shown in Table 8.3 provide the plaque numbers with the preliminary 
experiment using HSV-2 only.  This experiment aimed to optimise the plaque 
assay technique, and it was shown that plaques were detectable with each of the 
viral dilutions. 
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The subsequent experiments, with the viruses at a dilution of 10
-4
 as used in the 
previous cell-based experiments, honey was used initially at final concentrations 
of 5% and 10%.  These concentrations were found to destroy the monolayer of 
cells thus a final concentration of 2% honey was used in the subsequent 
experiments.  The plaque counts with each of the 2% honey treatments are shown 
in Figure 8.17 (a), (b) and (c).  It can be seen that each of the honeys gave a 
marked reduction in plaque formation and that each of the viruses were 
susceptible to the honey within the overlay.  It was interesting to observe such an 
effect of Manuka honey M155 given the previous observations indicating little 
antiviral activity.  There is however some variability between numbers counted, 
which makes the results somewhat unreliable.  Nevertheless, the degree of 
inhibition seen 71.4% to 97.0 % makes it conclusive that the honeys decreased to 
a large degree the ability of the viral infection to spread from cell to cell. 
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Chapter 9   
 
The antiviral activity of honey: 
Study using ELISA  
______________________________________________ 
This Chapter describes the work done to investigate the mode of action of the 
previously successful neutralisation treatments against each virus, using ELISA to 
detect specific proteins important for viral attachment to the host cell. 
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9.1 INTRODUCTION  
Enzyme-linked immunosorbant assays (ELISA) can be used as a sensitive measure to 
detect the amount of a specific antigen within a sample.  This technique can therefore 
be used to test for changes to the proteins on a virus caused by a preceding treatment. 
 
By firstly optimising experimental conditions for the detection of antigens on each 
virus using ELISA, followed by testing the virus after treatment with honey (as in 
Chapter 6), it is possible to see whether the successful neutralisation treatments have 
caused specific alterations to the virus.   
 
Observations in earlier chapters have suggested that when honey is used to treat a 
virus it causes delays of development of severe CPE compared with the untreated 
virus.  This has been shown with each of the cell-based experiments which suggests 
either a direct effect of the honey on the virus or an effect of the honey on the cells or 
both.  If honey is interacting with viral surface proteins, it would prevent viral 
attachment to the host cell and therefore prevent viral infection.  The trend of reduced 
CPE related to the increasing concentration of honey and duration of exposure to it 
observed early after infection with the neutralisation experiments with many of the 
honey treatments, could be explained by viral surface protein modification.  To test 
whether the honey causes a direct effect on the virus by potentially attaching to 
and/or causing protein modifications of the viral surface proteins involved in the 
attachment of the virus to the host cell (see Sections 2.1.4 and 2.2.4) ELISA was used 
to measure the amount of protein on the viruses before and after treatment with 
honey.   
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This method is not limited by the concentration of honey used or qualitative 
observations.  This technique can provide justification of the previous reports of 
antiviral activity. 
 
9.2 EXPERIMENTS 
The antibodies to detect adenovirus and herpes simplex virus surface proteins were 
obtained from AbD Serotec, Mouse anti-Adenovirus hexon, and Mouse anti-Herpes 
simplex virus 1 & 2 specific to an epitope within glycoprotein D.  The enzyme-linked 
secondary antibody was also from AdD Serotec, Goat anti-mouse IgG, A, M:HRP 
(human absorbed). 
 
9.2.1 Determining optimal dilutions of the primary and secondary antibodies 
for the detection of high concentrations of antigen 
9.2.1.1 Methods 
One hundred µl of the appropriate antigen (stock virus diluted to 10
-1
 in 0% medium 
(RPMI 1640, without the addition of FCS)) was used to coat the wells of ELISA 
modules (NUNC-Immuno modules) these were left overnight at 4ºC.  The antigen 
was removed from the modules and each well was washed once with wash buffer 
(0.05% Tween 20 in phosphate buffered saline pH 7.4 (PBS)) using a multichannel 
pipette.  Two hundred µl of blocking buffer (1% bovine serum albumin (BSA) from 
Sigma chemical company prepared in PBS pH 7.4) was added to each well and this 
was incubated at 37ºC for 30 minutes.  After incubation with the blocking buffer, the 
wells were washed 3 times with wash buffer for 5 minutes and air dried, 100 µl of the 
primary antibody was prepared in 0.02% sodium azide in PBS pH 7.4 was then added 
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to each well (dilutions from 1/100 to 1/3200 were used: 10 µg/ml, 5 µg/ml, 2.5 
µg/ml, 1.25 µg/ml, 0.625 µg/ml, 0.3125 µg/ml) and incubated at 37ºC for 1 hour with 
gentle shaking.  After incubation with primary antibody, the wells were washed 3 
times with wash buffer for 5 minutes, and 100 µl of the secondary antibody prepared 
in PBS was added to each well (dilutions 1/100 to 1/6400: 10 µg/ml, 5 µg/ml, 2.5 
µg/ml, 1.25 µg/ml, 0.625 µg/ml, 0.3125 µg/ml, 0.156 µg/ml) and incubated at 37ºC 
for 1 hour with gentle shaking.  After incubation with the secondary antibody, the 
wells were washed 3 times with wash buffer for 5 minutes and once with distilled 
water.  During the last wash the substrate was prepared by mixing 30 ml of substrate 
buffer (citric acid prepared with di-sodium hydrogen phosphate pH 5) with a 30 mg 
Ortho-phenylenediamine dihydrochloride (OPD) tablet from Sigma chemical 
company, once the tablet had dissolved, 200 µl 6% H2O2 was added.  One hundred µl 
of substrate was added to each well and incubated at 37º for 30 minutes in the dark.   
After incubation, 50 µl 2 mol/L H2SO4 was added to each well.  The absorbance was 
then read at 492 nm using a plate reader.   
 
9.2.1.2 Results 
The results of the first experiments are shown in Figures 9.1 to 9.4 as plots of 
absorbance against secondary antibody dilution.  Each plotted line represents a 
different primary antibody dilution as indicated by the key. 
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Figure 9.1 ELISA absorbance readings using various dilutions of both the primary 
and secondary antibodies with: (a) Ad3, (b) HSV-1, (c) HSV-2 at dilutions of 10
-1
, 
and (d) no virus 
 
(a) Ad3 
 
 
 
(b) HSV-1 
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(c) HSV-2 
 
 
(d) No virus 
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9.2.1.3 Discussion 
This experiment using combinations of primary and secondary antibody dilutions 
provided an overview of the specificity and absorbance range with a high amount of 
antigen.  It was shown that the antibodies used to detect HSV were binding non-
specifically as indicated by the colour development in the absence of antigen in 
Figure 9.4.   
 
From the absorbance readings from these experiments with different combinations of 
the primary and secondary antibodies, a selection of dilutions were chosen to be 
tested with and without the antigen and in the presence and absence of one or both 
antibodies.  From the raw data (used in Figure 9.1), dilutions of the antibodies that 
gave absorbance readings of about 1.5 were selected.  For Ad3, the primary antibody 
dilutions, 1/100 to 1/1600 with secondary antibody dilution 1/400 gave readings in 
this range thus 1/100, 1/200, and 1/400 dilutions of the primary antibody were chosen 
to use with a 1/400 dilution of the secondary antibody.  For HSV-1 and HSV-2, 
1/400, 1/800, and 1/1600 primary dilutions with 1/200 dilution of the secondary 
antibody were chosen.   
 
9.2.2 Further examination of antibody dilutions, with increased time of 
exposure to and concentration of blocking buffer 
9.2.2.1 Methods 
The method used was as described in Section 9.2.1.1 and was completed in triplicate 
with the following changes:  The incubation with blocking buffer was increased to 1 
Chapter Nine The antiviral activity of honey: Study using ELISA 
268 
 
hour and the concentration of BSA within the blocking buffer was increased to 2% 
BSA in PBS to reduce the background colour development.  For Ad3, primary 
antibody dilutions 1/100, 1/200, and 1/400 (10 µg/ml, 5 µg/ml, and 2.5 µg/ml) were 
used with the secondary antibody at 1/400 dilution (1.25 µg/ml).  
 
For Herpes simplex type 1, primary antibody dilutions 1/400, 1/800, and 1/1600 (2.5 
µg/ml, 1.25 µg/ml, and 0.625 µg/ml) were used with the secondary antibody at 1/200 
dilution (5 µg/ml).   
 
This experiment included test wells with and without the primary and/or secondary 
antibody to detect non-specific background caused by the antibodies with and without 
the antigen. 
 
The means, SD, and % CV were calculated for each combination of antigen and 
antibody dilution. 
 
9.2.2.2 Results 
The results using different combinations of antibodies are shown in Tables 9.1 to 9.3.  
Abbreviations Y (Yes) and N (No) indicate whether the virus or antibody was 
included in the test combination.  If the antibody was included the dilution used has 
been given.  
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Table 9.1 Absorbance readings using various dilutions of the primary antibody with 
one dilution of the secondary antibody, with: (a) Ad3, (b) HSV-1, and (c) HSV-2 at 
dilutions of 10
-1
 
 
 
(a) Ad3  
 
 Absorbance 
Ad3 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
Y 1/100 1/400 1.930 0.024 1.2 
Y 1/200 1/400 1.691 0.076 4.5 
Y 1/400 1/400 1.247 0.040 3.2 
N 1/100 1/400 1.871 1.119 59.8 
N 1/200 1/400 0.895 0.387 43.2 
N 1/400 1/400 0.437 0.097 22.2 
Y 1/100 N 0.059 0.019 32.6 
Y 1/200 N 0.057 0.004 6.3 
Y 1/400 N 0.049 0.007 14.4 
N 1/100 N 0.051 0.002 4.2 
N 1/200 N 0.051 0.008 16.6 
N 1/400 N 0.053 0.004 6.7 
Y N 1/400 0.374 0.093 25.0 
N N 1/400 0.072 0.002 3.0 
Y N N 0.040 0.003 7.1 
N N N 0.043 0.004 9.9 
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(b) HSV-1 
   Absorbance 
HSV-1 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
Y 1/400 1/200 1.177 0.410 34.8 
Y 1/800 1/200 1.215 0.124 10.2 
Y 1/1600 1/200 1.090 0.505 46.3 
N 1/400 1/200 0.209 0.142 67.8 
N 1/800 1/200 0.185 0.047 25.2 
N 1/1600 1/200 0.429 0.401 93.6 
Y 1/400 N 0.065 0.006 8.7 
Y 1/800 N 0.065 0.014 21.8 
Y 1/1600 N 0.073 0.016 22.4 
N 1/400 N 0.063 0.006 10.2 
N 1/800 N 0.064 0.009 14.5 
N 1/1600 N 0.061 0.007 11.6 
Y N 1/200 0.186 0.032 17.2 
N N 1/200 0.161 0.004 2.6 
Y N N 0.048 0.002 4.5 
N N N 0.046 0.003 6.2 
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(c) HSV-2 
   Absorbance 
HSV-2 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean  SD % CV 
Y 1/400 1/200 0.672 0.333 49.6 
Y 1/800 1/200 0.799 0.307 38.4 
Y 1/1600 1/200 0.898 0.268 29.8 
N 1/400 1/200 0.227 0.159 70.3 
N 1/800 1/200 0.243 0.163 67.1 
N 1/1600 1/200 0.467 0.164 35.2 
Y 1/400 N 0.067 0.038 56.7 
Y 1/800 N 0.063 0.040 63.9 
Y 1/1600 N 0.062 0.042 68.2 
N 1/400 N 0.059 0.030 50.2 
N 1/800 N 0.059 0.032 55.0 
N 1/1600 N 0.056 0.036 63.6 
Y N 1/200 0.158 0.044 28.1 
N N 1/200 0.122 0.040 33.1 
Y N N 0.059 0.010 16.2 
N N N 0.055 0.015 27.2 
 
 
9.2.2.3 Discussion 
Table 9.1 shows the results using the dilutions of antibody found to be suitable in 
Section 9.2.1 with each virus at a dilution of 10
-1
.  It is apparent that the increased 
incubation period and increased concentration of BSA in the blocking buffer lowered 
the non-specific binding seen with the absence of the antigen.  When the primary 
antibody was excluded from the test combination with the antigen present, moderate 
readings were obtained suggesting that the secondary antibody was non-specifically 
binding to the wells.   
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9.2.3 Repeats of specific combinations with or without antigen/antibodies 
9.2.3.1 Methods 
The method used was as described in Section 9.2.1.1 with the modifications outlined 
in Section 9.2.2.1.  In addition, the substrate incubation period was reduced to 10 
minutes due to rapid colour development.  Combinations tested were for Ad3, with 
and without antigen, and without the antigen including the primary antibody, and for 
HSV-1, with and without antigen, and with and without antigen excluding the 
primary antibody, each completed in triplicate. 
 
9.2.3.2 Results 
The results repeating specific combinations of the antibodies are shown in Tables 9.4 
to 9.5.  Abbreviations Y (Yes) and N (No) indicate whether the virus or antibody was 
included in the test combination.  If the antibody was included the dilution used has 
been given.  
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Table 9.2 Absorbance readings using various dilutions of the primary antibody and 
one dilution of the secondary antibody, with: (a) Ad3 and (b) at dilutions of 10
-1
 
 
(a) Ad3 
 
   Absorbance 
Ad3 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
Y 1/100 1/400 1.856 0.028 1.5 
Y 1/200 1/400 1.387 0.457 33.0 
Y 1/400 1/400 0.838 0.348 41.6 
N 1/100 1/400 1.853 0.424 22.9 
N 1/200 1/400 0.701 0.072 10.2 
N 1/400 1/400 0.391 0.066 16.9 
Y N 1/400 0.193 0.002 1.1 
 
 
(b) HSV-1 
   Absorbance 
HSV-1 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
Y 1/400 1/200 0.660 0.098 14.8 
Y 1/800 1/200 0.545 0.134 24.6 
Y 1/1600 1/200 0.397 0.163 41.2 
N 1/400 1/200 0.152 0.012 8.0 
N 1/800 1/200 0.104 0.010 9.6 
N 1/1600 1/200 0.103 0.012 11.7 
Y N 1/200 0.121 0.004 4.1 
N N 1/200 0.081 0.006 8.0 
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9.2.4 Measurement of antigen on serially diluted virus using previously 
successful dilutions of each antibody 
9.2.4.1 Methods 
Using the method described in Section 9.2.1.1 with the modifications outlined in 
Sections 9.2.2.1, and 9.2.3.1, for Ad3, a 1/100 dilution (10 µg/ml) of the primary 
antibody was used with a 1/400 dilution (2.5 µg/ml) of the secondary antibody to 
detect the antigens on the virus diluted from 10
-1
 to 10
-4
.  For HSV-1, a 1/400 dilution 
(2.5 µg/ml) of the primary antibody was used with a 1/200 dilution (5 µg/ml) of the 
secondary antibody to detect the antigens on the virus diluted from 10
-1
 to 10
-4
.  Each 
combination was done in triplicate.  In addition, skim milk powder was added to the 
blocking buffer at a concentration of 5% (to make the composition of the blocking 
buffer 5% skim milk powder, 2% BSA in PBS) to reduce the background colour 
development. 
 
In addition to the means, SD, and % CV the equation of the trend line and R
2
 value 
were calculated using Excel. 
 
9.2.4.2 Results 
The results are presented in Figures 9.2 to 9.3 and Tables 9.3 to 9.4.   
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Figure 9.2 Absorbance readings of Ad3 serially diluted from 10
-1
 to 10
-4
 with a 
1/100 dilution of the primary antibody and a 1/400 dilution of the secondary 
antibody 
 
 
 
 
Table 9.3 Absorbance means, SD, and % CV of the data shown in Figure 9.2 
 
Ad3 dilution Mean SD % CV 
10
-1
 0.688 0.074 10.7 
10
-2
 0.542 0.074 13.7 
10
-3
 0.256 0.013 5.3 
10
-4
 0.199 0.029 14.3 
N 0.187 0.040 21.4 
N 0.193 0.028 14.7 
N 0.183 0.011 5.8 
N 0.128 0.009 6.8 
 
 
 
 
10
-1
                                  10
-2
                                 10
-3
                               10
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Figure 9.3 Absorbance readings of serially diluted HSV-1 with a 1/400 dilution of 
the primary antibody and a 1/200 dilution of the secondary antibody 
 
 
 
 
Table 9.4 Absorbance means, SD, and % CV of the data shown in Figure 9.3 
 
HSV-1 dilution Mean SD % CV 
10
-1
 0.418 0.019 4.6 
10
-2
 0.267 0.018 7.0 
10
-3
 0.144 0.014 9.8 
10
-4
 0.126 0.003 2.4 
N 0.128 0.006 4.3 
N 0.126 0.017 13.5 
N 0.139 0.029 20.7 
N 0.122 0.010 8.4 
 
 
9.2.4.3 Discussion 
In these experiments 5% skim milk powder was added to the blocking buffer to try to 
reduce the background colour development.  It was shown that the dilutions of the 
10
-1
                                  10
-2
                                 10
-3
                               10
-4 
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antibodies that were used previously to detect high amounts of antigen were not able 
to give very high absorbance readings when the virus was diluted to 10
-4
.  Even with 
the virus diluted to 10
-1
 as used previously, lower absorbance readings were observed 
in this experiment than seen before using the same dilution.   
 
9.2.5 Measurement of antigens on serially diluted virus using higher 
concentrations of each antibody 
9.2.5.1 Methods 
The method used was as described in Sections 9.2.1.1, 9.2.2.1, and 9.2.3.1, however, 
the period of incubation with blocking buffer was increased to overnight at 4°C.  
With Ad3, 1/100 and 1/200 dilutions (10 µg/ml and 5 µg/ml) of the primary antibody 
were used, with 1/100 and 1/200 dilutions (10 µg/ml and 5 µg/ml) of the secondary 
antibody.  With HSV-1 and HSV-2, 1/400 and 1/800 dilutions (2.5 µg/ml and 1.125 
µg/ml) of the primary antibody were used, with 1/100 and 1/200 dilutions (10 µg/ml 
and 5 µg/ml) of the secondary antibody.  Each combination was completed in 
triplicate. 
 
9.2.5.2 Results 
The results are presented in Table 9.5. 
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Table 9.5 Absorbance readings using serially diluted (a) Ad3, (b) HSV-1, and (c) 
HSV-2,  with higher concentrations of primary and secondary antibodies 
 
(a) Ad3  
 
   Absorbance 
Ad3 
dilution 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
10
-1
 1/100 1/100 2.813 0.102 3.6 
10
-2
 1/100 1/100 1.484 0.105 7.1 
10
-3
 1/100 1/100 0.471 0.011 2.4 
10
-4
 1/100 1/100 0.312 0.008 2.5 
10
-1
 1/100 1/200 1.594 0.006 0.4 
10
-2
 1/100 1/200 1.255 0.076 6.2 
10
-3
 1/100 1/200 0.664 0.035 5.3 
10
-4
 1/100 1/200 0.642 0.028 4.3 
10
-1
 1/200 1/100 1.455 0.323 22.2 
10
-2
 1/200 1/100 0.785 0.042 5.4 
10
-3
 1/200 1/100 0.438 0.013 3.0 
10
-4
 1/200 1/100 0.316 0.008 2.7 
10
-1
 1/200 1/200 1.204 0.119 9.9 
10
-2
 1/200 1/200 1.008 0.125 12.4 
10
-3
 1/200 1/200 0.516 0.067 12.9 
10
-4
 1/200 1/200 0.427 0.083 19.5 
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(b) HSV-1 
   Absorbance 
HSV-1 
dilution 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
10
-1
 1/400 1/100 0.512 0.033 6.4 
10
-2
 1/400 1/100 0.292 0.019 6.5 
10
-3
 1/400 1/100 0.178 0.045 25.5 
10
-4
 1/400 1/100 0.095 0.006 6.3 
10
-1
 1/400 1/200 0.381 0.023 6.0 
10
-2
 1/400 1/200 0.265 0.014 5.2 
10
-3
 1/400 1/200 0.129 0.004 3.1 
10
-4
 1/400 1/200 0.104 0.015 14.4 
10
-1
 1/800 1/100 0.427 0.025 6.0 
10
-2
 1/800 1/100 0.324 0.010 3.2 
10
-3
 1/800 1/100 0.207 0.022 10.4 
10
-4
 1/800 1/100 0.121 0.008 6.5 
10
-1
 1/800 1/200 0.354 0.070 19.9 
10
-2
 1/800 1/200 0.211 0.011 5.3 
10
-3
 1/800 1/200 0.118 0.013 11.1 
10
-4
 1/800 1/200 0.086 0.001 1.3 
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(c) HSV-2 
   Absorbance 
HSV-2 
dilution 
Primary 
antibody 
dilution 
Secondary 
antibody 
dilution Mean SD % CV 
10
-1
 1/400 1/100 0.397 0.031 7.8 
10
-2
 1/400 1/100 0.268 0.023 8.6 
10
-3
 1/400 1/100 0.136 0.012 8.8 
10
-4
 1/400 1/100 0.097 0.007 7.3 
10
-1
 1/400 1/200 0.377 0.059 15.6 
10
-2
 1/400 1/200 0.243 0.033 13.6 
10
-3
 1/400 1/200 0.138 0.020 14.1 
10
-4
 1/400 1/200 0.115 0.007 6.1 
10
-1
 1/800 1/100 0.315 0.042 13.4 
10
-2
 1/800 1/100 0.223 0.040 18.1 
10
-3
 1/800 1/100 0.142 0.027 19.1 
10
-4
 1/800 1/100 0.117 0.021 18.1 
10
-1
 1/800 1/200 0.236 0.017 7.1 
10
-2
 1/800 1/200 0.160 0.027 17.1 
10
-3
 1/800 1/200 0.122 0.002 1.2 
10
-4
 1/800 1/200 0.122 0.027 22.0 
 
 
9.2.5.3 Discussion 
With the successful neutralisation treatments that were to be tested, the virus was 
used at a dilution of 10
-4
 thus higher concentrations of antibodies needed to be used to 
detect this lower level of antigen.  The experiment described in Section 9.2.4 was 
repeated using higher antibody concentrations and increased incubation with blocking 
buffer (overnight at 4°C).  Higher absorbance readings were observed with Ad3 
however, with HSV-1 and HSV-2 the absorbance readings remained quite low. 
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9.2.6 First experiments with honey 
9.2.6.1 Methods 
Using the method described in Section 9.2.1.1, with the modifications outlined in 
Section 9.2.4.1 and 9.2.5.1 (changes to blocking buffer), the previously successful 
neutralisation treatments at each exposure period found in Chapter 6, Table 6.2, plus 
the associated controls of untreated virus, medium only (used to prepare the viral 
solution), and honey solutions without virus, were used to coat the wells overnight at 
4°C.  For Ad3, 1/100 of the primary antibody was used with 1/200 of the secondary 
antibody, and for HSV-1 and HSV-2, a 1/400 dilution of the primary antibody was 
used, with a 1/200 dilution of the secondary antibody.  Each of the combinations was 
completed in triplicate.  The means, SD, and % CV were calculated as well as the 
final absorbance as [mean absorbance of the treatment] – [mean absorbance of the 
appropriate control]. 
 
9.2.6.2 Results 
The results are presented in Table 9.6.  The type, concentration of honey, and time of 
exposure are shown in column 1 of each Table. 
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Table 9.6 Effect of honey on the detection of antigens of (a) Ad3, (b) HSV-1, and 
(c) HSV-2 absorbance readings with virus treated and not treated with honey  
 
(a) Ad3 
 
Treatment Mean SD % CV Final absorbance 
Medium only 0.322 0.011 3.272  
Ad3 only 0.393 0.031 7.771 0.071 
Honey solutions   
10% M116 1.860 0.146 7.831  
10% M157 1.092 0.215 19.736  
10% HD19 2.065 0.315 15.252  
5%  HD19 0.572 0.046 7.986  
Honey plus virus  
Ad3, 10% M116, 8 hour 0.412 0.018 4.429 -1.448 
Ad3, 10% M157, 8 hour 0.255 0.039 15.189 -0.837 
Ad3, 10% HD19, 8 hour 0.591 0.072 12.186 -1.474 
Ad3, 5% HD19, 8 hour 0.317 0.062 19.681 -0.255 
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(b) HSV-1 
Treatment Mean SD % CV Final absorbance 
Medium only 0.130 0.012 8.9  
HSV-1 only 0.176 0.001 0.4 0.046 
HSV-1 (4H) only 0.131 0.001 0.5 0.001 
Honey solutions   
10% M116 0.247 0.037 15.0  
5% M116 0.247 0.027 10.8  
10% M112 0.382 0.047 12.4  
10% M157 0.276 0.036 13.0  
10% R19/06 0.350 0.047 13.3  
5% R19/06 0.397 0.119 30.0  
10% R19/06 (4H) 0.480 0.129 26.8  
Honey plus virus  
HSV-1 10% M116 8H 0.262 0.015 5.7 0.015 
HSV-1 5% M116 8H 0.276 0.024 8.7 0.029 
HSV-1 10% M112 8H 0.446 0.024 5.3 0.064 
HSV-1 10% M157 8H 0.244 0.009 3.5 -0.032 
HSV-1 10% R19/06 8H  0.315 0.036 11.3 -0.035 
HSV-1 5% R19/06 8H 0.299 0.015 4.9 -0.098 
HSV-1 10% R19/06 4H 0.361 0.006 1.5 -0.119 
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(c) HSV-2 
Treatment Mean SD % CV 
Medium only 0.174 0.042 24.1 
HSV-2 only 0.178 0.036 20.3 
HSV-2 (4H) only 0.195 0.027 13.6 
HSV-2 (2H) only 0.160 0.018 11.3 
Honey solutions  
10% M116 0.320 0.052 16.2 
10% M112 0.570 0.060 10.5 
10 % M112 (4H) 0.711 0.067 9.5 
10 % M112 (2H) 0.346 0.051 14.7 
10% HD19 0.617 0.038 6.1 
10% LH27 0.513 0.084 16.5 
5% LH27 0.357 0.101 28.3 
1% LH27 0.252 0.075 29.6 
2% LH27 0.106 0.012 11.2 
2.5% LH27 0.154 0.021 13.5 
10% LH27 (4H) 0.192 0.008 4.1 
5% LH27 (4H) 0.158 0.011 7.2 
Honey plus virus 
HSV-2 10% M116 8H 0.249 0.029 11.7 
HSV-2 10% M112 8H 0.373 0.005 1.3 
HSV-2 10 % M112 4H 0.642 0.024 3.7 
HSV-2 10 % M112 2H 0.828 0.030 3.6 
HSV-2 10% HD19 8H 0.560 0.072 12.8 
HSV-2 10% LH27 8H 0.498 0.049 9.9 
HSV-2 5% LH27 8H 0.324 0.052 16.1 
HSV-2 1% LH27 8H 0.249 0.063 25.4 
HSV-2 2% LH27 8H 0.159 0.019 11.729 
HSV-2 2.5% LH27 8H 0.147 0.008 5.772 
HSV-2 10% LH27 4H 0.262 0.087 33.088 
HSV-2 5% LH27 4H 0.278 0.049 17.7 
 
 
9.2.6.3 Discussion 
These experiments testing each of the viruses that had been subjected to successful 
neutralisation treatments, with each virus the honey solutions that did not contain 
antigen caused higher absorbance readings than the untreated virus, and with the 
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medium only (used in preparation of the virus) high absorbance readings were 
recorded which caused very low final absorbance results.  This further suggested non-
specific binding.   
 
9.2.7 Further optimisation to detect antigens on viruses treated with honey 
9.2.7.1 Methods 
The method used was the similar to that outlined in Sections 9.2.1.1, with the 
modifications described in Sections 9.2.4.1 and 9.2.5.1.  However, the wash step 
between the coating and blocking was omitted and the antibodies were prepared in 
growth medium (that contained 10% FCS) to try to reduce the non-specific binding.  
Virus diluted to 10
-4
 was used to coat the wells, as well as the honey solutions that 
had previously caused the greatest absorbance readings with each virus.  The primary 
antibody was diluted to 1/100 (10 µg/ml) and used with secondary antibody diluted to 
1/500 (2 µg/ml).  This experiment was completed with six replicates. 
 
9.2.7.2 Results 
The results are presented in Table 9.7.  The first column gives the virus, and type and 
concentration of honey. 
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Table 9.7 Absorbance readings with the antibodies prepared in growth medium, 
with Ad3, HSV-1, HSV-2, and honey solutions   
 
Treatment Mean SD % CV 
Ad3 only 0.212 0.018 8.6 
10% M157 0.094 0.010 11.1 
HSV-1 only 0.258 0.020 7.9 
10% R19/06 0.099 0.018 17.8 
HSV-2 only 0.246 0.021 8.7 
10% M112 0.091 0.015 16.9 
 
 
9.2.7.3 Discussion 
To overcome the non-specific colour development, the solutions used in the 
preparation of the antibody dilutions were changed to growth medium which 
provided high amounts of protein that could competitively bind and so eliminate the 
non-specific binding.  This experiment was undertaken to test each virus at a dilution 
of 10
-4
 and the honey solutions that had previously caused high absorbance readings 
(shown in Table 9.6).  A 1/200 dilution of the primary antibody was used with a 
1/500 dilution of the secondary antibody, due to the use of a higher protein content 
solution to prepare the antibodies higher dilutions of each antibody should give 
suitable absorbance readings.  The results in Table 9.7 clearly show detectable 
absorbance levels with each of the viruses, and with the honey solutions low 
absorbance readings indicating a reduction of the non-specific binding. 
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9.2.8 Further experiments with honey 
9.2.8.1 Methods 
Using the method described in Section 9.2.7 with the associated modifications, the 
successful neutralisation treatments of Chapter 6 plus the honey solutions were re-
tested in triplicate.    
 
9.2.8.2 Results 
The results are presented in Table 9.8 and 9.9.  The first column indicates the virus, 
type and concentration of honey, and the time of exposure.  The final absorbance is 
given as the [mean absorbance of the treatment] – [mean absorbance of the 
appropriate control]. 
 
Table 9.8 Effect of honey on the detection of antigens of (a) Ad3, (b) HSV-1, and 
(c) HSV-2, absorbance readings with virus treated and not treated with honey 
 
(a) Ad3  
 
Treatment Mean SD % CV Final absorbance 
Medium only 0.105 0.001 1.3  
Ad3 only 0.151 0.006 4.2 0.046 
Honey solutions   
10% M116 0.123 0.023 19.0  
10% M157 0.051 0.009 18.2  
10% HD19 0.157 0.033 21.2  
5% HD19 0.127 0.024 18.9  
Honey plus virus  
Ad3 10% M116 8H 0.080 0.002 2.2 -0.043 
Ad3 10% M157 8H 0.136 0.005 3.7 0.085 
Ad3 10% HD19 8H 0.110 0.047 42.7 -0.047 
Ad3 5% HD19 8H 0.142 0.023 16.1 0.015 
 
 
Chapter Nine The antiviral activity of honey: Study using ELISA 
288 
 
 
(b) HSV-1 
Treatment Mean SD % CV Final absorbance 
Medium only 0.106 0.013 12.2  
HSV-1 only 0.116 0.012 10.5 0.010 
HSV-1 (4H) only 0.127 0.018 13.8 0.021 
Honey solutions   
10% M116 0.063 0.005 7.3  
5% M116 0.110 0.025 22.7  
10% M112 0.139 0.009 6.2  
10% M157 0.101 0.014 13.6  
10% R19/06 0.121 0.017 13.7  
5% R19/06 0.131 0.021 16.2  
10% R19/06 (4H) 0.117 0.025 21.6  
Honey plus virus  
HSV-1 10% M116 8H 0.109 0.007 6.8 0.046 
HSV-1 5% M116 8H 0.067 0.011 15.8 -0.043 
HSV-1 10% M112 8H 0.092 0.034 37.2 -0.047 
HSV-1 10% M157 8H 0.110 0.030 27.6 0.009 
HSV-1 10% R19/06 8H 0.098 0.031 32.1 -0.023 
HSV-1 5% R19/06 8H 0.108 0.023 21.2 -0.023 
HSV-1 10% R19/06 4H 0.100 0.014 14.0 -0.017 
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(c) HSV-2 
Treatment Mean SD % CV Final absorbance 
Medium only 0.080 0.023 29.3  
HSV-2 only 0.083 0.025 29.9 0.003 
HSV-2 (4H) only 0.070 0.002 3.0 -0.01 
HSV-2 (2H) only 0.066 0.002 2.6 -0.014 
Honey solutions   
10% M116 0.088 0.031 35.8  
10% M112 0.061 0.011 17.1  
10 % M112 (4H) 0.098 0.019 19.1  
10 % M112 (2H) 0.066 0.006 8.4  
10% HD19 0.068 0.011 16.2  
10% LH27 0.078 0.005 6.8  
5% LH27 0.092 0.024 26.4  
1% LH27 0.095 0.008 8.4  
2% LH27 0.088 0.011 12.7  
2.5% LH27 0.063 0.018 27.7  
10% LH27 (4H) 0.060 0.012 20.5  
5% LH27 (4H) 0.067 0.017 25.3  
Honey plus virus 
HSV-2 10% M116 8H 0.097 0.022 22.3 0.009 
HSV-2 10% M112 8H 0.089 0.022 24.6 0.028 
HSV-2 10 % M112 4H 0.096 0.014 14.0 -0.002 
HSV-2 10 % M112 2H 0.075 0.017 22.6 0.009 
HSV-2 10% HD19 8H 0.120 0.022 18.5 0.052 
HSV-2 10% LH27 8H 0.089 0.017 19.2 0.011 
HSV-2 5% LH27 8H 0.114 0.060 52.5 0.022 
HSV-2 1% LH27 8H 0.088 0.027 30.4 -0.007 
HSV-2 2% LH27 8H 0.083 0.003 3.4 -0.005 
HSV-2 2.5% LH27 8H 0.094 0.017 17.9 0.031 
HSV-2 10% LH27 4H 0.067 0.000 0.0 0.007 
HSV-2 5% LH27 4H 0.092 0.007 7.7 0.025 
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Table 9.9 Effect of honey on the detection of antigens of (a) HSV-1 and (b) HSV-2 
absorbance readings with virus treated and not treated with honey (repeats) 
 
(a) HSV-1 
 
Treatment Mean SD % CV 
HSV-1 only 0.061 0.012 18.9 
Honey plus virus 
HSV-1 10% M116 8H 0.047 0.004 8.5 
HSV-1 5% M116 8H 0.053 0.014 26.2 
HSV-1 10% M112 8H 0.044 0.003 5.7 
HSV-1 10% M157 8H 0.037 0.003 7.2 
HSV-1 10% R19/06 8H  0.065 0.024 36.2 
HSV-1 5% R19/06 8H 0.052 0.013 25.8 
HSV-1 10% R19/06 4H 0.061 0.012 19.0 
 
(b) HSV-2 
Treatment Mean SD % CV 
Medium only 0.039 0.004 10.6 
HSV-2 only 0.060 0.006 9.4 
HSV-2 (4H) only 0.051 0.015 29.3 
HSV-2 (2H) only 0.042 0.007 17.0 
Honey plus virus 
HSV-2 10% M116 8H 0.047 0.004 8.5 
HSV-2 10% M112 8H 0.033 0.009 28.4 
HSV-2 10 % M112 4H 0.037 0.002 4.2 
HSV-2 10 % M112 2H 0.042 0.011 26.4 
HSV-2 10% HD19 8H 0.051 0.010 19.9 
HSV-2 10% LH27 8H 0.047 0.003 5.4 
HSV-2 5% LH27 8H 0.042 0.007 16.6 
HSV-2 1% LH27 8H 0.036 0.002 6.4 
HSV-2 2% LH27 8H 0.057 0.012 21.2 
HSV-2 2.5% LH27 8H 0.034 0.005 14.9 
HSV-2 10% LH27 4H 0.051 0.015 29.6 
HSV-2 5% LH27 4H 0.046 0.008 17.3 
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9.2.8.3 Discussion 
The experiments with honey used 1/200 and 1/500 dilutions of the antibodies 
prepared in growth medium shown in Tables 9.8 and 9.9 caused low absorbance 
readings with the controls that did not contain antigen.  However, as with the first 
experiments with honey (Table 9.6) low absorbance readings were obtained with each 
of the viruses that were not treated with honey.  These low readings could be 
explained by the heating at 37°C during the neutralisation period which as a 
consequence may have caused alterations to the epitope of the surface protein thus 
making it undetectable by these antibodies.  Table 9.7 shows that the virus at a 
dilution of 10
-4 
can
 
be detected when it had been freshly prepared prior to coating the 
plates, and in the neutralisation experiments, the untreated virus caused a CPE 
suggesting that there was virus present after the neutralisation period at 37°C.  The 
successful honey treatments against HSV-1 and HSV-2 were re-tested without the 
control honey solutions to see whether similar absorbance readings would be 
recorded, again low absorbance readings were observed as shown in Table 9.9. 
 
Due to the very low absorbance readings, comparisons between the final absorbance 
results of the untreated virus and the honey-treated virus are inconclusive as to 
whether the honey or the heating is responsible for the resulting absorbance readings, 
and it has not shown whether the honey has caused alterations to the surface proteins. 
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This investigation using ELISA has shown that this technique with additional 
optimisation may be feasible for the detection of proteins after treatment with honey.
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Chapter 10   
Discussion and further work 
____________________________________________ 
The aim of the present study was to extend knowledge of the sensitivity of viral 
species to whole honey.  This chapter is a final discussion of the effect each type 
of honey had against the viruses tested in this thesis.  The observations are 
compared with work done by other researchers, and suggestions of the possible 
modes of action are outlined as well as recommendations for further work.  The 
benefits of honey over current therapy are also discussed.  
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10.1 SUMMARY OF THE IMPACT THE HONEYS HAD ON THE 
VIRUSES 
The preliminary investigations using Manuka honey M157 in Chapter 5 provided 
some evidence that the honey was working both on or within the uninfected and 
infected cells, and directly on the virus.  It was shown further by results of 
Chapter 6 a direct effect of the honeys at various concentrations on the prevention 
of CPE development after infection of the cells with each virus.  On determining 
if the successful neutralisation treatments were virustatic or virucidal it was 
shown that the previously successful treatments using Manuka honey against 
HSV-1 and HSV-2 were virucidal, as were the Manuka honey treatments against 
Ad3 with the exception of M112.  The other honeys that had been successful in 
the neutralisation experiments were shown to have virustatic activity, as there was 
development of viral infection at some stage over the observation period.  as there 
was development of viral infection at some stage over the observation period.  
This suggested an effect of the high levels of methylglyoxal present in the 
Manuka honeys as Manuka honey M151 (very low activity levels) was 
unsuccessful in causing an antiviral effect.  The experiments testing 
methylglyoxal at equivalent concentrations to what was present in each of the 
honeys showed that it was not solely responsible for the antiviral activity.   
 
In the experiments studying the prevention of viral infection, Manuka honey 
M116 and Honeydew honey HD19 were the most successful in inhibiting the 
spread of virus.  It was shown that when the honey was used to treat virally 
infected cells that it can delay the development of CPE when the infected cells are 
mixed with uninfected cells.  The plaque reduction assays confirmed that honey 
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can decrease the spread of infection from infected cells to uninfected cells by 
71.4% to 97.0%.  The final experiments using ELISA in this study failed to 
indicate whether the viral surface proteins were being modified by the preceding 
honey treatment.  It is therefore unknown whether honey acts in this way. 
 
10.2 COMPARISONS WITH PREVIOUS RESREACH 
The Manuka or pasture honey used in previous investigations by French (2002) to 
test the antiviral activity of honey against HSV-1 were indicated to be close to the 
median antibacterial activity for each type of antibacterial activity (peroxide/non-
peroxide), equivalent to 17.5% (w/v) phenol for peroxide activity with no 
detectable non-peroxide activity for the pasture honey, and the Manuka honey 
used had a non-peroxide activity equivalent to 16.8% (w/v) phenol. 
 
French’s (2002) results suggested neutralisation of HSV-1, which was defined as 
the absence of subsequent viral infection (CPE) after treatment of the virus with 
10% Manuka honey.  Likewise neutralisation was suggested with one replicate of 
10% pasture honey and with all replicates after treatment of the virus with 15% 
pasture honey.  The period of exposure of the virus to honey in French’s 
investigation was 1 hour followed by dialysis.  The table of results given did not 
give details of how long after inoculation of the cells the observations of viral 
CPE were made or whether they were all taken at the same time.  Despite this, 
results are comparable with these in the present study as HSV-1, although 
examined under slightly different methodology, was neutralised by 10% Manuka 
honey.  Similarly, Rewarewa honey (which has antibacterial activity due to 
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hydrogen peroxide) was shown to cause neutralisation at 10% in the present 
study, like one replicate of the pasture honey did.  
 
When comparing the current results with those of the study undertaken by Zeina 
et al. (1996) it was apparent that far lower concentrations of honey were able to 
eliminate Rubella infection than found in the present study against Adenovirus or 
Herpes virus.  In the study of Zeina concentrations of honey from 0.001% to 50% 
were found to cause absence of viral infection and retained the viability of the 
vero cells over the course of infection (four days).  This suggests that Rubella 
virus was particularly susceptible to the honey treatments, and that the vero cell 
line can withstand very high concentrations of honey for a prolonged period 
compared with the A549 cells in the present study which were seen to withstand 
no more than 2% honey.  There is a possibility that the vero cells were rendered 
non-viable by the osmolarity (hence infection could not develop) but that the 
monolayer remained intact so that the non-viability was not detected.  The method 
of how the viability was tested for was not provided. 
 
The current study has verified the study undertaken by Al-Waili (2004) that tested 
the topical application of raw honey versus acyclovir for the treatment of recurrent 
herpes lesions.  It has been now shown in vitro that the clinical observations could 
have been due to an effect of honey on the virus and not just on the symptoms of 
infection.   
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From the results of previous investigations and those found in the current study, 
the antiviral activity has been shown to be a property of more than one type of 
honey.  Although the efficacy differs within and between honeys of various floral 
sources against the different viral isolates, in each case the magnitude of viral 
infection is usually reduced with a treatment of honey.  Manuka honey was found 
to have the greatest effect against all three types of virus studied, where the other 
honeys seemed to be slightly more specific with the virus they acted most 
successfully upon.  There is potential then for other dsDNA viruses to be 
susceptible to treatment with honey. 
 
10.3 POSSIBLE MODES OF ACTION 
The preliminary experiments and further testing of the antiviral activity of a range 
of honeys has shown in each of the different experiments that honey had an effect 
on the development of viral CPE.  This suggests that the honey acts on the cells, 
on the surface or within, as well as directly on the virus in the absence of the cells.    
 
As discussed in Chapter 5, the honey maybe entering the cell and working against 
the virus during its replication, it may be causing an antiviral response, or it 
maybe coating cellular receptors preventing the attachment of the virus.  It may be 
thought that the toxic nature of honey may be slowing cellular growth eliminating 
the optimal environment for viral infection.  However, when considering the 
evidence for honey increasing the rate of cell growth in wound healing (as 
reviewed by Molan, 2006) it is unlikely.  The delay rather than prevention of CPE 
can suggest a possible loss of the inhibition factor in the honey through chemical 
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reaction or metabolism over the observation period, although it is also possible 
that it is due to the progress of viral infection being only partially inhibited and 
thus slowed. 
 
The results of Chapter 6 indicate that honey at the appropriate concentrations (see 
Table 6.2) can neutralise the virus and so prevent it from displaying CPE within 
susceptible cells.  The period of which the cells were exposed to the viral-honey 
inoculum was 15 minutes followed by replacement of the inoculum with 
maintenance medium.  It is reasoned that during this short period that the honey 
would have had very little effect on the cells and with the removal of the 
inoculum any remaining honey would have been greatly diluted to well below 
inhibitory levels. 
 
By the delays observed in the onset of viral infection the honey may be preventing 
the spread of infection from cell to cell.  This could have been due to the honey 
blocking viral or cellular receptors, or by slowing the replication and release of 
viral particles.  A further possibility is that the honey causes the induction of 
antiviral cytokines in the cells. 
 
With the experimental conditions testing the protective and neutralisation effects 
of honey, the virus may have bound to and entered an original cell during the 
inoculation period, then taken a prolonged period to replicate or release viral 
particles to infect surrounding cells due to the preceding honey treatment (on the 
cells or on the virus).   
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The honey could be bound in some way to the cell surface where it may not only 
be blocking the appropriate cellular receptors, but may be modifying them in 
some way and so preventing viral attachment.  Ad3 attaches to coxsachie-
adenovirus receptors (CARs), CD80 and CD86 cellular proteins, and integrins.  
HSV-1 and HSV-2 attach to glycosaminoglycans (GAGs) and interact with 
nectins, herpes virus mediator, and specific forms of heparin sulphate (3-OS HS).  
Honey may enter the cell and alter viral entry and transportation mechanisms to 
the nucleus. 
 
Alternatively, the honey may cause alterations to the viral particle preventing 
successful attachment and penetration into the susceptible cell, thus the infection 
observed after inoculation was due to those viral particles that were not altered by 
the honey.  This fits with the reduction of CPE related to the concentration of 
honey and time of exposure to it, as in effect a proportion of the viral particles 
would have been removed.  Experiments were undertaken to try to find, by 
ELISA immunochemistry, if there was binding to the virus but unfortunately the 
results were inconclusive because of practical problems. 
 
It is possible that the morphology of the viral particle was not altered by the honey 
treatment but that the honey had some affect on the viral life cycle within the cell, 
such as damage to the DNA therefore preventing the expression of genes essential 
to viral replication, particle formation, and viral release (egress).  Due to the 
sequential manner in which these viruses are expressed (see Chapter 2), damage 
to the DNA at any stage would prevent viral release and so would prevent further 
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infection of other cells.  This possibility again fits with the reduction of CPE with 
increasing concentration of honey and time exposed to it, as greater DNA damage 
due to prolonged exposure may have a greater effect than damage over a short 
period, similarly the infection observed may be due to those viral particles that 
escaped the effects of the honey.   
 
These possibilities may be being caused by methylglyoxal present in high levels 
in especially Manuka honeys that may be binding to DNA or amino groups on the 
viruses or on the cellular receptor proteins.  The hydrogen peroxide responsible 
for the antibacterial activity of non-Manuka honeys may oxidatively modify viral 
or cellular proteins, and the antioxidants may prevent oxidative activation of 
NFκB. 
 
10.4 RECOMMENDATIONS FOR FURTHER WORK 
In order to identify the component(s) within honey that are responsible for the 
antiviral action, the honey could be fractionated and the fractions then tested 
separately and in combination against the viruses.  It is also important to address 
the modifications that may be occurring to the host cell receptors suggested by 
experiments which showed protection and prevention of viral infection.   This 
could be done by optimising the ELISA methodology.  PCR and real time PCR 
may be further used to see if honey alters the gene expression of either the virus or 
the cells and so determine the impact of honey of the replication of the virus.  
Also suitable for further investigation is the effect of honey on cellular pathways 
such as NFκB crucial for viral replication known to be effected by methylglyoxal 
Chapter Ten Discussion and further work 
 
301 
 
which is found within honey.   The NFκB pathway is also possibly affected by 
honey antioxidants. 
 
It would be of therapeutic benefit to test the honeys in vivo against the infections 
caused by these viruses (cold sores, genital infection, and eye infections) to 
compare the healing with the conventional treatments.  The results of this study do 
not show whether honey will work clinically, but do justify the running of clinical 
trials.  Further, cells on the surface of living tissue have circulation that can 
replace osmotically withdrawn water they can therefore withstand 100% honey 
unlike the A549 cells used in this investigation, it is likely that when honey is 
used at this concentration in vivo that it would be effective against these 
infections. 
 
10.5 POTENTIAL BENEFITS OF HONEY OVER CURRENT THERAPY 
Cidofovir as discussed in Chapter 2 can have toxic effects and is ineffective 
against some viral isolates due to resistance (Kinchington et al., 2005).  For this 
reason honey is more likely to be a better therapeutic option for the treatment of 
Adenoviral infections if clinical trials prove the effectiveness indicated by the in 
vitro results in the present study.  It is feasible to use honey for eye infections as 
honey has been used in numerous cases to treat ailments of the eyes (Fotidar & 
Fotidar, 1945; Imperato & Traore, 1969; Molan, 1999).  No allergic reactions 
(Kiistala, et al., 1995) or other reactions have been recorded other than a transient 
stinging described by some patients with honey (Betts & Molan 2001). 
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With the current therapy for herpes infections, acyclovir, resistance is possible 
through mutations of thymidine kinase and HSV DNA polymerase rendering 
these treatments inactive.  Honey therefore is a promising treatment for herpes 
infections as with this study it was found to inhibit or delay viral infection in vitro.  
 
Due to the observations that honey when used topically to treat wounds 
accelerates healing such as with the healing of chronic leg ulcers, post-operative 
wounds, and burns (Molan, 2001; Molan, 2006), it has been reasoned that honey 
may help combat viral infections of both eye infections and Herpes lesions.  This 
stimulatory effect of honey may help with the repair of tissue damage caused by 
the viral infection.   
 
The evidence of an immunostimulatory action of honey (Tonks, 2003; 2007) 
would augment the direct antiviral action and so can contribute to the body’s own 
defences to clear the virus and heal the infection within a short period.  The 
antibacterial activity of honey in addition will provide protection from secondary 
infections commonly associated with infections.   
 
The anti-inflammatory activity will help reduce the pain associated with the viral 
infections.  Honey has been shown to reduce odema associated with wounds 
through a direct action and not a secondary result of removal of infection (as 
reviewed by Molan, 2006). 
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In conclusion this thesis has confirmed the antiviral activity of honey against HSV 
and extended the scope of susceptible viral species.  It has been confirmed that the 
action of honey observed previously in clinical trials which could have been an 
effect on the symptoms, actually could have been a direct antiviral action.  It has 
been shown that honey has an antiviral action on other dsDNA viruses as well. 
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